

A/box

Seq

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

JC525 U.S. PTO

JC525 U.S. PTO 10/22/99

APPLICATION ELEMENTS

1. Fee Transmittal Form

2. Specification and Drawings [Total Pages 132]
 - Specification - (108 pages)
 - Claims - (20 pages)
 - Abstract - (1 page)
 - Sheets of Drawings - (3 sheets)

Formal
 Informal

3. Oath or Declaration [Total Pages 1]
 a. Newly executed (original)
 b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 4 below]

4. Incorporation by Reference (usable if Box 3b is checked)
 The entire Disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

5. Microfiche Computer Program (*Appendix*)

6. Nucleotide and/or Amino Acid Sequence Submission
 Computer Readable Copy
 Paper Copy (identical to computer copy)
 Statement verifying identify of above copies

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
 Continuation Divisional Continuation-in-part (CIP) of prior application Serial No. ____/____.
 Priority to the above application(s) is claimed under 35 U.S.C. 120.
 Prior application information: Examiner: _____. Group/Art Unit: _____.

18. Priority - 35 U.S.C. 119
 Priority of application Serial No. 60/105,507 filed on 10/23/98 in the U.S. and application Serial No. 60/108,685 filed on 11/16/1998 in the U.S. is claimed under 35 U.S.C. 119.
 The certified copy has been filed in prior U.S. application Serial No. ____/____ on _____.
 The certified copy will follow.

ADDRESS TO: **Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231****ACCOMPANYING APPLICATION PARTS**

7. 37 CFR 3.73(b) Statement (when there is an assignee)
 Power of Attorney

8. English Translation Document (*if applicable*)

9. Information Disclosure Statement (IDS)/PTO-1449
 Copies of IDS Citations

10. Preliminary Amendment
 Drawings [Total Sheets 1]
 Letter to Official Draftsperson Including Drawings [Total Pages 1]

11. Return Receipt Postcard

12. Small Entity Statement(s)
 Statements filed in prior application, (Status still proper and desired)

13. Certified Copy of Priority Document(s)

14. Deletion of Inventor(s)
 Signed statement attached deleting inventor(s) named in the prior application.

15. Patent Application Data Entry Form

16. Other: _____

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
 Testa, Hurwitz & Thibeault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK

Date: **10/22/99**
 Reg. No. 43,526
 Tel. No.: (617) 248-7476
 Fax No.: (617) 248-7100

Respectfully submitted
Jennifer A. Camacho
 Jennifer A. Camacho
 Atty/Agent for Applicant(s)
 Testa, Hurwitz & Thibeault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110

Inventor Information

Inventor One Given Name :: Hiroaki
Family Name :: Kawasaki
Name Suffix ::
Postal Address Line One :: 3-20-2, Aoba
Postal Address Line Two ::
City :: Higashi-Ku
State/Province :: Fukuoka,
Country :: JAPAN
Postal or Zip Code :: 813-0025
City of Residence :: Higashi-Ku
State/Prov. of Residence :: Fukuoka,
Country of Residence :: Japan
Citizenship :: Japan

Inventor Two Given Name :: Ann
Family Name :: Graybiel
Name Suffix ::
Postal Address Line One :: Boyce Farm Road
Postal Address Line Two ::
City :: Lincoln
State/Province :: Massachusetts
Country :: U.S.A.
Postal or Zip Code :: 01773
City of Residence :: Lincoln
State/Prov. of Residence :: Massachusetts
Country of Residence :: U.S.A.
Citizenship :: U.S.A.

Inventor Three Given Name :: David
Family Name :: Housman
Name Suffix ::
Postal Address Line One :: 64 Homer Street
Postal Address Line Two ::
City :: Newton
State/Province :: Massachusetts
Country :: U.S.A.
Postal or Zip Code ::
City of Residence :: Newton
State/Prov. of Residence :: Massachusetts
Country of Residence :: U.S.A.
Citizenship :: U.S.A.

Correspondence Information

Correspondence Customer Number :: 021323

Application Information

Title Line One :: Genes Integrating Signal Transduction Pathways
Title Line Two ::
Total Drawing Sheets :: 3
Formal Drawings :: N
Application Type :: Utility
Docket Number :: MIT-103
Licensed - U S Government Agency :: NIH
Contract Numbers: NICHD RO1; NCI PO1; NHLBI PO1; NCHGR RO1
Grant Numbers:: HD28341; CA42063; HL41484; HG00299
Secrecy Order in Parent Application ::

Representative Information

Representative Customer Number :: 021323

Continuity Information

This application:: Claims Benefit of
>Application One :: 60/105,507
Filing Date :: October 23, 1998
Patent Number ::

This application:: Claims Benefit of
>Application Two :: 60/108,685
Filing Date :: November 16, 1998
Patent Number ::

Prior Foreign Applications

Foreign Application One ::
Filing Date ::
Country ::
Priority Claimed ::

479JAC5473/111.A877130-1

GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS**Related Applications**

This application claims the benefit of U.S. Application Nos. 60/105,507, filed on October 23, 1998, and 60/108,685, filed on November 16, 1998.

5 Field of the Invention

The present invention relates generally to novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic, and research utilities for these polynucleotides and proteins.

10 Background of the Invention

Ras proteins are key regulators of growth, differentiation and malignant transformation. In addition, these proteins are implicated in synaptic function and region-specific learning and memory functions in the brain.

As shown schematically in Figure 1, Ras proteins cycle between inactive GDP-complexed and active GTP-complexed states. GTPase-activating proteins (GAPs) inactivate Ras proteins by stimulating hydrolysis of the bound GTP to GDP, whereas guanine nucleotide exchange factors (GEFs) activate Ras proteins by stimulating release of GDP and the uptake of GTP. So essential are GEFs to Ras action, that genetic loss of GEF function has similar effects to those induced by loss of the Ras proteins themselves. Loss of GEF function can be circumvented by mutations that constitutively activate the Ras proteins, such as an oncogene mutation, or, in some cases, through loss of GAP activity. Activated Ras proteins, which are localized at the plasma membrane, transmit signals from tyrosine kinases to a cascade of serine/threonine kinases, which delivers the signals to the cell nucleus.

Activation of Ras can result in the activation of the mitogen-activated protein (MAP) kinase (also known as extracellular-signal regulated kinase, or ERK) pathway. For example, a receptor tyrosine kinase is activated by a peptide mitogen such as epidermal growth factor

(EGF). The EGF-stimulated receptor undergoes autophosphorylation of specific tyrosine residues in its cytoplasmic domain which creates phosphotyrosyl binding sites for the Src homology 2 (SH2) and/or phosphotyrosyl binding (PTB) domains of certain adapter proteins. The adapter protein becomes autophosphorylated on association with activated receptor tyrosine 5 kinases. The GEF is stably associated with the adapter protein which, upon autophosphorylation, mediates translocation of the GEF to the plasma membrane. The GEF then activates the Ras protein. Activated Ras relays its signal downstream through a cascade of cytoplasmic proteins, including Raf-1 serine/threonine kinase. The Ras:Raf association promotes translocation of the 10 normally cytoplasmic Raf protein to the plasma membrane, where subsequent events lead to the activation of its kinase function. Upon activation, Raf phosphorylates and activates two MAP kinases (also known as MEKs). MEKs directly associate with the catalytic domain of Raf-1 and are phosphorylated by Raf. Activated MEKs function as dual-specificity kinases and phosphorylate tandem threonine and tyrosine residues in the MAP kinases to activate them. Once activated, the MAP kinases translocate to the nucleus where they phosphorylate and 15 activate a variety of substrates.

Rap proteins, members of the Ras small GTPase superfamily, can inhibit Ras signaling of the Ras/Raf-1(a serine/threonine kinase)/MAP kinase pathway or, through B-Raf, can activate MAP kinase. Rap1 consists of two isoforms, Rap1A and Rap1B, which differ mainly at the C-terminus. Characteristic features of Rap1 are its geranylgeranyl modification at the C-terminus, 20 which is responsible for membrane attachments, and a threonine residue at position 61. In most other GTPases, the corresponding residue is a glutamine. Rap proteins, like Ras proteins, cycle between inactive GDP-complexed and active GTP-complexed states. GEFs are required to activate Rap proteins by stimulating the release of GDP and the uptake of GTP.

Constitutive activation of the Ras pathway contributes to malignant transformation. In 25 fact, the Ras gene has been implicated in many human cancers, including lung cancer, breast cancer, colorectal cancer, exocrine pancreatic cancer, and myeloid leukemia. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein since Ras must be localized in the plasma membrane and must bind with GTP in order to transform cells. Gibbs et al., 53 MICROBIOL. REV. 171-286 (1989).

Targeting components of the Ras signaling pathways has been proposed as one approach for the development of anti-Ras drugs for cancer treatment. One potential approach for targeting Ras for cancer treatment involves the use of farnesyltransferase inhibitors (FTIs). Inhibition of farnesyl-protein transferase, and thereby of farnesylation of the Ras protein, blocks the ability of Ras to transform normal cells to cancer cells. Certain inhibitors of Ras farnesylation cause an increase in soluble Ras which can act as a dominant negative inhibitor of Ras function. While soluble Ras in cancer cells can become a dominant negative inhibitor, soluble Ras in normal cells would not be an inhibitor. A cytosol-localized and activated form of Ras acts as a dominant negative Ras inhibitor of membrane-bound Ras function. Gibbs et al., 86 PROC. NAT'L ACAD. SCI. USA 6630-34 (1989). FTIs block Ras function by preventing its post-translational modification by the farnesyl isoprenoid.

Intervention of Ras signaling at multiple or various points can significantly impact the ability of Ras to cause cellular transformation. Since Ras protein function is believed to be crucial to so many cellular processes, targeting only a subset of Ras functions by downstream intervention may provide significant advantages. Thus, there remains a need for identifying additional means for disrupting the Ras pathway. Applicants have discovered four new targets, namely GEFs specific for Rap1A, for disrupting the Ras pathway.

20 Summary of the Invention

Applicants have discovered four mammalian genes which have been designated CalDAG-GEFI, CalDAG-GEFII, cAMP-GEFI, and cAMP-GEFII, which encode proteins having a substrate specificity for Rap1A. The proteins encoded by CalDAG-GEFI and CalDAG-GEFII, referred to herein generally as "CalDAG-GEF," have dual binding domains for calcium and diacylglycerol. The proteins cAMP-GEFI and cAMP-GEFII, referred to herein generally as "cAMP-GEF," have a binding domain for cyclic adenosine 3', 5'-monophosphate. The present disclosure provides polypeptide and polynucleotide sequences for *Mus musculus* CalDAG-GEFI, *Homo sapiens* CalDAG-GEFI, *Rattus norvegicus* CalDAG-GEFII, *Homo sapiens* CalDAG-GEFII, *Rattus norvegicus* cAMP-GEFI, *Homo sapiens* cAMP-GEFI, *Homo sapiens* alternatively spliced cAMP-GEFI, *Rattus norvegicus* cAMP-GEFII, and *Homo sapiens* cAMP-GEFII. See

Kawasaki et al., 95 Proc. Natl. Acad. Sci. USA 13278-83 (1998), and Kawasaki et al., 282 Sci. 2275-79 (1998), the disclosures of both of which are incorporated by reference herein.

Thus, in one series of embodiments, the present invention provides isolated nucleic acids including nucleotide sequences comprising or derived from CalDAG-GEF or cAMP-GEF, or 5 encoding polypeptides comprising or derived from CalDAG-GEF or cAMP-GEF proteins. The sequences of the invention include the specifically disclosed sequences, splice variants of these sequences, allelic variants of these sequences, synonymous sequences, and homologous or orthologous variants of these sequences. Thus, for example, the invention provides nucleic acid sequences from the *Mus musculus* CalDAG-GEFI, *Homo sapiens* CalDAG-GEFI, *Rattus 10 norvegicus* CalDAG-GEFII, *Homo sapiens* CalDAG-GEFII, *Rattus norvegicus* cAMP-GEFI, *Homo sapiens* cAMP-GEFI, *Homo sapiens* alternatively spliced cAMP-GEFI, *Rattus norvegicus* cAMP-GEFII, and *Homo sapiens* cAMP-GEFII. The present invention also provides allelic 15 variants and homologous or orthologous sequences by providing methods by which such variants may be routinely obtained. Because the nucleic acids of the invention may be used in a variety of diagnostic, therapeutic and recombinant applications, various subsets of the CalDAG-GEF and cAMP-GEF sequences are also provided. For example, for use in allele specific hybridization screening or PCR amplification techniques, subsets of the CalDAG-GEF and cAMP-GEF sequences, including both sense and antisense sequences, and both normal and mutant sequences, as well as intronic, exonic and untranslated sequences, are provided. Such sequences may 20 comprise a small number of consecutive nucleotides from the sequences which are disclosed or otherwise enabled herein, but preferably include at least 8-10, more preferably 10-15, and most preferably 15-25, consecutive nucleotides from a CalDAG-GEF or cAMP-GEF sequence. In another embodiment, such sequences include between 25-500 consecutive nucleotides. Other preferred subsets of a CalDAG-GEF or cAMP-GEF sequence include those encoding one or 25 more of the functional domains or antigenic determinants of the CalDAG-GEF or cAMP-GEF protein and, in particular, may include either normal (wild-type) or mutant sequences. The invention also provides for various nucleic acid constructs in which CalDAG-GEF or cAMP-GEF sequences, either complete or subsets, are operably joined to exogenous sequences to form cloning vectors, expression vectors, fusion vectors, transgenic constructs, and the like. Thus, in 30 accordance with another aspect of the invention, a recombinant vector for transforming a

mammalian or invertebrate tissue cell to express a normal or mutant CalDAG-GEF and/or cAMP-GEF sequence in the cells is provided.

In another series of embodiments, the present invention provides for host cells which have been transfected or otherwise transformed with one of the nucleic acids of the invention.

5 The cells may be transformed merely for purposes of propagating the nucleic acid constructs of the invention, or may be transformed so as to express the CalDAG-GEF and/or cAMP-GEF sequences. The transformed cells of the invention may be used in assays to identify proteins and/or other compounds which affect normal or mutant CalDAG-GEF and/or cAMP-GEF expression, which interact with the normal or mutant CalDAG-GEF and/or cAMP-GEF proteins, and/or which modulate the function or effects of the normal or mutant proteins, or to produce the 10 CalDAG-GEF and/or cAMP-GEF proteins, fusion proteins, functional domains, antigenic determinants, and/or antibodies of the invention. Transformed cells may also be implanted into hosts, including humans, for therapeutic or other reasons. Preferred host cells include mammalian cells, including pure or mixed cell cultures, as well as bacterial, yeast, nematode, 15 insect and other invertebrate cells. For uses as described below, preferred cells also include embryonic stem cells, zygotes, gametes, and germ line cells.

In another series of embodiments, the present invention provides transgenic animal models of diseases or disorders associated with mutations in the CalDAG-GEF and/or cAMP-GEF genes. The animal may be essentially any non-human mammal, including rats, mice, 20 hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. In addition, invertebrate models, including nematodes and insects, may be used for certain applications. The animal models are produced by standard transgenic methods including microinjection, electroporation, transfection, or other forms of transformation of embryonic stem cells, zygotes, gametes, and germ line cells with vectors including genomic or cDNA fragments, 25 minigenes, homologous recombination vectors, viral insertion vectors and the like. Suitable vectors include vaccinia virus, adenovirus, adeno-associated virus, retrovirus, liposome transport, neuraltropic viruses, and Herpes simplex virus. The animal models may include transgenic sequences comprising or derived from the CalDAG-GEF and/or cAMP-GEF genes, including normal and mutant sequences, intronic, exonic and untranslated sequences, and sequences 30 encoding subsets of the CalDAG-GEF and/or cAMP-GEF proteins, such as functional domains.

The major types of animal models provided include: (1) Animals in which a normal human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; in which a

5 normal human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly substituted for one or both copies of the animal's homologous CalDAG-GEF and/or cAMP-GEF gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous CalDAG-GEF and/or cAMP-GEF genes have been recombinantly "humanized" by the partial substitution of sequences encoding the human homologue by

10 homologous recombination or gene targeting; (2) Animals in which a mutant human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; in which a mutant human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly substituted for one or both

15 copies of the animal's homologous CalDAG-GEF and/or cAMP-GEF gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous CalDAG-GEF and/or cAMP-GEF gene have been recombinantly "humanized" by the partial substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting; (3) Animals in which a mutant version of one of that animal's

20 CalDAG-GEF or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; and/or in which a mutant version of one of that animal's CalDAG-GEF or cAMP-GEF gene has been recombinantly substituted for one or both copies of the animal's homologous CalDAG-GEF or

25 cAMP-GEF gene by homologous recombination or gene targeting; and (4) "Knock-out" animals in which one or both copies of one of the animal's CalDAG-GEF or cAMP-GEF genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences.

In another series of embodiments, the present invention provides for substantially pure protein preparations including polypeptides comprising or derived from the CalDAG-GEF and/or cAMP-GEF proteins. The CalDAG-GEF and cAMP-GEF protein sequences of the invention include the specifically disclosed sequences, variants of these sequences resulting from

5 alternative mRNA splicing, allelic variants of these sequences, and homologous or orthologous variants of these sequences. Thus, for example, the invention provides amino acid sequences from the *Mus musculus* CalDAG-GEFI protein, *Homo sapiens* CalDAG-GEFI protein, *Rattus norvegicus* CalDAG-GEFII protein, *Homo sapiens* CalDAG-GEFII protein, *Rattus norvegicus* cAMP-GEFI protein, *Homo sapiens* cAMP-GEFI protein, *Homo sapiens* alternatively spliced cAMP-GEFI protein, *Rattus norvegicus* cAMP-GEFII protein, and *Homo sapiens* cAMP-GEFII protein. The present invention also provides allelic variants and homologous or orthologous proteins by providing methods by which such variants may be routinely obtained. The present invention also specifically provides for mutant or disease-causing variants of CalDAG-GEF and cAMP-GEF by providing methods by which such variants may be routinely obtained. Because

10 the proteins of the invention may be used in a variety of diagnostic, therapeutic and recombinant applications, various subsets of the CalDAG-GEF and cAMP-GEF protein sequences and combinations of the CalDAG-GEF and cAMP-GEF protein sequences with heterologous sequences are also provided. For example, for use as immunogens or in binding assays, subsets of the CalDAG-GEF and cAMP-GEF protein sequences, including both normal and mutant sequences, are provided. Such protein sequences may comprise a small number of consecutive amino acid residues from the sequences which are disclosed or otherwise enabled herein, but

15 preferably include at least 4-8, and preferably at least 9-15 consecutive amino acid residues from a CalDAG-GEF or cAMP-GEF sequence. In another embodiment, such sequences comprise at least 15-200 consecutive amino acid residues. Other preferred subsets of the CalDAG-GEF and

20 cAMP-GEF protein sequences include those corresponding to one or more of the functional domains or antigenic determinants of the CalDAG-GEF and cAMP-GEF proteins and, in particular, may include either normal (wild-type) or mutant sequences. The invention also provides for various protein constructs in which a CalDAG-GEF and/or cAMP-GEF sequences, either complete or subsets thereof, are joined to exogenous sequences to form fusion proteins and

25 the like. In accordance with these embodiments, the present invention also provides for methods

30

of producing all of the above described proteins which comprise, or are derived from, CalDAG-GEF and/or cAMP-GEF.

In another series of embodiments, the present invention provides for the production and use of polyclonal and monoclonal antibodies, including antibody fragments, including Fab 5 fragments, F(ab')₂, and single chain antibody fragments, which selectively bind to CalDAG-GEF or cAMP-GEF, or to specific antigenic determinants of CalDAG-GEF or cAMP-GEF. The antibodies may be raised in mouse, rabbit, goat or other suitable animals, or may be produced recombinantly in cultured cells such as hybridoma cell lines. Preferably, the antibodies 10 selectively bind to a sequence comprising at least 4-8, and preferably at least 9-15, and more preferably at least 15-200 consecutive amino acid residues from a CalDAG-GEF or cAMP-GEF sequence. The antibodies of the invention may be used in the various diagnostic, therapeutic and technical applications described herein.

In another series of embodiments, the present invention provides methods of screening or identifying proteins, small molecules or other compounds which are capable of inducing or 15 inhibiting the expression and/or function of the CalDAG-GEF and/or cAMP-GEF genes or proteins. The assays may be performed *in vitro* using non-transformed cells, immortalized cell lines, or recombinant cell lines, or *in vivo* using the transgenic animal models enabled herein. In particular, the assays may detect the presence of increased or decreased expression of CalDAG-GEF and/or cAMP-GEF-related genes or proteins on the basis of increased or decreased mRNA 20 expression, increased or decreased levels of CalDAG-GEF and/or cAMP-GEF-related protein products, or increased or decreased levels of expression of a marker gene (e.g., β -galactosidase, green fluorescent protein, alkaline phosphatase or luciferase) operably joined to a 5' regulatory region in a recombinant construct. Cells known to express CalDAG-GEF or cAMP-GEF, or transformed to express CalDAG-GEF or cAMP-GEF, are incubated and one or more test 25 compounds are added to the medium. After allowing a sufficient period of time (e.g., 0-72 hours) for the compound to induce or inhibit the expression of the CalDAG-GEF or cAMP-GEF, any change in levels of expression from an established baseline may be detected using any of the techniques described above. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line, or 30 are transformed cells of the invention.

In another series of embodiments, the present invention provides methods for identifying proteins and other compounds which bind to, or otherwise directly interact with, CalDAG-GEF and/or cAMP-GEF. The proteins and compounds will include endogenous cellular components which interact with the CalDAG-GEF and/or cAMP-GEF *in vivo* and which, therefore, provide

5 new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic, and otherwise exogenous compounds which may have CalDAG-GEF and/or cAMP-GEF binding capacity and, therefore, may be candidates for pharmaceutical agents. Particularly useful components will bind with a SCR1, SCR2, SCR3, EF hand, DAG-binding or cAMP-binding domain. Thus, in one series of embodiments, cell lysates or tissue homogenates (e.g., human

10 brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant CalDAG-GEF or cAMP-GEF proteins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), may be screened for CalDAG-GEF or cAMP-GEF binding capacity. In each of these embodiments, an assay is conducted to detect binding between a

15 "CalDAG-GEF component" or a "cAMP-GEF component" and some other moiety. The "CalDAG-GEF component" or the "cAMP-GEF component" in these assays may be any polypeptide comprising or derived from a normal or mutant CalDAG-GEF or cAMP-GEF protein, including functional domains or antigenic determinants of CalDAG-GEF or cAMP-GEF, or CalDAG-GEF or cAMP-GEF fusion proteins. In one embodiment, a CalDAG-GEF

20 component is a SCR1, SCR2, SCR3, EF hand, or DAG-binding domain. In another embodiment a cAMP-GEF component is a SCR1, SCR2, SCR3, or cAMP-binding domain. Binding may be detected by non-specific measures (e.g., changes in intracellular Ca^{2+} , GTP/GDP ratio) or by specific measures (e.g., changes in the expression of downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE

25 methods). The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of CalDAG-GEF or cAMP-GEF components and bound proteins or other compounds by immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems.

In another series of embodiments, the present invention provides for methods of

30 identifying proteins, small molecules and other compounds capable of modulating the activity of

normal or mutant CalDAG-GEF or cAMP-GEF. Using normal cells or animals, the transformed cells and transgenic animal models of the present invention, or cells obtained from subjects bearing normal or mutant CalDAG-GEF or cAMP-GEF genes, the present invention provides methods of identifying such compounds on the basis of their ability to affect the expression of

5 CalDAG-GEF and/or cAMP-GEF, the intracellular localization of the CalDAG-GEF and/or cAMP-GEF, or other biochemical, histological, or physiological markers which distinguish cells bearing normal and mutant CalDAG-GEF and/or cAMP-GEF sequences. Using the transgenic animals of the invention, methods of identifying such compounds are also provided on the basis of the ability of the compounds to affect behavioral, physiological or histological phenotypes

10 associated with mutations in CalDAG-GEF and/or cAMP-GEF.

In another series of embodiments, the present invention provides methods and reagents for the screening and diagnosis of diseases or disorders associated with mutations in the CalDAG-GEF and/or cAMP-GEF genes. Screening and/or diagnosis can be accomplished by methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences),

15 proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect failure or augmentation of the normal CalDAG-GEF and/or cAMP-GEF activity and/or the presence of specific new activities conferred by the mutant CalDAG-GEF and/or cAMP-GEF. Thus, for example, screens and diagnostics based upon CalDAG-GEF and/or cAMP-GEF proteins are provided which detect differences between mutant and normal CalDAG-GEF or

20 cAMP-GEF in electrophoretic mobility, in proteolytic cleavage patterns, in molar ratios of the various amino acid residues, or in ability to bind specific antibodies. In addition, screens and diagnostics based upon nucleic acids (gDNA, cDNA or mRNA) are provided which detect differences in nucleotide sequences by direct nucleotide sequencing, hybridization using allele specific oligonucleotides, restriction enzyme digest and mapping (e.g., RFLP, REF-SSCP),

25 electrophoretic mobility (e.g., SSCP, DGGE), PCR mapping, RNase protection, chemical mismatch cleavage, ligase-mediated detection, and various other methods. Other methods are also provided which detect abnormal processing of CalDAG-GEF and/or cAMP-GEF or proteins reacting with CalDAG-GEF and/or cAMP-GEF, alterations in CalDAG-GEF and/or cAMP-GEF transcription, translation, and post-translational modification; alterations in the intracellular and

30 extracellular trafficking of CalDAG-GEF and/or cAMP-GEF gene products; or abnormal

intracellular localization of CalDAG-GEF and/or cAMP-GEF. Such methods and reagents are also useful in the analysis of neoplasias and mammalian immune system function, as well as functional *in vivo* imaging of mammalian organ systems. In accordance with these 5 embodiments, diagnostic kits are also provided which will include the reagents necessary for the above-described diagnostic screens.

In another series of embodiments, the present invention provides methods and therapeutic agents for use in the treatment of conditions such as neurological and neuropsychiatric disorders such as Huntington's disease, Parkinson's disease, Alzheimer's disease, dystonia, Tourette's syndrome, obsessive-compulsive disorder, attention deficit/hyperactive disorder, depression, 10 schizophrenia, and stroke; neoplasias such as solid tumors including colon, breast, lung, prostate, and hematopoietic tumors such as leukemia, Hodgkins, and non-Hodgkins lymphomas; and autoimmune diseases, allergies, and asthma; as well as for the enhancement of the immune response in normal and immunocompromised individuals. These methods and therapeutic agents may be based upon (1) administration of normal CalDAG-GEF and/or cAMP-GEF proteins; (2) 15 gene therapy with normal CalDAG-GEF and/or cAMP-GEF genes to compensate for or replace the mutant genes; (3) gene therapy based upon antisense sequences to mutant CalDAG-GEF and/or cAMP-GEF genes or upon sequences which "knock-out" the mutant genes; (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of CalDAG-GEF and/or cAMP-GEF mutants; (5) immunotherapy based upon antibodies 20 to normal and/or mutant CalDAG-GEF and/or cAMP-GEF proteins; or (6) small molecules (drugs) which alter CalDAG-GEF and/or cAMP-GEF expression, block interactions between (normal or mutant) forms of CalDAG-GEF and/or cAMP-GEF and other proteins or ligands, or which otherwise block the function of (normal or mutant) CalDAG-GEF and/or cAMP-GEF 25 proteins by altering the structure of the proteins, by enhancing their metabolic clearance, or by inhibiting their function.

In accordance with another aspect of the invention, the proteins of the invention can be used as starting points for rational drug design to provide ligands, therapeutic drugs or other types of small chemical molecules. Alternatively, small molecules or other compounds identified by the above-described screening assays may serve as "lead compounds" in rational 30 drug design.

Brief Description of the Drawings

Figure 1 is a partial schematic diagram of a Ras pathway.

Figure 2A shows human (h) and mouse (m) CalDAG-GEFI, human (h) and rat (r)

5 CalDAG-GEFII, and *C. elegans* (cel) (F25B3.3, GenBank accession number: 1262950) CalDAG-GEF. Figure 2B shows a computer-generated phylogenetic tree analysis of the GEF domains of CalDAG-GEFI and CalDAG-GEFII in relation to other Ras-superfamily GEFs. Figure 2C shows multiple alignment of GEF structurally conserved regions (SCRs) of CalDAG-GEFs and several other GEFs of the Ras superfamily. Figure 2D shows the full-length amino acid sequences of human (h) and mouse (m) CalDAG-GEFI (box indicates amino acid differences). Figure 2E shows the sequence similarity (black indicates identity) of EF-hand domains in CalDAG-GEFs and other calcium binding proteins. Figure 2F shows the sequence similarity of DAG-binding domains of CalDAG-GEFs and PKC (protein kinase C) family proteins.

15 Figure 3A is a schematic representation of cAMP-GEF family proteins, including human (h) and rat (r) cAMP-GEFI, human (h) cAMP-GEFII and *C. elegans* (cel) (T2OG5.5, GenBank accession number: 458480) cAMP-GEF. Figure 3B is a phylogenetic tree analysis of cAMP binding domains of cAMP-GEFI and II and other cyclic nucleotide binding proteins. Figure 3C is a phylogenetic tree analysis of GEF domains of cAMP-GEFI and II and other Ras superfamily GEFs. Figure 3D shows the amino acid sequences of the structurally conserved regions (SCRs) of cAMP-GEFs and other Ras superfamily GEFs (black indicates identity). Figure 3E shows the amino acid sequences of the cAMP binding pockets of cAMP-GEFI and II and other cyclic nucleotide-binding proteins. The positions of invariant amino acid residues are shown by black diamonds. The open diamond indicates the amino acid that determines the binding specificity for cAMP or cGMP. The arrow indicates the position of amino acid substitutions specific to cAMP-GEFs. Figure 3F is the full-length amino acid sequences of human cAMP-GEFI and II (boxes indicate amino acid identity).

Detailed Description of the Invention

The present invention is based, in part, upon the discovery of a family of mammalian genes which are associated with the Ras pathway. The discovery of these genes, designated CalDAG-GEFI, CalDAG-GEFII, cAMP-GEFI, and cAMP-GEFII, as well as the characterization 5 of these genes, their protein products, mutants, and possible functional roles, are described below.

I. Definitions

In order to facilitate review of the various embodiments of the invention, and an 10 understanding of the various elements and constituents used in making and using the invention, the following definitions are provided for particular terms used in the description and the claims 15 which follow:

CalDAG-GEF. As used without further modification herein, the terms "CalDAG-GEF" or "CalDAG-GEFs" refer to the CalDAG-GEFI and/or the CalDAG-GEFII genes/proteins. In 15 particular, the unmodified terms "CalDAG-GEF" or "CalDAG-GEFs" refer to the mammalian genes/proteins and, preferably, the human genes/proteins.

cAMP-GEF. As used without further modification herein, the terms "cAMP-GEF" or "cAMP-GEFs" refer to the cAMP-GEFI and/or the cAMP-GEFII genes/proteins. In particular, the unmodified terms "cAMP-GEF" or "cAMP-GEFs" refer to the mammalian genes/proteins 20 and, preferably, the human genes/proteins.

CalDAG-GEF gene. As used herein, the term "CalDAG-GEF gene" means the 25 mammalian genes represented by SEQ ID NOS: 1, 3, 5, and 7, as well as any allelic variants and heterospecific mammalian homologues. A murine CalDAG-GEFI cDNA sequence is disclosed herein as SEQ ID NO: 1, and a human CalDAG-GEFI cDNA sequence is disclosed herein as SEQ ID NO: 3. A rat CalDAG-GEFII cDNA sequence is disclosed herein as SEQ ID NO: 5, and a human CalDAG-GEFII cDNA sequence is disclosed herein as SEQ ID NO: 7. The term 30 "CalDAG-GEF gene" primarily relates to a coding sequence, but can also include some or all of the flanking regulatory regions and/or introns. The term "CalDAG-GEF gene" specifically includes artificial or recombinant genes created from cDNA or genomic DNA, including recombinant genes based upon splice variants.

CalDAG-GEF protein. As used herein, the term "CalDAG-GEF protein" means a protein encoded by a CalDAG-GEF gene, including allelic variants and heterospecific mammalian homologues. A murine CalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 2, and a human CalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 4. A rat

5 CalDAG-GEFII protein sequence is disclosed herein as SEQ ID NO: 6, and a human CalDAG-GEFII protein sequence is disclosed herein as SEQ ID NO: 8. Splice variants are also embraced by the term CalDAG-GEF protein as used herein. The protein may be produced by recombinant cells or organisms, may be substantially purified from natural tissues or cell lines, or may be synthesized chemically or enzymatically. Therefore, the term "CalDAG-GEF protein" is

10 intended to include the protein in glycosylated, partially glycosylated, or unglycosylated forms, as well as in phosphorylated, partially phosphorylated, unphosphorylated, sulphated, partially sulphated, or unsulphated forms. The term also includes allelic variants and other functional equivalents of the CalDAG-GEF amino acid sequences, including biologically active proteolytic or other fragments.

15 hCalDAG-GEF gene and/or protein. As used herein, the abbreviation "hCalDAG-GEF" refers to the human homologue and human allelic variants of the CalDAG-GEF genes and/or proteins. Two cDNA sequences of the human CalDAG-GEF genes are disclosed herein as SEQ ID NOS: 3 and 7. The corresponding hCalDAG-GEF protein sequences are disclosed herein as SEQ ID NOS: 4 and 8. Allelic variants, including deleterious mutants, are enabled in the

20 description which follows.

mCalDAG-GEF gene and/or protein. As used herein, the abbreviation "mCalDAG-GEF" refers to the murine homologues and murine allelic variants of the CalDAG-GEF gene and/or protein. A cDNA sequence of one murine CalDAG-GEF gene is disclosed herein as SEQ ID NO: 16. The corresponding mCalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 17. Allelic variants, including deleterious mutants, are enabled in the description which follows.

25 rCalDAG-GEF gene and/or protein. As used herein, the abbreviation "rCalDAG-GEF" refers to the rat homologue and rat allelic variants of the CalDAG-GEF genes and/or proteins. A cDNA sequence of one rat CalDAG-GEF gene is disclosed herein as SEQ ID NO: 5. The

corresponding rCalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 6. Allelic variants, including deleterious mutants, are enabled in the description which follows.

cAMP-GEF gene. As used herein, the term "cAMP-GEF gene" means the mammalian genes represented by SEQ ID NOS: 9, 11, 13, 15, and 17, as well as any allelic variants and heterospecific mammalian homologues. A rat cAMP-GEFI cDNA sequence is disclosed herein as SEQ ID NO: 9, and a human cAMP-GEFI cDNA sequence is disclosed as SEQ ID NO: 11.

5 Another human cAMP-GEFI cDNA sequence, resulting from alternative splicing of the mRNA transcript, is disclosed as SEQ ID NO: 13. A rat cAMP-GEFII cDNA sequence is disclosed as SEQ ID NO: 15, and a human cAMP-GEFII cDNA sequence is disclosed as SEQ ID NO: 17.

10 The term "cAMP-GEF gene" primarily relates to a coding sequence, but can also include some or all of the flanking regulatory regions and/or introns. The term cAMP-GEF gene specifically includes artificial or recombinant genes created from cDNA or genomic DNA, including recombinant genes based upon splice variants.

cAMP-GEF protein. As used herein, the term "cAMP-GEF protein" means a protein encoded by a cAMP-GEF gene, including allelic variants and heterospecific mammalian homologues. A rat cAMP-GEFI protein sequence is disclosed herein as SEQ ID NO: 10, and a human cAMP-GEFI protein sequence is disclosed as SEQ ID NO: 12. Another human cAMP-GEFI protein sequence, resulting from alternative splicing of the mRNA transcript, is disclosed as SEQ ID NO: 14. A rat cAMP-GEFII protein sequence is disclosed as SEQ ID NO: 16, and a human cAMP-GEFII protein sequence is disclosed as SEQ ID NO: 18. Splice variants are also embraced by the term cAMP-GEF protein as used herein. The protein may be produced by recombinant cells or organisms, may be substantially purified from natural tissues or cell lines, or may be synthesized chemically or enzymatically. Therefore, the term "cAMP-GEF protein" is intended to include the protein in glycosylated, partially glycosylated, or unglycosylated forms, as well as in phosphorylated, partially phosphorylated, unphosphorylated, sulphated, partially sulphated, or unsulphated forms. The term also includes allelic variants and other functional equivalents of the cAMP-GEF amino acid sequences, including biologically active proteolytic or other fragments.

hcAMP-GEF gene and/or protein. As used herein, the abbreviation "hcAMP-GEF" refers 30 to the human homologue and human allelic variants of the cAMP-GEF gene and/or protein. One

cDNA sequences of the human cAMP-GEF gene is disclosed herein as SEQ ID NO: 18. The corresponding hcAMP-GEF protein sequence is disclosed herein as SEQ ID NO: 19. Numerous allelic variants, including deleterious mutants, are disclosed and enabled throughout the description which follows.

5 rcAMP-GEF gene and/or protein. As used herein, the abbreviation "rcAMP-GEF" refers to the rat homologue and rat allelic variants of the cAMP-GEF gene and/or protein. Two cDNA sequences of rat cAMP-GEF genes are disclosed herein as SEQ ID NOS: 9 and 15. The corresponding rcAMP-GEF protein sequences are disclosed herein as SEQ ID NOS: 10 and 16.. Numerous allelic variants, including deleterious mutants, are disclosed and enabled throughout
10 the description which follows.

Normal. As used herein with respect to genes, the term "normal" refers to a gene which encodes and expresses a normal protein. As used herein with respect to proteins, the term "normal" means a protein which performs its usual or normal physiological role and which is not associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, 15 the term "normal" is essentially synonymous with the usual meaning of the phrase "wild type." For any given gene, or corresponding protein, a multiplicity of normal allelic variants may exist, none of which is associated with the development of a pathogenic condition or state. Such normal allelic variants include, but are not limited to, variants in which one or more nucleotide substitutions do not result in a change in the encoded amino acid sequence.

20 Mutant. As used herein with respect to genes, the term "mutant" refers to a gene which encodes a mutant protein and/or fails to express a normal protein. As used herein with respect to proteins, the term "mutant" means a protein which does not perform its usual or normal physiological role and which is associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "mutant" is essentially synonymous with the terms
25 "dysfunctional," "pathogenic," "disease-causing," and "deleterious." With respect to the CalDAG-GEF and cAMP-GEF genes and proteins of the present invention, the term "mutant" refers to CalDAG-GEF and cAMP-GEF genes/proteins bearing one or more nucleotide/amino acid substitutions, insertions and/or deletions which cause the genes/proteins to be dysfunctional, pathogenic, disease-causing or otherwise deleterious. This definition is understood to include the
30 various mutations that naturally exist, including but not limited to those disclosed herein, as well

as synthetic or recombinant mutations produced by human intervention. The term "mutant," as applied to the CalDAG-GEF and cAMP-GEF genes, is not intended to embrace sequence variants which, due to the degeneracy of the genetic code, encode proteins identical to the normal sequences disclosed or otherwise enabled herein; nor is it intended to embrace sequence variants which, although they encode different proteins, encode proteins which are functionally equivalent to normal CalDAG-GEF and/or cAMP-GEF proteins.

Functional equivalent. As used herein in describing gene sequences and amino acid sequences, the term "functional equivalent" means that a recited sequence need not be identical to a particularly disclosed sequence of the SEQ ID NOs but need only provide a sequence which 10 functions biologically and/or chemically as the equivalent of the disclosed sequence.

Substantially pure. As used herein with respect to protein preparations, the term "substantially pure" means a preparation which contains at least 60% (by dry weight) the protein of interest, exclusive of the weight of other intentionally included compounds. Preferably the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by 15 dry weight the protein of interest, exclusive of the weight of other intentionally included compounds. Purity can be measured by any appropriate method, e.g., column chromatography, gel electrophoresis, or HPLC analysis. If a preparation intentionally includes two or more different proteins of the invention, a "substantially pure" preparation means a preparation in which the total dry weight of the proteins of the invention is at least 60% of the total dry weight, exclusive of the weight of other intentionally included compounds. Preferably, for such 20 preparations containing two or more proteins of the invention, the total weight of the proteins of the invention be at least 75%, more preferably at least 90%, and most preferably at least 99%, of the total dry weight of the preparation, exclusive of the weight of other intentionally included compounds. Thus, if the proteins of the invention are mixed with one or more other proteins 25 (e.g., serum albumin, 6-OST) or compounds (e.g., diluents, detergents, excipients, salts, polysaccharides, sugars, lipids) for purposes of administration, stability, storage, and the like, the weight of such other proteins or compounds is ignored in the calculation of the purity of the preparation.

Isolated nucleic acid. As used herein, an "isolated nucleic acid" is a ribonucleic acid, 30 deoxyribonucleic acid, or nucleic acid analog comprising a polynucleotide sequence that has

been isolated or separated from sequences that are immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived.

The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a

5 prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences and/or including exogenous regulatory elements.

Transformed cell. As used herein, a "transformed cell" is a cell into which (or into an

10 ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule of interest. The nucleic acid of interest will typically encode a peptide or protein. The transformed cell may express the sequence of interest or may be used only to propagate the sequence. The term "transformed" may be used herein to embrace any method of introducing exogenous nucleic acids including, but not limited to, transformation, transfection, 15 electroporation, microinjection, viral-mediated transfection, and the like.

Operably joined. As used herein, a coding sequence and a regulatory region are said to be "operably joined" when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory region. If it

20 is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of promoter function results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the regulatory region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory region would be 25 operably joined to a coding sequence if the regulatory region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

Stringent hybridization conditions. Stringent hybridization conditions is a term of art understood by those of ordinary skill in the art. For any given nucleic acid sequence, stringent

30 hybridization conditions are those conditions of temperature, chaotropic acids, buffer, and ionic

strength which will permit hybridization of that nucleic acid sequence to its complementary sequence and not to substantially different sequences. The exact conditions which constitute "stringent" conditions, depend upon the nature of the nucleic acid sequence, the length of the sequence, and the frequency of occurrence of subsets of that sequence within other non-identical sequences. By varying hybridization conditions from a level of stringency at which non-specific hybridization occurs to a level at which only specific hybridization is observed, one of ordinary skill in the art can, without undue experimentation, determine conditions which will allow a given sequence to hybridize only with complementary sequences. Suitable ranges of such stringency conditions are described in KRAUSE ET AL., METHODS IN ENZYMOLOGY, 200: 546-56 (1991). Stringent hybridization conditions, depending upon the length and commonality of a sequence, may include temperatures of 20°C-65°C and ionic strengths from 5x to 0.1x SSC. Highly stringent hybridization conditions may include temperatures as low as 40-42°C (when denaturants such as formamide are included) or up to 60-65°C in ionic strengths as low as 0.1x SSC. These ranges, however, are only illustrative and, depending upon the nature of the target sequence, and possible future technological developments, may be more stringent than necessary. Less than stringent conditions are employed to isolate nucleic acid sequences which are substantially similar, allelic or homologous to any given sequence.

Selectively bind. As used herein with respect to antibodies, an antibody is said to "selectively bind" to a target if the antibody recognizes and binds the target of interest but does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, which includes the target of interest.

CalDAG-GEF- or cAMP-GEF-associated disorder, condition, or disease. As used herein, the term "CalDAG-GEF or cAMP-GEF associated disorder, condition, or disease" means any disorder, condition, or disease to which a normal or mutant CalDAG-GEF and/or cAMP-GEF is related in any manner, such as in the causation, prevention, exacerbation, alleviation of the disorder. Thus, as used herein, a CalDAG-GEF- or cAMP-GEF-associated disorder, condition, or disease includes disorders related to the Ras-pathway, such as Ras-related cancers.

Adapter protein. As used herein, the term "adapter protein" means any protein that binds or is bound to a CalDAG-GEF or a cAMP-GEF protein, and facilitates localization of the bound CalDAG-GEF or cAMP-GEF at the plasma membrane, thereby facilitating Ras activation.

Variant. As used herein a “variant” sequence has, or will result in having, a sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention. In order to produce variants of the disclosed sequences that may also functionally serve as a CalDAG-GEF or cAMP-GEF protein, any one or more of the naturally-occurring

5 CalDAG-GEF or cAMP-GEF sequences disclosed herein may be used as a reference sequence to determine whether a candidate sequence possesses sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention. Preferably, variant sequences are at least 70% similar or 60% identical, more preferably at least 75% similar or 65% identical, and most preferably 80% similar or 70% identical to one of the disclosed, naturally-
10 occurring sequences.

To determine whether a candidate peptide region has the requisite percentage similarity or identity to a reference polypeptide or peptide oligomer, the candidate amino acid sequence and the reference amino acid sequence are first aligned using the dynamic programming algorithm described in Smith and Waterman (1981), J. Mol. Biol. 147:195-197, in combination with the

15 BLOSUM62 substitution matrix described in Figure 2 of Henikoff and Henikoff (1992), “Amino acid substitution matrices from protein blocks”, PNAS (1992 Nov), 89:10915-10919. For the present invention, an appropriate value for the gap insertion penalty is -12, and an appropriate value for the gap extension penalty is -4. Computer programs performing alignments using the algorithm of Smith-Waterman and the BLOSUM62 matrix, such as the GCG program suite
20 (Oxford Molecular Group, Oxford, England), are commercially available and widely used by those skilled in the art.

Once the alignment between the candidate and reference sequence is made, a percent similarity score may be calculated. The individual amino acids of each sequence are compared sequentially according to their similarity to each other. If the value in the BLOSUM62 matrix
25 corresponding to the two aligned amino acids is zero or a negative number, the pairwise similarity score is zero; otherwise the pairwise similarity score is 1.0. The raw similarity score is the sum of the pairwise similarity scores of the aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent similarity. Alternatively, to
30 calculate a percent identity, the aligned amino acids of each sequence are again compared

sequentially. If the amino acids are non-identical, the pairwise identity score is zero; otherwise the pairwise identity score is 1.0. The raw identity score is the sum of the identical aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent 5 identity. Insertions and deletions are ignored for the purposes of calculating percent similarity and identity. Accordingly, gap penalties are not used in this calculation, although they are used in the initial alignment.

In all instances, variants of the naturally-occurring CalDAG-GEF or cAMP-GEF proteins, as described above, must be tested for biological activity as described below. 10 Specifically, the proteins must exhibit guanine nucleotide exchange factor activity, and, preferably, they have the ability to inhibit Ras signaling of the Ras/Raf-1/MAP kinase pathway.

II. The CalDAG-GEFs

CalDAG-GEFI has a substrate specificity for Rap1A, dual binding domains for calcium 15 (Ca^{2+}) and diacylglycerol (DAG), and enriched expression in brain basal ganglia pathways and their axon-terminal regions. Expression of CalDAG-GEFI activates Rap1A and inhibits Ras-dependent activation of the Erk/MAP kinase cascade in 293T cells. Ca^{2+} ionophore and phorbol ester strongly and additively enhance this Rap1A activation. By contrast, CalDAG-GEFII exhibits a different brain expression pattern and fails to activate Rap1A, but activates H-Ras, R- 20 Ras and the Erk/MAP kinase cascade under Ca^{2+} and DAG modulation. The CalDAG-GEF proteins have a critical neuronal function in determining the relative activation of Ras and Rap1 signaling induced by Ca^{2+} and DAG mobilization. The expression of CalDAG-GEFI and CalDAG-GEFII in hematopoietic organs indicates that such control has broad significance in Ras/Rap regulation of normal and malignant states.

25 The basal ganglia are centrally implicated in movement control and in forms of procedural learning related to habit formation. It is not yet known whether particular neurochemical specializations of the basal ganglia contribute to these behavioral functions. The basal ganglia do, however, have a unique double-inhibitory pathway design combined with abundant expression of neuromodulators in striatal neurons. A number of genes with 30 differentially high expression in the striatum have also been identified. These include genes

coding for proteins with signaling functions, such as adenylate cyclase V (Glatt et al., 361 NATURE (LONDON), 536-38 (1993)) and DARPP-32 (Hemmings et al., 310 NATURE (LONDON) 502-05 (1984)). To identify other cellular signaling molecules that could contribute to basal ganglia functions, a search for striatum-enriched transcripts was performed by a differential 5 display method, as discussed in Example 1. Among the transcripts identified in this search were a family of genes characterized by the presence of a Ras superfamily (GEF) domain.

Specific domains identified include structurally conserved GEF regions SCR1, SCR2, and SCR3, as shown in Figures 2C and 3D, and as shown in the following table.

TABLE 1

Gene	SCR1	SCR2	SCR3
hCalDAG-GEFI	SEQ ID NO.3: 605-677 SEQ ID NO.4: 149-173	SEQ ID NO.3: 817-946 SEQ ID NO.4: 219-262	SEQ ID NO.3: 1053-1185 SEQ ID NO.4: 298-320
hCalDAG-GEFII	SEQ ID NO.7: 728-800 SEQ ID NO.8: 205-229	SEQ ID NO.7: 913-1042 SEQ ID NO.8: 270-313	SEQ ID NO.7: 1084-1216 SEQ ID NO.8: 348-371
hcAMP-GEFI	SEQ ID NO.11: 2058-2130 SEQ ID NO.12: 205-229	SEQ ID NO.11: 2276-2405 SEQ ID NO.12: 688-731	SEQ ID NO.11: 2516-2582 SEQ ID NO.12: 767-789
rcAMP-GEFI	SEQ ID NO.9: 2050-2122 SEQ ID NO.10: 618-642	SEQ ID NO.9: 2267-2396 SEQ ID NO.10: 691-734	SEQ ID NO.9: 2502-2568 SEQ ID NO.10: 770-792
hcAMP-GEFII	SEQ ID NO.17: 2707-2779 SEQ ID NO.18: 767-791		
rcAMP-GEFII	SEQ ID NO.15: 576-648 SEQ ID NO.16: 192-216		

In addition, the EF hand and DAG-binding domains were identified as shown in Figures 2E and 2F, and as shown in the following table:

Table 2

Gene	EF Hand Domain	DAG-Binding Domain
hCalDaG-GEFI	SEQ ID NO.3: 1456-1516 SEQ ID NO.4: 432-452	SEQ ID NO.3: 1652-1804 SEQ ID NO.4: 498-548
hCalDAG-GEFII	SEQ ID NO.7: 1384-1444 SEQ ID NO.8: 427-447	SEQ ID NO.7: 1579-1729 SEQ ID NO.8: 492-542

5

Finally, the cAMP-binding domains were identified as shown in Figure 3E, and as shown in the following table:

Table 3

Gene	cAMP-Binding Domain
hcAMP-GEFI	SEQ ID NO.11: 2012-2255 SEQ ID NO.12: 219-300
rcAMP-GEFI	SEQ ID NO.9: 853-1096 SEQ ID NO.10: 219-300
rcAMP-GEFII	SEQ ID NO.17: 1522-1765 SEQ ID NO.18: 372-453

III. The cAMP-GEFs

Cyclic adenosine 3', 5'-monophosphate (cAMP) is a universal second messenger that induces a variety of physiological responses in eukaryotic cells ranging from growth, differentiation, and gene expression to secretion and neurotransmission. The cAMP second messenger system has also been centrally implicated in modulating synaptic function, neuroplasticity and learning and memory. Most of these effects have been attributed to the binding of cAMP to cAMP-dependent protein kinase (PKA), leading in turn to the activation of intracellular phosphorylation cascades. Reported herein is the identification of a new family of cAMP binding proteins that are differentially distributed in the brain and body organs and that are characterized by the presence of both a cAMP binding domain and a guanine nucleotide exchange factor (GEF) domain. These proteins, cAMP-GEFs, bind cAMP and selectively activate the Ras superfamily small G protein, Rap1A, in a cAMP-dependent but PKA-independent manner.

The general concept of cAMP signaling involves the sequential activation (or inhibition) of cAMP production by G proteins, the binding of cAMP to PKA, and the triggering of a series of downstream serine-threonine phosphorylation cascades. Viewed as the nearly exclusive target of cAMP binding in eukaryotic cells, PKA has been considered the essential effector molecule mediating a wide range of physiological effects of G protein/cAMP-triggered phosphorylation cascades. As the main cAMP effector, PKA has also been shown to function in the indirect coupling of the cAMP signal transduction system to other intracellular signaling cascades. The cAMP signaling system has also been strongly implicated in neuronal functions ranging from neurotransmitter-initiated signaling to neuroplasticity underlying development and memory, but PKA has not been clearly linked to all of these neuronal functions, and region-specific neuronal effects have been observed as well. The cAMP-GEF gene has a Ras superfamily GEF motif. Thus, the gene codes for a novel cAMP binding protein that directly couples the cAMP signal transduction system to Ras superfamily cascades.

IV. Preferred Embodiments

Based, in part, upon the discoveries disclosed and described herein, the following preferred embodiments of the present invention are provided.

1. Isolated Nucleic Acids

In one series of embodiments, the present invention provides isolated nucleic acids corresponding to, or relating to, the CalDAG-GEF or cAMP-GEF nucleic acid sequences disclosed herein. As described more fully below, these sequences include normal CalDAG-GEF and cAMP-GEF sequences from humans and other mammalian species, mutant CalDAG-GEF and cAMP-GEF sequences from humans and other mammalian species, homologous sequences from non-mammalian species such as *Drosophila* and *C. elegans*, subsets of these sequences useful as probes and PCR primers, subsets of these sequences encoding fragments of the CalDAG-GEF or cAMP-GEF proteins or corresponding to particular domains or polymorphic regions, complementary or antisense sequences corresponding to fragments of the CalDAG-GEF or cAMP-GEF genes, sequences in which the CalDAG-GEF and/or cAMP-GEF coding regions have been operably joined to exogenous regulatory regions, and sequences encoding fusion proteins of the portions of the CalDAG-GEF or cAMP-GEF proteins fused to other proteins useful as markers of expression, as "tags" for purification, or in screens and assays for proteins interacting with the CalDAG-GEFs and/or cAMP-GEFs.

Thus, in a first series of embodiments, isolated nucleic acid sequences are provided which encode normal versions of the CalDAG-GEF and cAMP-GEF proteins. Examples of such nucleic acid sequences are disclosed herein. These nucleic acids may be genomic sequences or may be cDNA sequences (e.g., SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17). Thus, for example, the invention provides nucleic acid sequences in which the alternative splice variants described herein are incorporated at the DNA level, thereby, enabling cells including these sequences to express only one of the alternative splice variants at each splice position. For example, a recombinant gene may be produced in which one of the splice variants of cAMP-GEF is incorporated into DNA such that cells having this recombinant gene can express only one of these variants. For purposes of reducing the size of a recombinant CalDAG-GEF or cAMP-GEF gene, a cDNA gene may be employed or various combinations of the introns and untranslated exons may be removed from a DNA construct. Such constructs may be particularly useful, as described below, in identifying compounds which can induce or repress the expression of the CalDAG-GEF or cAMP-GEF genes.

In addition to the disclosed CalDAG-GEF and/or cAMP-GEF sequences, one of ordinary skill in the art is now enabled to identify and isolate nucleic acids corresponding to CalDAG-GEF or cAMP-GEF genes or cDNAs which are allelic to the disclosed sequences or which are heterospecific homologues. Thus, the present invention provides isolated nucleic acids

5 corresponding to these alleles and homologues, as well as various recombinant constructs derived from these sequences, by means which are well known in the art. Briefly, one of ordinary skill in the art may now screen preparations of genomic or cDNA, including samples prepared from individual organisms (e.g., human cancer patients or their family members) as well as bacterial, viral, yeast or other libraries of genomic or cDNA, using probes or PCR

10 primers to identify allelic or homologous sequences. Because it is desirable to identify additional CalDAG-GEF and/or cAMP-GEF gene mutations which may contribute to the development of Ras-related cancers, because it is desirable to identify additional CalDAG-GEF and/or cAMP-GEF polymorphisms which are not mutant or have antitumorigenic effects, and because it is also desired to create a variety of animal models which may be used to study Ras-related cancers and

15 screen for potential therapeutics, it is particularly contemplated that additional CalDAG-GEF and/or cAMP-GEF sequences will be isolated from other preparations or libraries of human nucleic acids and from preparations or libraries from animals including rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. Furthermore, CalDAG-GEF and/or cAMP-GEF homologues from yeast or invertebrate species, including *C. elegans* and other nematodes, as well as *Drosophila* and other insects, may have particular utility for drug screening. For example, invertebrates bearing mutant CalDAG-GEF and/or cAMP-GEF homologues (or mammalian CalDAG-GEF and/or cAMP-GEF transgenes) which cause a rapidly occurring and easily scored phenotype (e.g., abnormal eye development after several days) can be used as screens for drugs which block the effect of the mutant gene. Such invertebrates may

20 prove far more rapid and efficient for mass screenings than larger vertebrate animals. Once lead compounds are found through such screens, they may be tested in higher animals.

25

Depending upon the intended use, the present invention provides nucleic acid subsequences of the CalDAG-GEF and/or cAMP-GEF genes which may have lengths varying from 8-10 nucleotides (e.g., for use as PCR primers) to nearly the full size of the CalDAG-GEF and/or cAMP-GEF genes. Thus, the present invention provides isolated nucleic acids

30

comprising sequences corresponding to at least 8, preferably at least 10, and more preferably at least 15 consecutive, nucleotides of the CalDAG-GEF and/or cAMP-GEF genes, as disclosed or otherwise enabled herein, or to their complements.

In another series of embodiments, the present invention provides for isolated nucleic acids encoding all or a portion of the CalDAG-GEF and/or cAMP-GEF proteins in the form of a fusion protein. In these embodiments, a nucleic acid regulatory region (endogenous or exogenous) is operably joined to a first coding region which is covalently joined in-frame to a second coding region. The CalDAG-GEF and/or cAMP-GEF sequences of the fusion protein may represent the first, second, or any additional coding regions. The CalDAG-GEF and/or cAMP-GEF sequences may be conserved or non-conserved domains and can be placed in any coding region for the fusion protein.

In another series of embodiments, the present invention provides isolated nucleic acids in the form of recombinant DNA constructs in which a marker or reporter gene (e.g., β -galactosidase, luciferase) is operably joined to the 5' regulatory region of a CalDAG-GEF and/or cAMP-GEF gene such that expression of the marker gene is under the control of the CalDAG-GEF and/or cAMP-GEF regulatory sequences. Such isolated nucleic acids may be used to produce cells, cell lines or transgenic animals which are useful in the identification of compounds which can, directly or indirectly, differentially affect the expression of the CalDAG-GEFs and/or cAMP-GEFs.

Finally, the isolated nucleic acids of the present invention include any of the above described sequences when included in vectors. Appropriate vectors include cloning vectors and expression vectors of all types, including plasmids, phagemids, cosmids, episomes, and the like, as well as integration vectors. The vectors may also include various marker genes (e.g., antibiotic resistance or susceptibility genes) which are useful in identifying cells successfully transformed therewith. In addition, the vectors may include regulatory sequences to which the nucleic acids of the invention are operably joined, and/or may also include coding regions such that the nucleic acids of the invention, when appropriately ligated into the vector, are expressed as fusion proteins. Such vectors may also include vectors for use in yeast "two hybrid," baculovirus, and phage-display systems.

2. Substantially Pure Proteins

The present invention provides for substantially pure preparations of the CalDAG-GEF and/or cAMP-GEF proteins, fragments of the CalDAG-GEF and/or cAMP-GEF proteins, and fusion proteins including the CalDAG-GEFs and/or cAMP-GEFs or fragments thereof. The 5 proteins, fragments and fusions have utility, as described herein, in the generation of antibodies to normal and mutant CalDAG-GEFs and/or cAMP-GEFs, in the identification of CalDAG-GEF and/or cAMP-GEF binding proteins, and in diagnostic and therapeutic methods. Therefore, depending upon the intended use, the present invention provides substantially pure proteins or peptides comprising amino acid sequences which are subsequences of the complete CalDAG- 10 GEF and/or cAMP-GEF proteins and which may have lengths varying from 4-8 amino acids (e.g., for use as immunogens), or 9-15 amino acids (e.g., for use in binding assays), to the complete CalDAG-GEF and/or cAMP-GEF proteins. Thus, the present invention provides substantially pure proteins or peptides comprising sequences corresponding to at least 4, preferably at least 9, more preferably at least 15 consecutive amino acids of the CalDAG-GEF 15 and/or cAMP-GEF proteins, as disclosed or otherwise enabled herein.

Purification can be achieved using standard protein purification procedures including, but not limited to, gel-filtration chromatography, ion-exchange chromatography, high-performance liquid chromatography (RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing chromatography, hydrophobic interaction chromatography, 20 immunoprecipitation, or immunoaffinity purification. Gel electrophoresis (e.g., PAGE, SDS-PAGE) can also be used to isolate a protein or peptide based on its molecular weight, charge properties, and hydrophobicity.

A CalDAG-GEF or cAMP-GEF protein, or a fragment thereof, may also be conveniently purified by creating a fusion protein including the desired CalDAG-GEF or cAMP-GEF 25 sequence fused to another peptide such as an antigenic determinant or poly-His tag (e.g., QIAexpress vectors, (QIAGEN Corp., Chatsworth, CA)), or a larger protein (e.g., GST using the pGEX-27 vector (Amrad, USA) or green fluorescent protein using the Green Lantern vector (GIBCO/BRL. Gaithersburg, MD)).

3. Antibodies to the CalDAG-GEF and/or cAMP-GEFs

The present invention also provides antibodies, and methods of making antibodies, which selectively bind to the CalDAG-GEF and/or cAMP-GEF proteins or fragments thereof. The antibodies of the invention have utility as laboratory reagents for, *inter alia*, immunoaffinity 5 purification of the CalDAG-GEFs and/or cAMP-GEFs, Western blotting to identify cells or tissues expressing the CalDAG-GEFs and/or cAMP-GEFs, and immunocytochemistry or immunofluorescence techniques to establish the subcellular location of the protein.

The antibodies of the invention may be generated in a host using the entire CalDAG-GEF and/or cAMP-GEF proteins of the invention or using any CalDAG-GEF and/or cAMP-GEF 10 epitope which is characteristic of that protein and which substantially distinguishes it from host proteins. Such epitopes may be identified by comparing sequences of, for example, 4-8 amino acid residues from a CalDAG-GEF and/or cAMP-GEF sequence to computer databases of protein sequences from the relevant host. Antibodies against highly conserved domains are expected to have the greatest utility for purification or identification of CalDAG-GEFs and/or 15 cAMP-GEFs.

Amino acid residue positions which are potential antigenic sites in the CalDAG-GEF or cAMP-GEF proteins and which may be useful in generating the antibodies of the invention may be determined by using computer programs such as the IBI Pustell program. Other methods of choosing antigenic determinants are known in the art and may, of course, be employed. In 20 addition, larger fragments (*e.g.* 9-15 residues) including some of these epitopes may also be employed. Even larger fragments, including, for example, entire functional domains or multiple functional domains may also be preferred. For an overview of antibody techniques, see Antibody Engineering: A Practical Guide, Borrebaek, ed., W.H. Freeman & Company, NY 25 (1992), or Antibody Engineering, 2nd Ed., Borrebaek, ed., Oxford University Press, Oxford (1995).

The antibodies of the invention may be labelled or conjugated with other compounds or materials for diagnostic and/or therapeutic uses. For example, they may be coupled to radionuclides, fluorescent compounds, or enzymes for imaging or therapy, or to liposomes for the targeting of compounds contained in the liposomes to a specific tissue location.

4. Transformed Cell Lines

The present invention also provides for cells or cell lines, both prokaryotic and eukaryotic, which have been transformed or transfected with the nucleic acids of the present invention so as to cause clonal propagation of those nucleic acids and/or expression of the 5 proteins or peptides encoded thereby. Such cells or cell lines will have utility not only in the propagation and production of the nucleic acids and proteins of the present invention but also, as further described herein, as model systems for diagnostic and therapeutic assays. As used herein, the term "transformed cell" is intended to embrace any cell, or the descendant of any cell, into which has been introduced any of the nucleic acids of the invention, whether by transformation, 10 transfection, infection, electroporation, microinjection or other means. Methods of producing appropriate vectors, transforming cells with those vectors, and identifying transformants are well known in the art and are only briefly reviewed here (see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

15 Vectors may be introduced into the recipient or "host" cells by various methods well known in the art including, but not limited to, calcium phosphate transfection, strontium phosphate transfection, DEAE dextran transfection, electroporation, lipofection (*e.g.*, Dosper Liposomal transfection reagent, Boehringer Mannheim, Germany), microinjection, ballistic insertion on micro-beads, protoplast fusion or, for viral or phage vectors, by infection with the 20 recombinant virus or phage.

5. Transgenic Animal Models

The present invention also provides for the production of transgenic non-human animal models for the study of Ras-related cancers, for the screening of candidate pharmaceutical 25 compounds, for the creation of explanted mammalian cell cultures (*e.g.*, neuronal, glial, organotypic or mixed cell cultures) in which mutant or wild type CalDAG-GEF and/or cAMP-GEF sequences are expressed or in which the CalDAG-GEF and/or cAMP-GEF genes have been inactivated (*e.g.*, "knock-out" deletions), and for the evaluation of potential therapeutic interventions.

Species suitable for use as animal models in the present invention include, but are not limited to, rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates (e.g., Rhesus monkeys, chimpanzees).

Various techniques for generating transgenic animals, as well as techniques for 5 homologous recombination or gene targeting, are now widely accepted and practiced. See, for example, Hogan et al., *Manipulating Mouse Embryo* (1986). To create a transgene, the target sequence of interest (e.g., mutant or wild-type CalDAG-GEF or cAMP-GEF sequences) is typically ligated into a cloning site located downstream of a promoter element which will regulate the expression of RNA from the CalDAG-GEF or cAMP-GEF sequence. An alternate 10 approach to creating a transgene is to use endogenous CalDAG-GEF or cAMP-GEF regulatory sequences to drive expression of the CalDAG-GEF or cAMP-GEF transgene.

6. Assays for Drugs Which Affect CalDAG-GEF and/or cAMP-GEF Expression

In another series of embodiments, the present invention provides assays for identifying 15 small molecules or other compounds which are capable of inducing or inhibiting the expression of the CalDAG-GEF or cAMP-GEF genes and proteins. The assays may be performed *in vitro* using non-transformed cells, immortalized cell lines, or recombinant cell lines, or *in vivo* using the transgenic animal models enabled herein.

In particular, the assays may detect the presence of increased or decreased expression of 20 CalDAG-GEF, cAMP-GEF, or other CalDAG-GEF or cAMP-GEF-related genes or proteins, on the basis of increased or decreased mRNA expression (using, e.g., the nucleic acid probes disclosed and enabled herein), increased or decreased levels of CalDAG-GEF, cAMP-GEF or other CalDAG-GEF or cAMP-GEF-related protein products (using, e.g., the anti-CalDAG-GEF or anti-cAMP-GEF antibodies disclosed and enabled herein), or increased or decreased levels of 25 expression of a marker gene (e.g., β -galactosidase or luciferase) operably joined to a CalDAG-GEF or cAMP-GEF 5' regulatory region in a recombinant construct.

Thus, for example, one may culture cells known to express a particular CalDAG-GEF or cAMP-GEF and add to the culture medium one or more test compounds. After allowing a sufficient period of time (e.g., 0-72 hours) for the compound to induce or inhibit the expression 30 of the CalDAG-GEF or cAMP-GEF, any change in levels of expression from an established

baseline may be detected using any of the techniques described above and well known in the art. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line. Using the nucleic acid probes and/or antibodies disclosed and enabled herein, detection of changes in the expression of a

5 CalDAG-GEF or cAMP-GEF and thus, identification of the compound as an inducer or repressor of CalDAG-GEF and/or cAMP-GEF expression, requires only routine experimentation.

In particularly preferred embodiments, a recombinant assay is employed in which a reporter gene such a β -galactosidase, green fluorescent protein, alkaline phosphatase, or luciferase is operably joined to a 5' regulatory region of a CalDAG-GEF or cAMP-GEF gene.

10 The reporter gene and regulatory regions are joined in-frame (or in each of the three possible reading frames) so that transcription and translation of the reporter gene may proceed under the control of the CalDAG-GEF or cAMP-GEF regulatory elements. The recombinant construct may then be introduced into any appropriate cell type, although mammalian cells are preferred, and human cells are most preferred. The transformed cells may be grown in culture and, after 15 establishing the baseline level of expression of the reporter gene, test compounds may be added to the medium. The ease of detection of the expression of the reporter gene provides for a rapid, high through-put assay for the identification of inducers and repressors of the CalDAG-GEF or cAMP-GEF gene.

20 Compounds identified by this method will have potential utility in modifying the expression of the CalDAG-GEF, cAMP-GEF or other CalDAG-GEF or cAMP-GEF-related genes *in vivo*. These compounds may be further tested in the animal models disclosed and enabled herein to identify those compounds having the most potent *in vivo* effects. In addition, as described herein with respect to small molecules having CalDAG-GEF or cAMP-GEF-binding activity, these molecules may serve as "lead compounds" for the further development of 25 pharmaceuticals by, for example, subjecting the compounds to sequential modifications, molecular modeling, and other routine procedures employed in rational drug design.

7. Identification of Compounds with CalDAG-GEF and/or cAMP-GEF Binding Capacity

In light of the present disclosure, one of ordinary skill in the art is enabled to practice new 30 screening methodologies which will be useful in the identification of proteins and other

compounds which bind to, or otherwise directly interact with, the CalDAG-GEFs or cAMP-GEFs. The proteins and compounds will include endogenous cellular components which interact with the CalDAG-GEFs or cAMP-GEFs *in vivo* and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous compounds which may have CalDAG-GEF or cAMP-GEF binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one series of embodiments, cell lysates or tissue homogenates (e.g., human brain homogenates, leukocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant CalDAG-GEFs and/or cAMP-GEFs. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), may be screened for CalDAG-GEF or cAMP-GEF binding capacity. Small molecules are particularly preferred in this context because they are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the blood brain barrier than larger molecules such as nucleic acids or proteins. The methods of the present invention are particularly useful in that they may be used to identify molecules which selectively or preferentially bind to a mutant form of a CalDAG-GEF or cAMP-GEF protein (rather than a normal form) and, therefore, may have particular utility in treating the heterozygous victims of a CalDAG-GEF or cAMP-GEF associated disorder.

Compounds which bind to normal, mutant or both forms of the CalDAG-GEFs or cAMP-GEFs may have utility in treatments and diagnostics. Compounds which bind only to a normal CalDAG-GEF or cAMP-GEF may, for example, act as enhancers of its normal activity and thereby at least partially compensate for the lost or abnormal activity of mutant forms of the CalDAG-GEF or cAMP-GEF in victims suffering from CalDAG-GEF- or cAMP-GEF-associated disorders. Compounds which bind to both normal and mutant forms of a CalDAG-GEF or cAMP-GEF may have utility if they differentially affect the activities of the two forms so as to alleviate the overall departure from normal function. Alternatively, blocking the activity of both normal and mutant forms of either CalDAG-GEF or cAMP-GEF may have less severe physiological and clinical consequences than the normal progress of the disorder and, therefore, compounds which bind to and inhibit the activity of both normal and mutant forms of a CalDAG-GEF or cAMP-GEF may be therapeutically useful. Preferably, however, compounds

are identified which have a higher affinity of binding to mutant CalDAG-GEF or cAMP-GEF than to normal CalDAG-GEF or cAMP-GEF, and which selectively or preferentially inhibit the activity of the mutant form. Such compounds may be identified by using any of the techniques described herein, and then comparing the binding affinities of the candidate compound(s) for the

5 normal and mutant forms of CalDAG-GEF or cAMP-GEF.

The effect of agents which bind to the CalDAG-GEFs or cAMP-GEFs (normal or mutant forms of either) can be monitored either by direct monitoring of this binding (*e.g.*, using the BIACore assay, LKB Pharmacia, Sweden) or by indirect monitoring of binding by detecting, for example, a change in fluorescence, molecular weight, or concentration of either the binding agent

10 or CalDAG-GEF or cAMP-GEF component, either in a soluble phase or in a substrate-bound phase.

Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (*e.g.*, μ g or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (*see, e.g.*,

15 REMINGTON'S PHARMACEUTICAL SCIENCES, Gennaro, A., ed., Mack Pub., (1990)). These candidate compounds may then be administered to the transformed cells of the invention, to the transgenic animal models of the invention, to cell lines derived from the animal models or from human patients, or to patients with CalDAG-GEF- or cAMP-GEF-associated disorders. The animal models described and enabled herein are of particular utility in further testing candidate

20 compounds which bind to normal or mutant CalDAG-GEF or cAMP-GEF for their therapeutic efficacy.

In addition, once identified by the methods described above, the candidate compounds may also serve as "lead compounds" in the design and development of new pharmaceuticals. For example, as is well known in the art, sequential modification of small molecules (*e.g.*, amino acid residue replacement for peptides; functional group replacement for peptide or non-peptide compounds) is a standard approach in the pharmaceutical industry for the development of new pharmaceuticals. Such development generally proceeds from a "lead compound" which is shown to have at least some of the activity (*e.g.*, CalDAG-GEF or cAMP-GEF binding or blocking ability) of the desired pharmaceutical. In particular, when one or more compounds having at

30 least some activity of interest (*e.g.*, modulation of CalDAG-GEF or cAMP-GEF activity) are

identified, structural comparison of the molecules can greatly inform the skilled practitioner by suggesting portions of the lead compounds which should be conserved and portions which may be varied in the design of new candidate compounds. Thus, the present invention also provides a means of identifying lead compounds which may be sequentially modified to produce new 5 candidate compounds for use in the treatment of CalDAG-GEF- or cAMP-GEF-associated disorders. These new compounds then may be tested both for CalDAG-GEF or cAMP-GEF- binding or blocking (e.g., in the binding assays described above) and for therapeutic efficacy (e.g., in the animal models described herein). This procedure may be iterated until compounds having the desired therapeutic activity and/or efficacy are identified.

10 In each of the present series of embodiments, an assay is conducted to detect binding between a “CalDAG-GEF component” or a “cAMP-GEF component” and some other moiety. Of particular utility will be sequential assays in which compounds are tested for the ability to bind to only the normal or only the mutant forms of the CalDAG-GEF or cAMP-GEF functional domains using mutant and normal CalDAG-GEF or cAMP-GEF components in the binding 15 assays. Such compounds are expected to have the greatest therapeutic utilities, as described more fully below. The “CalDAG-GEF component” or the “cAMP-GEF component” in these assays may be a complete normal or mutant form of a CalDAG-GEF or cAMP-GEF protein (e.g., an hCalDAG-GEF or hcAMP-GEF variant) but need not be, or a specific domain of a CalDAG-GEF or cAMP-GEF.. Rather, particular functional domains of the CalDAG-GEFs or cAMP- 20 GEFs, as described above, may be employed either as separate molecules or as part of a fusion protein. For example, to isolate proteins or compounds that interact with these functional domains, screening may be carried out using fusion constructs and/or synthetic peptides corresponding to these regions. Obviously, various combinations of fusion proteins and functional domains from CalDAG-GEF or cAMP-GEF are possible. In addition, the functional 25 domains may be altered so as to aid in the assay by, for example, introducing into the functional domain a reactive group or amino acid residue (e.g., cysteine) which will facilitate immobilization of the domain on a substrate (e.g., using sulphhydryl reactions).

Methods for screening cellular lysates, tissue homogenates, or small molecule libraries for candidate CalDAG-GEF or cAMP-GEF-binding molecules are well known in the art and, in 30 light of the present disclosure, may now be employed to identify compounds which bind to

normal or mutant CalDAG-GEF or cAMP-GEF components or which modulate CalDAG-GEF or cAMP-GEF activity as defined by non-specific measures (*e.g.*, changes in intracellular Ca^{2+} , GTP/GDP ratio) or by specific measures (*e.g.*, changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential

5 hybridization, or SAGE methods). The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of CalDAG-GEF or cAMP-GEF components and bound proteins or other compounds by immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems. These and others are discussed separately below.

10 **A. Affinity Chromatography**

In light of the present disclosure, a variety of affinity binding techniques well known in the art may be employed to isolate proteins or other compounds which bind to the CalDAG-GEFs or cAMP-GEFs disclosed or otherwise enabled herein. In general, a CalDAG-GEF or cAMP-GEF component may be immobilized on a substrate (*e.g.*, a column or filter) and a 15 solution including the test compound(s) is contacted with the CalDAG-GEF or cAMP-GEF protein, fusion or fragment under conditions which are permissive for binding. The substrate is then washed with a solution to remove unbound or weakly bound molecules. A second wash may then elute those compounds which strongly bound to the immobilized normal or mutant CalDAG-GEF or cAMP-GEF component. Alternatively, the test compounds may be 20 immobilized and a solution containing one or more CalDAG-GEF or cAMP-GEF components may be contacted with the column, filter, or other substrate. The ability of the CalDAG-GEF or cAMP-GEF component to bind to the test compounds may be determined as above or a labeled form of the CalDAG-GEF or cAMP-GEF component (*e.g.*, a radio-labeled or chemiluminescent functional domain) may be used to more rapidly assess binding to the substrate-immobilized 25 compound(s).

B. Co-Immunoprecipitation

Another well characterized technique for the isolation of the CalDAG-GEF or cAMP-GEF components and their associated proteins or other compounds is direct immunoprecipitation with antibodies. This procedure has been successfully used, for example, to isolate many of the 30 synaptic vesicle associated proteins (Phizicky et al., 59 J. BIOL. CHEM. 94-123 (1994)). Thus,

either normal or mutant CalDAG-GEF or cAMP-GEF components may be mixed in a solution with the candidate compound(s) under conditions which are permissive for binding, and the CalDAG-GEF or cAMP-GEF component may be immunoprecipitated. Proteins or other compounds which co-immunoprecipitate with the CalDAG-GEF or cAMP-GEF component may 5 then be identified by standard techniques as described above. General techniques for immunoprecipitation may be found in, for example, Harlow et al., ANTIBODIES: A LABORATORY MANUAL (1988).

The antibodies employed in this assay, as described and enabled herein, may be polyclonal or monoclonal, and include the various antibody fragments as well as single chain 10 antibodies, and the like.

C. The Biomolecular Interaction Assay

Another useful method for the detection and isolation of binding proteins is the Biomolecular Interaction Assay or "BIAcore" system developed by Pharmacia Biosensor and described in the manufacturer's protocol (LKB Pharmacia, Sweden). In light of the present 15 disclosure, one of ordinary skill in the art is now enabled to employ this system, or a substantial equivalent, to identify proteins or other compounds having CalDAG-GEF or cAMP-GEF binding capacity. The BIAcore system uses an affinity purified anti-GST antibody to immobilize GST-fusion proteins onto a sensor chip. Obviously, other fusion proteins and corresponding 20 antibodies may be substituted. The sensor utilizes surface plasmon resonance which is an optical phenomenon that detects changes in refractive indices. A homogenate of a tissue of interest is passed over the immobilized fusion protein and protein-protein interactions are registered as changes in the refractive index. This system can be used to determine the kinetics of binding and to assess whether any observed binding is of physiological relevance.

D. The Yeast Two-Hybrid System

25 The yeast "two-hybrid" system takes advantage of transcriptional factors that are composed of two physically separable, functional domains. One commonly used system employs the yeast GAL4 transcriptional activator, consisting of a DNA binding domain and a transcriptional activation domain. Two different cloning vectors are used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins

are co-expressed, targeted to the nucleus and, if interactions occur, activation of a reporter gene (e.g., lacZ) produces a detectable phenotype.

E. Other Methods

The nucleotide sequences and protein products, including both mutant and normal forms of these nucleic acids and their corresponding proteins, can be used with the above techniques to isolate other interacting proteins, and to identify other genes whose expression is altered by the over-expression of normal CalDAG-GEF or cAMP-GEF sequences, by the under-expression of normal CalDAG-GEFs or cAMP-GEFs sequences, or by the expression of mutant CalDAG-GEF and/or cAMP-GEF sequences. Identification of these interacting proteins, as well as the identification of other genes whose expression levels are altered in the face of mutant CalDAG-GEF or cAMP-GEF sequences (for instance) will identify other gene targets which have direct relevance to the pathogenesis of this disease in its clinical or pathological forms. Specifically, these techniques rely on PCR-based and/or hybridization-based methods to identify genes which are differentially expressed between two conditions (a cell line expressing normal CalDAG-GEFs or cAMP-GEFs compared to the same cell type expressing a mutant CalDAG-GEF or cAMP-GEF sequence). These techniques include differential display, serial analysis of gene expression (SAGE), mass-spectrometry of protein, 2D-gels and subtractive hybridization (See, e.g., Nowak, 270 Sci. 368-371 (1995); Kahn, 270 Sci. 369-370 (1995)).

20 8. Methods of Identifying Compounds Modulating CalDAG-GEF and/or cAMP-GEF Activity

In another series of embodiments, the present invention provides for methods of identifying compounds with the ability to modulate the activity of normal and mutant CalDAG-GEFs and/or cAMP-GEFs. As used with respect to this series of embodiments, the term “activity” broadly includes gene and protein expression, CalDAG-GEF and/or cAMP-GEF protein post-translation processing, trafficking and localization, and any functional activity (e.g., enzymatic, receptor-effector, binding, channel), as well as downstream affects of any of these. Using the transformed cells and transgenic animal models of the present invention, cells obtained from subjects bearing a mutant CalDAG-GEF and/or cAMP-GEF gene, or animals or human subjects bearing naturally occurring CalDAG-GEF and/or cAMP-GEF mutations, it is now possible to screen candidate pharmaceuticals and treatments for their therapeutic effects by

detecting changes in one or more of the functional characteristics or phenotypic manifestations of normal or mutant CalDAG-GEF and/or cAMP-GEF expression.

Thus, the present invention provides methods for screening or assaying for proteins, small molecules or other compounds which modulate CalDAG-GEF and/or cAMP-GEF activity 5 by contacting a cell *in vivo* or *in vitro* with a candidate compound and assaying for a change in a marker associated with normal or mutant CalDAG-GEF and/or cAMP-GEF activity. The marker associated with CalDAG-GEF and/or cAMP-GEF activity may be any measurable biochemical, 10 physiological, histological and/or behavioral characteristic associated with CalDAG-GEF and/or cAMP-GEF expression. In particular, useful markers will include any measurable biochemical, physiological, histological and/or behavioral characteristic which distinguishes cells, tissues, animals or individuals bearing at least one mutant CalDAG-GEF and/or cAMP-GEF gene from their normal counterparts. In addition, the marker may be any specific or non-specific measure 15 of CalDAG-GEF and/or cAMP-GEF activity, such as the GDP/GTP bound to Rap1/Ras. CalDAG-GEF and/or cAMP-GEF specific measures include measures of CalDAG-GEF and/or 20 cAMP-GEF expression (*e.g.*, CalDAG-GEF and/or cAMP-GEF mRNA or protein levels) which may employ the nucleic acid probes or antibodies of the present invention. Non-specific measures include changes in cell physiology such as pH, intracellular calcium, cAMP levels, overall GTP/GDP ratios, phosphatidylinositol activity, protein phosphorylation, etc., which can be monitored by known methods. The activation or inhibition of CalDAG-GEF or cAMP-GEF 25 activity in its mutant or normal form can also be monitored by examining changes in the expression of other genes which are specific to the CalDAG-GEF and/or cAMP-GEF pathway. These can be assayed by such techniques as differential display, differential hybridization, and SAGE, as well as by 2-D gel electrophoresis of cellular lysates. In each case, the differentially-expressed genes can be ascertained by inspection of identical studies before and after application 30 of the candidate compound. Furthermore, as noted elsewhere, the particular genes whose expression is modulated by the administration of the candidate compound can be ascertained by cloning, nucleotide sequencing, amino acid sequencing, or mass spectrometry.

In general, a cell may be contacted with a candidate compound and, after an appropriate period (*e.g.*, 0-72 hours for most biochemical measures of cultured cells), the marker of 30 CalDAG-GEF or cAMP-GEF activity may be assayed and compared to a baseline measurement.

The baseline measurement may be made prior to contacting the cell with the candidate compound or may be an external baseline established by other experiments or known in the art. The cell may be a transformed cell of the present invention or an explant from an animal or individual. In particular, the cell may be an explant from a carrier of a CalDAG-GEF or cAMP-
5 GEF mutation or an animal model of the invention (e.g., a transgenic nematode or mouse bearing a mutant CalDAG-GEF or cAMP-GEF gene). Preferred cells include those from neurological tissues such as neuronal, glial or mixed cell cultures; and cultured fibroblasts, liver, kidney, spleen, or bone marrow. The cells may be contacted with the candidate compounds in a culture *in vitro* or may be administered *in vivo* to a live animal or human subject. For live animals or
10 human subjects, the test compound may be administered orally or by any parenteral route suitable to the compound. For clinical trials of human subjects, measurements may be conducted periodically (e.g., daily, weekly or monthly) for several months or years.

In light of the identification, characterization, and disclosure herein of the CalDAG-GEF or cAMP-GEF genes and proteins, the CalDAG-GEF or cAMP-GEF nucleic acid probes and
15 antibodies, and the CalDAG-GEF or cAMP-GEF transformed cells and transgenic animals of the invention, one of ordinary skill in the art is now enabled by perform a great variety of assays which will detect the modulation of CalDAG-GEF or cAMP-GEF activity by candidate compounds. Particularly preferred and contemplated embodiments are discussed in some detail below.

20 A. CalDAG-GEF and/or cAMP-GEF Expression

In one series of embodiments, specific measures of CalDAG-GEF or cAMP-GEF expression are employed to screen candidate compounds for their ability to affect CalDAG-GEF or cAMP-GEF activity. Thus, using the CalDAG-GEF or cAMP-GEF nucleic acids and
25 antibodies disclosed and otherwise enabled herein, one may use mRNA levels or protein levels as a marker for the ability of a candidate compound to modulate CalDAG-GEF or cAMP-GEF activity. The use of such probes and antibodies to measure gene and protein expression is well known in the art and discussed elsewhere herein.

 B. Intracellular Localization

In another series of embodiments, compounds may be screened for their ability to
30 modulate the activity of the CalDAG-GEFs or cAMP-GEFs based upon their effects on the

trafficking and intracellular localization of the CalDAG-GEFs or cAMP-GEFs. Differences in localization of mutant and normal CalDAG-GEFs and/or cAMP-GEFs may contribute to the etiology of CalDAG-GEF and/or cAMP-GEF-associated diseases. Compounds which can affect the localization of the CalDAG-GEFs and/or cAMP-GEFs may, therefore, be identified as potential therapeutics. Standard techniques known in the art may be employed to detect the localization of the CalDAG-GEFs and/or cAMP-GEFs. Generally, these techniques will employ the antibodies of the present invention, and in particular antibodies which selectively bind to one or more mutant CalDAG-GEFs or cAMP-GEFs but not to normal CalDAG-GEFs or cAMP-GEFs. As is well known in the art, such antibodies may be labeled by any of a variety of techniques (e.g., fluorescent or radioactive tags, labeled secondary antibodies, avidin-biotin, etc.) to aid in visualizing the intracellular location of the CalDAG-GEFs or cAMP-GEFs. The CalDAG-GEFs or cAMP-GEFs may be co-localized to particular structures, as is known in the art, using antibodies to markers of those structures (e.g., TGN38 for the Golgi, transferrin receptor for post-Golgi transport vesicles, LAMP2 for lysosomes). Western blots of purified fractions from cell lysates enriched for different intracellular membrane bound organelles (e.g., lysosomes, synaptosomes, Golgi) may also be employed. In addition, the relative orientation of different domains of the CalDAG-GEFs and/or cAMP-GEFs across cellular domains may be assayed using, for example, electron microscopy and antibodies raised to those domains.

20 9. Screening and Diagnostics for CalDAG-GEF- or cAMP-GEF-associated disorders

A. General Diagnostic Methods

The CalDAG-GEF or cAMP-GEF genes and gene products, as well as the CalDAG-GEF or cAMP-GEF-derived probes, primers and antibodies, disclosed or otherwise enabled herein, are useful in the screening for carriers of alleles associated with CalDAG-GEF- or cAMP-GEF-associated disorders. Individuals at risk for such a disorder or individuals not previously known to be at risk, may be routinely screened using probes to detect the presence of a mutant CalDAG-GEF or cAMP-GEF gene or protein by a variety of techniques. Diagnosis of inherited cases of these diseases can be accomplished by methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences), proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect increases or decreases of the normal CalDAG-

GEF or cAMP-GEF activity and/or the presence of specific new activities conferred by the mutant CalDAG-GEFs or cAMP-GEFs. Preferably, the methods and products are based upon the human CalDAG-GEF or cAMP-GEF nucleic acids, proteins or antibodies, as disclosed or otherwise enabled herein. For brevity of exposition, but without limiting the scope of the invention, the following description will focus upon uses of the human homologues of CalDAG-GEF and cAMP-GEF. It will be understood, however, that homologous sequences from other species, including those disclosed herein, will be equivalent for many purposes.

B. Protein Based Screens and Diagnostics

When a diagnostic assay is to be based upon CalDAG-GEF or cAMP-GEF proteins, a variety of approaches are possible. For example, diagnosis can be achieved by monitoring differences in the electrophoretic mobility of normal and mutant proteins. Such an approach will be particularly useful in identifying mutants in which insertions, deletions or substitutions have resulted in a significant change in the electrophoretic migration of the resultant protein.

Alternatively, diagnosis may be based upon differences in the proteolytic cleavage patterns of normal and mutant proteins, differences in molar ratios of the various amino acid residues, or by functional assays demonstrating altered function of the gene products.

C. Nucleic Acid Based Screens and Diagnostics

When the diagnostic assay is to be based upon nucleic acids from a sample, the assay may be based upon mRNA, cDNA or genomic DNA. Whether mRNA, cDNA, or genomic DNA is assayed, standard methods well known in the art may be used to detect the presence of a particular sequence either *in situ* or *in vitro* (See, e.g., Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. (1989)).

(1) Appropriate Probes and Primers

Whether for hybridization, RNase protection, ligase-mediated detection, PCR amplification or any other standards methods described herein and well known in the art, a variety of subsequences of the CalDAG-GEF and/or cAMP-GEF sequences disclosed or otherwise enabled herein will be useful as probes and/or primers. These sequences or subsequences will include both normal CalDAG-GEF or cAMP-GEF sequences and deleterious mutant sequences. In general, useful sequences will include at least 8-10, more preferably 10-15, and most preferably 15-25 consecutive nucleotides from the CalDAG-GEF or cAMP-GEF

introns, exons or intron/exon boundaries. Useful sequences will also include at least 25-500 consecutive nucleotides from the CalDAG-GEF or cAMP-GEF introns, exons or intron/exon boundaries. Depending upon the target sequence, the specificity required, and future technological developments, shorter sequences may also have utility. Therefore, any CalDAG-
5 GEF or cAMP-GEF derived sequence which is employed to isolate, clone, amplify, identify or otherwise manipulate a CalDAG-GEF or cAMP-GEF sequence may be regarded as an appropriate probe or primer.

15 (2) Hybridization Screening

For *in situ* detection of a normal or mutant CalDAG-GEF, cAMP-GEF or other CalDAG-
10 GEF and/or cAMP-GEF-associated nucleic acid sequence, a sample of tissue may be prepared by standard techniques and then contacted with one or more of the above-described probes, preferably one which is labeled to facilitate detection, and an assay for nucleic acid hybridization is conducted under stringent conditions which permit hybridization only between the probe and highly or perfectly complementary sequences.

15 (3) Restriction Mapping

Sequence alterations may also create or destroy fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by electrophoresis and visualization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Such restriction fragment length polymorphism analysis (RFLP), or restriction mapping, may be employed with genomic DNA, mRNA or cDNA. The CalDAG-GEF or cAMP-GEF sequences may be amplified by PCR using the above-described primers prior to restriction, in which case the lengths of the PCR products may indicate the presence or absence of particular restriction sites, and/or may be subjected to restriction after amplification. The
20 CalDAG-GEF or cAMP-GEF fragments may be visualized by any convenient means (e.g., under UV light in the presence of ethidium bromide).

25 (4) PCR Mapping

In another series of embodiments, a single base substitution mutation may be detected based on differential PCR product length or production in PCR. Thus, primers which span
30 mutant sites or which, preferably, have 3' termini at mutation sites, may be employed to amplify

a sample of genomic DNA, mRNA or cDNA from a subject. A mismatch at a mutational site may be expected to alter the ability of the normal or mutant primers to promote the polymerase reaction and, thereby, result in product profiles which differ between normal subjects and heterozygous and/or homozygous CalDAG-GEF or cAMP-GEF mutants.

5 (5) Electrophoretic Mobility

Genetic testing based on DNA sequence differences also may be achieved by detection of alterations in electrophoretic mobility of DNA, mRNA or cDNA fragments in gels. Small sequence deletions and insertions, for example, can be visualized by high resolution gel electrophoresis of single or double stranded DNA, or as changes in the migration pattern of DNA 10 heteroduplexes in non-denaturing gel electrophoresis.

(6) Chemical Cleavage of Mismatches

Mutations in the CalDAG-GEFs or cAMP-GEFs may also be detected by employing the chemical cleavage of mismatch (CCM) method (*See, e.g.*, Saleeba et al., METHODS IN ENZYMOLOGY, 217: 286-295 (1993)). In this technique, probes (up to ~ 1 kb) may be mixed 15 with a sample of genomic DNA, cDNA or mRNA obtained from a subject. The sample and probes are mixed and subjected to conditions which allow for heteroduplex formation (if any). Preferably, both the probe and sample nucleic acids are double-stranded, or the probe and sample may be PCR amplified together, to ensure creation of all possible mismatch heteroduplexes. Mismatched T residues are reactive to osmium tetroxide and mismatched C residues are reactive 20 to hydroxylamine. Because each mismatched A will be accompanied by a mismatched T, and each mismatched G will be accompanied by a mismatched C, any nucleotide differences between the probe and sample (including small insertions or deletions) will lead to the formation of at least one reactive heteroduplex. After treatment with osmium tetroxide and/or hydroxylamine to modify any mismatch sites, the mixture is subjected to chemical cleavage at any modified 25 mismatch sites by, for example, reaction with piperidine. The mixture may then be analyzed by standard techniques such as gel electrophoresis to detect cleavage products which would indicate mismatches between the probe and sample.

(7) Other Methods

Various other methods of detecting CalDAG-GEF or cAMP-GEF mutations, based upon 30 the CalDAG-GEF or cAMP-GEF sequences disclosed and otherwise enabled herein, will be

apparent to those of ordinary skill in the art. Any of these may be employed in accordance with the present invention. These include, but are not limited to, nuclease protection assays (S1 or ligase-mediated), ligated PCR, denaturing gradient gel electrophoresis (DGGE; *see, e.g.*, Fischer et al., 80 PROC. NAT'L ACAD. SCI (USA), 1578-83 (1983)), restriction endonuclease

5 fingerprinting combined with SSCP (REF-SSCP; *see, e.g.*, Liu et al., 18 BIOTECHNIQUES 470-79 (1995)), and the like.

D. Other Screens and Diagnostics

Diagnosis also can be made by observation of alterations in CalDAG-GEF or cAMP-GEF transcription, translation, and post-translational modification and processing as well as

10 alterations in the intracellular and extracellular trafficking of CalDAG-GEF or cAMP-GEF gene products in the brain and peripheral cells. Such changes will include alterations in the amount of CalDAG-GEF or cAMP-GEF messenger RNA and/or protein, alteration in phosphorylation state, abnormal intracellular location/distribution, abnormal extracellular distribution, etc. Such assays will include: Northern Blots (with CalDAG-GEF or cAMP-GEF-specific and non-specific 15 nucleotide probes), Western blots and enzyme-linked immunosorbent assays (ELISA) (with antibodies raised specifically to a CalDAG-GEF or a cAMP-GEF functional domain, including various post-translational modification states).

E. Screening and Diagnostic Kits

In accordance with the present invention, diagnostic kits are also provided which will

20 include the reagents necessary for the above-described diagnostic screens. For example, kits may be provided which include antibodies or sets of antibodies which are specific to one or more mutant epitopes. These antibodies may, in particular, be labeled by any of the standard means which facilitate visualization of binding. Alternatively, kits may be provided in which oligonucleotide probes or PCR primers, as described above, are present for the detection and/or 25 amplification of mutant CalDAG-GEF, cAMP-GEF or other CalDAG-GEF and/or cAMP-GEF-associated nucleotide sequences. Again, such probes may be labeled for easier detection of specific hybridization. As appropriate to the various diagnostic embodiments described above, the oligonucleotide probes or antibodies in such kits may be immobilized to substrates and appropriate controls may be provided.

10. Methods of Treatment

The present invention now provides a basis for therapeutic intervention in diseases which are associated to the CalDAG-GEFs or cAMP-GEFs in that they are caused, prevented, exacerbated, or alleviated, or which may be caused, prevented, exacerbated, or alleviated, by the either normal or mutant CalDAG-GEFs or cAMP-GEFs. In considering the various therapies described below, it is understood that such therapies may be targeted at tissue other than the brain where CalDAG-GEF or cAMP-GEF are also expressed.

Therapies to treat CalDAG-GEF and/or cAMP-GEF-associated diseases may be based upon (1) administration of normal CalDAG-GEF or cAMP-GEF proteins, (2) gene therapy with normal CalDAG-GEF or cAMP-GEF genes to compensate for or replace the mutant genes, (3) gene therapy based upon antisense sequences to mutant CalDAG-GEF or cAMP-GEF genes or which "knock-out" the mutant genes, (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of CalDAG-GEF or cAMP-GEF mutants, (5) immunotherapy based upon antibodies to normal and/or mutant CalDAG-GEF or cAMP-GEF proteins, or (6) small molecules (drugs) which alter CalDAG-GEF or cAMP-GEF expression, block abnormal interactions between mutant forms of CalDAG-GEF or cAMP-GEF and other proteins or ligands, or which otherwise block the aberrant function of mutant CalDAG-GEF or cAMP-GEF proteins by altering the structure of the mutant proteins, by enhancing their metabolic clearance, or by inhibiting their function.

20 A. Protein Therapy

Treatment of CalDAG-GEF and/or cAMP-GEF-associated disorders, or disorders resulting from CalDAG-GEF and/or cAMP-GEF mutations, may be performed by providing an excess of inactive mutant protein to decrease the effect of the normal function of the protein, or by providing an excess of normal protein to reduce the effect of any aberrant function of the mutant protein, by replacing a mutant protein with normal protein, or by modulating the function of the mutant protein.

B. Gene Therapy

In one series of embodiments, gene therapy may be employed in which normal or mutant copies of the CalDAG-GEF gene or the cAMP-GEF gene are introduced into patients to code successfully for normal or mutant protein in one or more different affected cell types. The gene

must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function. Thus, it is preferred that the recombinant gene be operably joined to a strong promoter so as to provide a high level of expression which will compensate for, or out-compete, the naturally-occurring proteins. As noted above, the recombinant construct 5 may contain endogenous or exogenous regulatory elements, inducible or repressible regulatory elements, or tissue-specific regulatory elements.

In another series of embodiments, gene therapy may be employed to replace the naturally-occurring gene by homologous recombination with a recombinant construct. The recombinant construct may contain a normal or a mutant copy of the targeted CalDAG-GEF 10 and/or cAMP-GEF gene, in which case the defect is corrected *in situ*, or may contain a "knock-out" construct which introduces a stop codon, missense mutation, or deletion which abolished function of the mutant gene. It should be noted in this respect that such a construct may knock-out both the normal and mutant copies of the targeted CalDAG-GEF and/or cAMP-GEF gene in 15 a heterozygous individual, but the total loss of CalDAG-GEF and/or cAMP-GEF gene function may be less deleterious to the individual than continued progression of the disease state.

In another series of embodiments, antisense gene therapy may be employed. The antisense therapy is based on the fact that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA or DNA and a complementary antisense species. The formation of a hybrid duplex may then interfere with the transcription of 20 the gene and/or the processing, transport, translation and/or stability of the target CalDAG-GEF and/or cAMP-GEF mRNA. Antisense strategies may use a variety of approaches including the administration of antisense oligonucleotides or antisense oligonucleotide analogs (e.g., analogs with phosphorothioate backbones) or transfection with antisense RNA expression vectors. Again, such vectors may include exogenous or endogenous regulatory regions, inducible or 25 repressible regulatory elements, or tissue-specific regulatory elements.

In another series of embodiments, gene therapy may be used to introduce a recombinant construct encoding a protein or peptide which blocks or otherwise corrects the aberrant function caused by a naturally-occurring CalDAG-GEF and/or cAMP-GEF gene. In one embodiment, the recombinant gene may encode a peptide which corresponds to a mutant domain of a CalDAG- 30 GEF and/or cAMP-GEF which has been found to abnormally interact with another cell protein or

other cell ligand. Alternatively, the portion of a protein which interacts with a mutant, but not a normal, CalDAG-GEF and/or cAMP-GEF may be encoded and expressed by a recombinant construct in order to compete with, and thereby inhibit or block, the aberrant interaction.

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. The targeted cells however must be able to divide and the expression of the levels of normal protein should be high. The full length CalDAG-GEF or cAMP-GEF genes, subsequences encoding functional domains of the CalDAG-GEFs or cAMP-GEFs, or any of the other therapeutic peptides described above, can be cloned into a retroviral vector and driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for the target cell type of interest. Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpes virus such as Epstein-Barr virus.

C. Immunotherapy

Antibodies may be raised to a mutant CalDAG-GEF or cAMP-GEF protein (or a portion thereof) and be administered to a patient to bind or block the mutant protein and prevent its deleterious effects. Alternatively, antibodies may be raised to specific complexes between mutant or wild-type CalDAG-GEF or cAMP-GEF and their interaction partners.

A further approach is to stimulate endogenous antibody production to the desired antigen. An immunogenic composition may be prepared as injectables, as liquid solutions or emulsions. The CalDAG-GEF or cAMP-GEF protein or other antigen may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.

The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.

D. Small Molecule Therapeutics

As described and enabled herein, the present invention provides for a number of methods of identifying small molecules or other compounds which may be useful in the treatment of CalDAG-GEF- or cAMP-GEF-associated disorders. Thus, for example, the present invention 5 provides for methods of identifying CalDAG-GEF or cAMP-GEF binding proteins and, in particular, methods for identifying proteins or other cell components which bind to or otherwise interact with mutant CalDAG-GEFs or cAMP-GEFs but not with the normal CalDAG-GEFs or cAMP-GEFs. The invention also provides for methods of identifying small molecules which can be used to disrupt undesired interactions between CalDAG-GEFs or cAMP-GEFs and other 10 proteins or other cell components.

By identifying these proteins and analyzing these interactions, it is possible to screen for or design compounds which counteract or prevent the interaction, thereby, providing treatment for abnormal interactions. Therapies can be designed to modulate these interactions and thereby, to modulate CalDAG-GEF- or cAMP-GEF-associated disorders. The potential efficacy of these 15 therapies can be tested by analyzing the affinity and function of these interactions after exposure to the therapeutic agent by standard pharmacokinetic measurements of affinity (e.g., Kd, Vmax) using synthetic peptides or recombinant proteins corresponding to functional domains of the CalDAG-GEF gene, the cAMP-GEF gene or other CalDAG-GEF and/or cAMP-GEF homologues. Another method for assaying the effect of any interactions involving functional 20 domains is to monitor changes in the intracellular trafficking and post-translational modification of the relevant genes by *in situ* hybridization, immunohistochemistry, Western blotting and metabolic pulse-chase labeling studies in the presence of, and in the absence of, the therapeutic agents. A further method is to monitor the effects of "downstream" events including changes in second messenger events, e.g., cAMP, intracellular Ca²⁺, protein kinase activities, etc.

25 The effect of potential therapeutic agents in cell lines and whole animals can be monitored by monitoring transcription, translation, and post-translational modification of the CalDAG-GEF and/or cAMP-GEF proteins. Methods for these studies include Western and Northern blots, immunoprecipitation after metabolic labelling (pulse-chase) with radio-labelled methionine and ATP, and immunohistochemistry. The effect of these agents can also be 30 monitored using studies which examine the relative binding affinities and relative amounts of

CalDAG-GEF or cAMP-GEF proteins involved in interactions with Rap1A, using either standard binding affinity assays or co-precipitation and Western blots using antibodies to Rap1A, CalDAG-GEF, cAMP-GEF, or other CalDAG-GEF and/or cAMP-GEF homologues.

Therapy using antisense oligonucleotides to block the expression of the mutant CalDAG-

5 GEF gene or the mutant cAMP-GEF gene, co-ordinated with gene replacement with normal CalDAG-GEF or cAMP-GEF gene can also be applied using standard techniques of either gene therapy or protein replacement therapy.

V. Examples

10

Example 1: Isolation and characterization of CalDAG-GEF.

Human full-length CalDAG-GEFI cDNAs were isolated from a human frontal cortex λZAPII cDNA library (Stratagene) and a U937 λZAPII cDNA library. Mouse full-length CalDAG-GEFI was identified in the mouse EST database (GenBank accession number:

15 W71787). Rat full-length CalDAG-GEFII cDNA was isolated from a rat whole brain λZAPII cDNA library by using human CalDAG-GEFII as a probe. Mouse ESTs identified through BLAST searches were purchased from Genome Systems Inc. (St. Louis, MO).

CalDAG-GEFI encodes an approximately 69-kD protein (Fig. 2D) that displays in its amino terminal region a GEF domain that is highly homologous to Ras-superfamily GEFs (Fig. 20 2A-2D). Multiple alignment analysis shows that genes of the CalDAG-GEF family form a cluster within the Ras-GEF superfamily distinct from Ras GEFs such as Sos1 and rRas-GEF (Fig. 2B). The region downstream of the GEF domain contains two tandem repeats of EF-hand Ca²⁺ binding motifs (Figs. 2A, 2E). The carboxy-terminal region displays a typical diacylglycerol/phorbol ester-binding domain, which is present in most PKC family proteins (Fig. 25 2A, 2F). Multiple sequence alignments and phylogenetic tree analysis were carried out with the LASERGENE Software Package (DNASTAR Inc.). Abbreviations and GenBank accession numbers of the protein sequences used in Figure 2 are as follows: C3G: 474982, mCdc25:

882120, rRas-GRF: 57665, hSos1 (human son-of-sevenless 1): 476780, BUD5: 171141,

hCalmodulin: 115512, hCalbindin D28k: 227666, hCalcineurin B: 105504, hParvalbumin a:

30 131100, hTroponin C: 136043, hPKCa: 125549, hPKCb1: 125538, hPKCg: 462455.

To determine the small G protein target of CalDAG-GEFI, guanine nucleotide exchange activity *in vivo* was analyzed using intact 293T cells cotransfected with a eukaryotic expression construct of mouse CalDAG-GEFI and GST-tagged Ras family proteins. Full-length mouse CalDAG-GEFI cDNA inserted into a pCMV-SPORT expression vector with a carboxy-terminal FLAG epitope was used for transfection. A PCR-amplified fragment of rat CalDAG-GEFII was subcloned into a pCAGGS expression vector with the addition of His₆-tag at its amino-terminus, resulting in pCAGGS-His-CalDAGII. pEBG-Krev1 that expresses Rap1A was used as a fusion protein to glutathione S-transferase (GST) in mammalian cells, as described in Gotoh et al., 15 Mol. Cell Biol. 6746-53 (1995), pEBG-R-Ras, other vectors for Ras-family proteins obtained by 10 inserting PCR-amplified cDNAs into pEBG expression vector, pCAGGS-C3G and pCAGGS- MSos1, and pCEV-H-RasV12. CalDAG-GEFI transfection produced a dramatic increase in GTP-bound Rap1A compared to the control but showed no or minimal activation of H-Ras, R- Ras, or Ral A. The increase in GTP-bound Rap1A was augmented in the presence of either the 15 Ca²⁺ ionophore, A23187, or the phorbol ester, phorbol-12-myristate-13-acetate (TPA). Further, A23187 and TPA had additive effects when administered together.

To determine the effect of CalDAG-GEFI on the Erk/MAP kinase cascade, Elk1 activation was measured in 293T cells transfected with CalDAG-GEFI or constitutively active H-Ras (RasV12), or both. 293T cells were transfected by SuperFect (Qiagen) as described in Gotoh, *supra*, with expression vectors for GST-tagged Ras family proteins and with those for 20 various GEFs. Cells were labeled 24 hours after transfection with ³²P_i for 2 hr. In some experiments, cells were stimulated with either 10 µM A23187 or 1 µM phorbol-12-myristate-13-acetate (TPA) for 3 min. GST-tagged Ras family proteins were collected from cell lysates with glutathione Sepharose. Guanine nucleotides bound to Ras family proteins were separated by thin layer chromatography (TLC). Activation of Elk1 was examined by the PathDetect Elk1 transreporting system (Stratagene). 293T cells were transfected with pFR-Luc and pFA-Elk1 with various expression vectors, and light output was detected and analyzed by the use of LAS1000 film. CalDAG-GEFI reduced RasV12 activation of Elk1 by approximately 4-fold and did not itself activate Elk1. Thus, CalDAG-GEFI strongly inhibits Ras-dependent stimulation of 25 the Erk/MAP kinase cascade.

Northern analysis showed that human CalDAG-GEFI is expressed strongly in the brain and that CalDAG-GEFI mRNA is strikingly enriched in the striatum. Probes used included human CalDAG-GEFI: 729-bp EcoRI fragment, human CalDAG-GEFII: 584-bp SacI and HindIII fragment, rat CalDAG-GEFI: 439-bp fragment of EST clone RBC565 (GenBank accession number: C06861, and rat CalDAG-GEFII: 508-bp PCR amplified and subcloned fragment (nucleic acids 2541 to 3048 of SEQ ID NO:5). *In situ* hybridization of sections from the adult rat brain confirmed these restricted distribution patterns. Intense signal was present in the striatum (caudoputamen) and the ventral striatum (nucleus accumbens, olfactory tubercle). There was weaker signal in the olfactory bulb.

A series of monoclonal antibodies against the carboxy-terminal half of mouse CalDAG-GEFI were raised. His₆-tagged mouse CalDAG-GEFI polypeptide (amino acids 349 to 608 of SEQ ID NO:1) was expressed in bacteria, purified over Ni²⁺-nitrilotriacetic acid-agarose resin, and then used to immunize BALB/c mice. The resultant polyclonal antiserum was monitored by ELISA, Western blot, immunoprecipitation, and immunofluorescence assays on CalDAG-GEFI-transfected COS-7 cells. Hybridomas were generated by PEG (polyethylene glycol)-mediated fusion of donor splenocytes to the SP2/O cell line. Positive hybridoma cell lines were identified by screening in the assays described above, and purified by limiting dilution and single-cell cloning. Three hybridoma cell lines against mouse CalDAG-GEFI (mAbs 18B11, 2D9, and 18A7), in addition to the polyclonal fusion serum, were identified. Western analysis showed that mAbs 18B11 and 2D9 were specific for CalDAG-GEFI. Lightly post-fixed, cryostat-cut 10 µm thick sections were immunostained by the ABC (Vectastain kit) method for CalDAG-GEFI with mAbs 18B11 and 2D9 and the polyclonal fusion serum, for tyrosine hydroxylase (TH) with monoclonal antibodies from INCSTAR, and for µ opioid receptor with polyclonal antiserum. Immunohistochemistry with mAb 18B11 showed a striking basal ganglia-enriched distribution pattern in sections of adult rat brain, with significant but weaker activity elsewhere. CalDAG-GEFI immunoreactivity marked the entire pathway from the striatal matrix compartment to the pallidum and substantia nigra pars reticulata, where very intense CalDAG-GEFI staining was present. Thus, CalDAG-GEFI is synthesized in striatal projection neurons and is transported to striatopallidal and striatonigral terminals.

To confirm that CalDAG-GEFI is synthesized in striatal projection neurons and transported to striatopallidal and striatonigral terminals in rats, intrastratial injections of ibotenic acid (20 μ g/ μ l, 1.5 μ l per site, 5 day survival) were made unilaterally at 2 sites in the mid-lateral caudoputamen, with contralateral vehicle control injections were made. In other rats, unilateral 5 subthalamic knife-cuts were made at an anteroposterior level between the entopeduncular nucleus and substantia nigra to sever the striatonigral efferents (1 and 3 days survivals), with control contralateral thalamic knife-cuts. These procedures all reduced CalDAG-GEFI staining in the substantia nigra. *In situ* hybridization was performed according to Simmons et al, 12 J. Histotechnol. 169-181 (1989). A 439bp rat EST clone RBC565 (98.4% identical to mouse 10 CalDAG-GEFI nucleic acids 1777 to 2216 of SEQ ID NO:1) was isolated by BLAST search and used for making RNA probes with 32 P-labeled UTP (2,000 Ci/mmol, NEN, 1 Ci = 37 GBq) and T3 and T7 RNA polymerase. Brains were processed as above for CalDAG-GEFI and TH immunostaining. Thus, CalDAG-GEFI is a protein transported in striatal axons to their 15 terminals. The terminal localization of CalDAG-GEFI was confirmed in subcellular fractionation experiments on dissected samples from the rat ventral midbrain, in which Western analysis showed the presence of CalDAG-GEFI in cytosol and in membrane fractions, including synaptosomes.

Because of the similarity of the GEF domains of CalDAG-GEFI and CalDAG-GEFII, the substrate specificity of CalDAG-GEFII with the same 293T cell assay system used for CalDAG-GEFI was examined. It was confirmed that CalDAG-GEFII activates Ras, and further shown 20 that it activates H-Ras and R-Ras, but not Ral A or Rap1A. H-Ras activation was enhanced by A23187 and TPA. Moreover, CalDAG-GEFII, unlike CalDAG-GEFI, increased the transcriptional activity of Elk1 downstream to Erk/MAP kinase. Thus, in the 293T system, CalDAG-GEFI and CalDAG-GEFII target different Ras-superfamily small G proteins and have 25 opposite effects on the MAP kinase cascade. Northern analysis further showed contrasting brain expression for CalDAG-GEFII, with highest expression being in the cerebellum, cerebral cortex, and amygdala, and low expression occurring in the striatum. Both genes are also expressed in hematopoietic organs in both human and rat.

30 Rap signaling is important in regulating basal ganglia output in response to Ca^{2+} and DAG. Corticostriatal inputs can activate the MAP kinase cascade in striatal projection neurons

(Sgambat et al., 18 J. Neurosci. 214-26 (1993)) and phosphoinositide (PI) signaling is strongly represented in these pathways (Fotuhi et al., 13 J. Neurosci. 3300-08 (1993)). Moreover, a number of receptor systems in the striatum and its striatonigral/striatopallidal pathways are linked to Ca^{2+} and PI signaling, notably including NMDA and metabotropic glutamate receptors,

5 D₂-class dopamine receptors, and tachykinin receptors (Fiorillo et al., 394 Nature 78-82 (1998)).

A previously unrecognized signaling target for some of these systems is likely to be Rap1, via CalDAG-GEFI. In addition, CalDAG-GEFI has a synaptic function as demonstrated by the heavy accumulation of CalDAG-GEFI in the target nuclei of striatal outputs and the localization of Rap1 in synaptosomes and synaptic vesicles. The particular basal ganglia projection systems 10 are enriched in CalDAG-GEFI and are differentially vulnerable to neurodegeneration in Huntington's disease.

Rap and Ras functions can be regulated coordinately or disjunctively by Ca^{2+} and DAG in the brain and hematopoietic organs, depending on the relative expression of CalDAG-GEFI and CalDAG-GEFII. In neurons, Ras/MAP kinase signaling has been directly implicated in synaptic 15 transmission and the neuroplasticity underlying learning and memory. Different CalDAG-GEFI and CalDAG-GEFII expression patterns in the brain influence region-specific neuroplasticity mediated by Ca^{2+} and DAG signaling pathways. The presence of CalDAG-GEFI and CalDAG-GEFII in the hematopoietic system demonstrates the direct input of Ca^{2+} and DAG to Ras/Rap regulation of normal growth and differentiation as well as malignant transformation.

20

Example 2: Isolation and characterization of cAMP-GEFs.

cAMP-GEFI and cAMP-GEFII have similar domain structures, with a cAMP binding domain at the amino terminus and a GEF domain at the carboxy terminus separated by a link region (LR) (Fig. 3A). These mammalian proteins show strong structural homology to a 25 predicted open reading frame (T20G5.5) in *C. elegans* cAMP-GEF (cel cAMP-GEF) (Fig. 3A). The cAMP binding domains of the cAMP-GEF family proteins form a distinct group within the cyclic nucleotide-binding protein superfamily and show the closest similarity to the B domains of PKA regulatory subunits (Fig. 3B). A PR(A/T)AT motif in the cAMP binding pocket is also conserved in the cAMP-GEF proteins (Fig. 3E). The first alanine of this motif confers cAMP

(alanine) as opposed to cGMP (threonine) binding specificity. All of the cAMP-GEF family members have alanine at this position, and therefore bind cAMP rather than cGMP.

The GEF domains of the cAMP-GEFs show high homology to those of Ras-GEF family proteins, but form an independent cluster distinct from Ras GEFs such as mCdc25, hSos1, and rRas-GRF (Fig. 3, C and D). The three structurally conserved regions specific to Ras-GEF family proteins (SCR1, SCR2, and SCR3) are present in all of the cAMP-GEF proteins (Fig. 3D). Multiple sequence alignments and phylogenetic tree analyses were carried out with LASERGENE (DNASTAR Inc.). Abbreviations and GenBank accession numbers of the protein sequences used in this figure: hPKARI α (human cAMP-dependent protein kinase regulatory subunit type I-alpha): 125193, hPKARI β : 1346362, hPKARII α : 125198, hPKARII β : 400115, hPKG α (human cGMP-dependent protein kinase type I-alpha): 1255602, hPKG β : 125379, hPKGII: 1906312, hCalDAG-GEFI: U71870, hCalDAG-GEFII: AF081195, C3G: 474982, hSos1 (human son-of-sevenless 1): 476780, mCdc25: 882120, rRas-GRF: 57665, BUD5: 171141.

In order to identify the small G protein substrate for cAMP-GEFI and II and the mode of cAMP regulation of GEF activity conferred by these proteins, the effects of cAMP-GEFI and cAMP-GEFII expression were analyzed in 293T cells on the ratio of GTP to GDP bound to different Ras family small G proteins in the presence or absence of forskolin and IBMX. Under basal conditions, in the absence of forskolin and IBMX, only Rap1 was activated significantly. In the presence of forskolin and IBMX, both cAMP-GEFI and II strongly and selectively activated Rap1A, but did not activate H-Ras, R-Ras or RalA. The effects of forskolin/IBMX treatment on cAMP-GEFI and II were dose-dependent with EC₅₀ values of 1.8 μ M and 0.3 μ M, respectively. Forskolin/IBMX treatment given alone had no effect.

A time-course analysis of the activation of Rap1A by forskolin/IBMX in cAMP-GEFI transfectants showed that the activation began within 10 sec, reached a maximum at 5 min, and continued for at least 60 min. Thus, cAMP-GEFI has a direct effect on Rap1A rather than secondary effects mediated by other Ras-superfamily GEFs. In addition, Sp-cAMPS, an analogue of cAMP, activated Rap1A at levels similar to those induced by forskolin/IBMX. Thus, cAMP has the capacity to activate the GEF domain of cAMP-GEFI.

Mutational analyses with cAMP-GEFI was performed to examine whether its cAMP-binding domain is required for the activation of Rap1A. In contrast to wild type cAMP-GEFI, a deletion mutant lacking a cAMP binding domain (pcDNA-rcAMP-GEFI:DcAMP(528) and (595)) did not activate Rap1A with or without forskolin/IBMX treatment. Mutants with a single 5 amino acid substitution at the cAMP binding pocket (pcDNA-rcAMP-GEFI:R(279)K) responded minimally to forskolin/IBMX treatment. Thus, the cAMP binding domain of cAMP-GEFI is necessary for its cAMP-dependent activation of Rap1A.

To assess further the cAMP binding capacity of cAMP-GEFI, a cAMP agarose affinity bead binding assay was performed. *In vitro* translated, radiolabeled cAMP-GEFI showed 10 selective binding to the beads that was competed by excess amounts of either cAMP or 8-Br-cAMP. cAMP-GEF protein can bind cAMP and that this binding can activate Rap1A.

cAMP-dependent activation of Rap1 has previously been ascribed to the phosphorylation of Rap1A by PKA, which raises its affinity to smgGDS, a GEF with broad substrate specificity. 15 However, at least in the 293T cell assay system, an increase of GTP-bound Rap1A in response to increasing cAMP levels with forskolin or treatment with the cAMP analogue, Sp-cAMPS was not detected in the absence of cAMP-GEFs. In addition, even in the presence of H-89, a potent and selective inhibitor of PKA, cAMP-GEFI and II could still activate Rap1A. The activation of Rap1A induced by cAMP-GEFI and II is independent of the PKA pathway.

Intracellular cAMP has been shown to interact directly with ion channels, but the vast 20 majority of cAMP-mediated effects in eukaryotes have been considered as sequels to cAMP binding by the regulatory subunits of the PKA tetramer. The diversity of physiological effects produced by cAMP have been attributed to the fact that, as a kinase, PKA has a large range of molecular targets. Reported herein are novel cAMP binding proteins that directly link the cAMP second messenger system to Ras superfamily signaling pathways and that appear selectively to 25 target Rap.

cAMP can exert profound cell-type specific effects on cell growth and differentiation and that cAMP is capable of inhibiting or stimulating the Ras/mitogen-activated protein (MAP) kinase/Erk pathway. The inhibition can occur at the initial translocation step by which Ras activates Raf, whereas activation of Rap1 is thought to occur through phosphorylation by PKA. 30 Activation of Rap1 has been suggested to be part of a switch mechanism determining whether

growth or differentiation occurs in response to nerve growth factor (NGF). cAMP-GEFs directly couple cAMP to Rap1, itself discovered as a negative regulator of Ras but suspected of having independent functions as well. Thus, different levels of cAMP-GEF expression confer cell-type specific regulation of Ras superfamily signaling systems.

5 The genes also exhibit developmentally regulated expression in the septum, medial thalamus and habenula, key structures in the limbic system variously linked to brain reward circuits, addiction and schizophrenia. Thus, cAMP-GEFs, in addition to PKA, underlie some of the neuronal functions of cAMP.

10 Example 3. Northern hybridization demonstrating the expression of CalDAG-GEFI and CalDAG-GEFII protein mRNAs in a variety of tissues.

15 Total cytoplasmic RNA was isolated from various human tissue samples including amygdala, cerebellum, corpus callosum, caudate nucleus, cortex, frontal lobe, hippocampus, subthalamic nucleus, thalamus, and temporal lobe, obtained from surgical pathology using standard procedures such as CsCl purification. The RNA was then electrophoresed on a formaldehyde gel to permit size fractionation. The nitrocellulose membrane was prepared and the RNA was then transferred onto the membrane. ³²P-labeled cDNA probes were prepared and added to the membrane in order for hybridization between the probe the RNA to occur. After 20 washing, the membrane was wrapped in plastic film and placed into imaging cassettes containing X-ray film. The autoradiographs were then allowed to develop for one to several days. Sizing was established by comparison to standard RNA markers. These northern blots demonstrated that the CalDAG-GEF genes are strongly expressed in the brain. Weaker hybridization was detectable elsewhere.

25 Example 4. Northern hybridization demonstrating the expression of cAMP-GEFI and cAMP-GEFII protein mRNAs in a variety of tissues.

30 Northern hybridization analysis was performed as in Example 3 to detect the expression of the cAMP-GEFI and cAMP-GEFII genes in a variety of human tissues. The tissues analyzed included adrenal gland, amygdala, bone marrow, cerebellum, corpus callosum, caudate nucleus,

colon (mucosal lining), caudputamen, cortex, frontal lobe, hippocampus, habenula, heart, kidney, liver, lung, lymph node, medulla obongata, occipital pole, olfactory bulb, ovary, pons, pancreas, putamen, septum, small intestines, skeletal muscle, spinal cord, spleen, stomach, substantia nigra, subthalamic nucleus, testis, thalamus, temporal lobe, thymus, trachea, and thyroid.

5 A striking contrast in the expression patterns of human cAMP-GEFI and II was observed by Northern analysis. Human cAMP-GEFI is widely expressed, with highest levels appearing in kidney, spleen, thyroid, heart, and pancreas. Human cAMP-GEFII shows a remarkably selective enrichment in the brain and the adrenal glands. Both genes were developmentally regulated. The expression patterns of the two genes in the nervous system also differ, with cAMP-GEFI
10 having a wider expression than cAMP-GEFII. These region-specific neuronal expression patterns were confirmed in *in situ* hybridization experiments. cAMP-GEFI mRNA is expressed broadly at low levels in the adult brain, but it is strongly and selectively expressed in parts of the neonatal brain, including the septum and the thalamus. By contrast, cAMP-GEFII is strongly expressed in the mature as well as the developing brain. Notable are the high levels of cAMP-
15 GEFII mRNA in the cerebral cortex, the hippocampus (especially CA3 and dentate gyrus), the habenula and the cerebellum. Genes of the cAMP-GEF family have widespread influence on cAMP functions in bodily organs and also region-specific functions in the brain.

Example 5. Isolation of CalDAG-GEF or cAMP-GEF binding proteins by yeast two-hybrid
20 system.

To identify proteins interacting with the CalDAG-GEF or cAMP-GEF proteins, a yeast expression plasmid vector (pAS2-1, Clontech) is generated by ligating an in-frame partial cDNA sequence encoding either residues of the CalDAG-GEF protein or residues of the cAMP-GEF protein into the EcoRI and BamHI sites of the vector. The resultant fusion protein contains the
25 GAL4 DNA binding domain coupled in-frame either to residues of the CalDAG-GEF protein or to residues of the cAMP-GEF protein. These expression plasmids are co-transformed, along with purified plasmid DNA from the human brain cDNA:pACT library, into yeast using the protocols of the Clontech Matchmaker yeast-two-hybrid kit (Clontech). Yeast clones bearing human brain cDNAs which interact with the CalDAG-GEF or cAMP-GEF fragments are
30 selected by HIS resistance and β gal+ activation. The clones are further selected by

cyclohexamide sensitivity and the inserts of the human brain cDNAs are isolated by PCR and sequenced.

Although preferred embodiments of the invention have been described herein in detail, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit of the invention or the scope of the following claims.

CLAIMS

3 What is claimed is:

1 1. An isolated nucleic acid comprising a nucleotide sequence encoding a protein
2 selected from the group consisting of a normal CalDAG-GEFI protein, a mutant CalDAG-GEFI
3 protein, a normal CalDAG-GEFII protein, and a mutant CalDAG-GEFII protein.

1 2. An isolated nucleic acid comprising a nucleotide sequence encoding a protein
2 selected from the group consisting of a normal cAMP-GEFI protein, a mutant cAMP-GEFI
3 protein, a normal cAMP-GEFII protein, and a mutant cAMP-GEFII protein.

1 3. An isolated nucleic acid as in claim 1 wherein said nucleic acid encodes a normal
2 CalDAG-GEF protein and wherein said nucleotide sequence is selected from the group
3 consisting of

4 (a) a sequence encoding a protein comprising the human CalDAG-GEFI amino acid
5 sequence of SEQ ID NO: 4;

6 (b) a sequence encoding a protein comprising the murine CalDAG-GEFI amino acid
7 sequence of SEQ ID NO: 2;

8 (c) a sequence encoding a protein comprising the human CalDAG-GEFII amino acid
9 sequence of SEQ ID NO: 8; and

10 (d) a sequence encoding a protein comprising the murine CalDAG-GEFII amino acid
11 sequence of SEQ ID NO: 6; and
12 (e) a sequence encoding a normal CalDAG-GEF protein and capable of hybridizing to
13 a sequence complementary to any sequence of (a) - (d) under stringent hybridization conditions.

1 4. An isolated nucleic acid as in claim 2 wherein said nucleic acid encodes a normal
2 cAMP-GEF protein and wherein said nucleotide sequence is selected from the group consisting
3 of

4 (a) a sequence encoding a protein comprising the human cAMP-GEFI amino acid
5 sequence of SEQ ID NO: 12;

6 (b) a sequence encoding a protein comprising the alternatively spliced human cAMP-
7 GEFI amino acid sequence of SEQ ID NO: 14;

8 (c) a sequence encoding a protein comprising the rat cAMP-GEFI amino acid
9 sequence of SEQ ID NO: 10;

10 (d) a sequence encoding a protein comprising the human cAMP-GEFII amino acid
11 sequence of SEQ ID NO: 18;

12 (e) a sequence encoding a protein comprising the rat cAMP-GEFII amino acid
13 sequence of SEQ ID NO: 16; and

14 (f) a sequence encoding a normal cAMP-GEF protein and capable of hybridizing to a
15 sequence complementary to any sequence of (a) - (e) under stringent hybridization conditions.

16
1 5. An isolated nucleic acid comprising a nucleotide sequence of at least 8 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.

1 6. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.

1 7. An isolated nucleic acid comprising a nucleotide sequence of at least 15 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.

1 8. An isolated nucleic acid comprising a nucleotide sequence encoding at least one
2 functional domain of a CalDAG-GEF protein selected from the group consisting of a normal
3 CalDAG-GEFI protein, a mutant CalDAG-GEFI protein, a normal CalDAG-GEFII protein, and a
4 mutant CalDAG-GEFII protein.

5

1 9. An isolated nucleic acid comprising a nucleotide sequence encoding at least one
2 functional domain of a cAMP-GEF protein selected from the group consisting of a normal
3 cAMP-GEFI protein, a normal cAMP-GEFII protein, a mutant cAMP-GEFI protein, and a
4 mutant cAMP-GEFII protein.

5

1 10. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic
2 determinant of a CalDAG-GEF protein selected from the group consisting of a normal CalDAG-
3 GEFI protein, a normal CalDAG-GEFII protein, a mutant CalDAG-GEFI protein, and a mutant
4 CalDAG-GEFII protein.

5

1 11. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic
2 determinant of a cAMP-GEF protein selected from the group consisting of a normal cAMP-GEFI
3 protein, a normal cAMP-GEFII protein, a mutant cAMP-GEFI protein, and a mutant cAMP-
4 GEFII protein.

5

1 12. A method for identifying an allelic variant or heterospecific homologue of a human
2 CalDAG-GEF gene comprising:

3 choosing a nucleic acid probe or primer capable of hybridizing to a human CalDAG-
4 GEF gene sequence under stringent hybridization conditions;

5 mixing said probe or primer with a sample of nucleic acids which may contain a
6 nucleic acid corresponding to said variant or homologue; and

7 detecting hybridization of said probe or primer to said nucleic acid corresponding to
8 said variant or homologue.

9

1 13. A method as in claim 12 wherein said human CalDAG-GEF gene sequence is
2 selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 7.

3

1 14. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of human genomic DNA, human mRNA, and human cDNA.

3

1 15. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and
3 mammalian cDNA.

4

1 16. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and
3 invertebrate cDNA.

5

1 17. A method as in claim 12 further comprising the step of isolating said nucleic acid
2 corresponding to said variant or homologue.

3

1 18. A method as in claim 12 wherein said nucleic acid is identified by hybridization.

2

1 19. A method as in claim 12 wherein said nucleic acid is identified by PCR amplification.

2

1 20. A method for identifying allelic variants or heterospecific homologues of a human
2 cAMP-GEF gene comprising:

3 choosing a nucleic acid probe or primer capable of hybridizing to a human cAMP-
4 GEF gene sequence under stringent hybridization conditions;

5 mixing said probe or primer with a sample of nucleic acids which may contain a
6 nucleic acid corresponding to said variant or homologue; and

7 detecting hybridization of said probe or primer to said nucleic acid corresponding to
8 said variant or homologue.

9

1 21. A method as in claim 12 wherein said human cAMP-GEF gene sequence is selected
2 from the group consisting of SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 17.

3

1 22. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of human genomic DNA, human mRNA, and human cDNA.

3

1 23. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and
3 mammalian cDNA.

4

1 24. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and
3 invertebrate cDNA.

4

1 25. A method as in claim 20 further comprising the step of isolating said nucleic acid
2 corresponding to said variant or homologue.

3

1 26. A method as in claim 20 wherein said nucleic acid is identified by hybridization.

2

1 27. A method as in claim 20 wherein said nucleic acid is identified by PCR amplification.

2

1 28. A method for identifying an allelic variant or heterospecific homologue of a human
2 CalDAG-GEF gene comprising:

3 choosing an antibody capable of selectively binding to a human CalDAG-GEF
4 protein;

5 mixing said antibody with a sample of proteins which may contain a protein
6 corresponding to said variant or homologue; and

7 detecting binding of said antibody to said protein corresponding to said variant or
8 homologue.

9
1 29. A method as in claim 28 wherein said sample comprises a sample of proteins selected
2 from the group consisting of human proteins, human fusion proteins, and proteolytic fragments
3 thereof.

4
1 30. A method as in claim 28 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian proteins, mammalian fusion proteins, and
3 proteolytic fragments thereof.

4
1 31. A method as in claim 28 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate proteins, invertebrate fusion proteins, and
3 proteolytic fragments thereof.

4
1 32. A method as in claim 28 further comprising the step of substantially purifying said
2 protein corresponding to said variant or homologue.

3
1 33. A method for identifying an allelic variant or heterospecific homologue of a human
2 cAMP-GEF gene comprising:
3 choosing an antibody capable of selectively binding to a human cAMP-GEF protein;
4 mixing said antibody with a sample of proteins which may contain a protein
5 corresponding to said variant or homologue; and
6 detecting binding of said antibody to said protein corresponding to said variant or
7 homologue.

8
1 34. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of human proteins, human fusion proteins, and proteolytic fragments
3 thereof.

4

1 35. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of mammalian proteins, mammalian fusion proteins, and proteolytic
3 fragments thereof.

4

1 36. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of invertebrate proteins, invertebrate fusion proteins, and proteolytic
3 fragments thereof.

4

1 37. A method as in claim 33 further comprising the step of substantially purifying said
2 protein corresponding to said variant or homologue.

3

1 38. An isolated nucleic acid comprising an allelic variant or a heterospecific homologue
2 of a gene selected from the group consisting of a human CalDAG-GEF gene, and a human
3 cAMP-GEF gene.

4

1 39. An isolated nucleic acid encoding an allelic variant or heterospecific homologue of a
2 protein selected from the group consisting of a human CalDAG-GEF protein, and a human
3 cAMP-GEF protein.

4

1 40. An isolated nucleic acid comprising a recombinant vector including a nucleotide
2 sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO:
4 17, and a sequence complementary to any of these sequences.

5

1 41. An isolated nucleic acid as in claim 40 wherein said vector is an expression vector
2 and said nucleotide sequence is operably joined to a regulatory region.

3

1 42. An isolated nucleic acid as in claim 41 wherein said expression vector may express
2 said nucleotide sequence in mammalian cells.

3

1 43. An isolated nucleic acid as in claim 42 wherein said cells are selected from the group
2 consisting of fibroblast, liver, kidney, spleen, bone marrow, and neurological cells.

3

1 44. An isolated nucleic acid as in claim 42 wherein said vector is selected from the group
2 consisting of vaccinia virus, adenovirus, retrovirus, neurotropic viruses, and Herpes simplex.

3

1 45. An isolated nucleic acid as in claim 41 wherein said expression vector encodes at
2 least a functional domain of a protein selected from the group consisting of normal CalDAG-
3 GEFI, a normal CalDAG-GEFII, a mutant CalDAG-GEFI, a mutant CalDAG-GEFII, a normal
4 cAMP-GEFI, a normal cAMP-GEFII, a mutant cAMP-GEFI, and a mutant cAMP-GEFII.

5

1 46. An isolated nucleic acid as in claim 41 wherein said vector further comprises
2 sequences encoding an exogenous protein operably joined to said nucleotide sequence and
3 whereby said vector encodes a fusion protein.

4

1 47. An isolated nucleic acid as in claim 46 wherein said exogenous protein is selected
2 from the group consisting of lacZ, trpE, maltose-binding protein, poly-His tags, and glutathione-
3 S-transferase.

4

1 48. An isolated nucleic acid comprising a recombinant expression vector including
2 nucleotide sequences corresponding to an endogenous regulatory region of a gene selected from
3 the group consisting of a CalDAG-GEF gene, and a cAMP-GEF gene.

4

1 49. An isolated nucleic acid as in claim 48 wherein said endogenous regulatory region is
2 operably joined to a marker gene.

3

1 50. A host cell transformed with an expression vector of any one of claims 41-49, or a
2 descendant thereof.

3

1 51. A host cell as in claim 50 wherein said host cell is selected from the group consisting
2 of bacterial cells and yeast cells.

3

1 52. A host cell as in claim 50 wherein said host cell is selected from the group consisting
2 of fetal cells, embryonic stem cells, zygotes, gametes, and germ line cells.

3

1 53. A host cell as in claim 50 wherein said cell is selected from the group consisting of
2 fibroblast, liver, kidney, spleen, bone marrow and neurological cells.

3

1 54. A host cell as in claim 50 wherein said cell is an invertebrate cell.

2

1 55. A non-human animal model for cancer, wherein a genome of said animal, or an
2 ancestor thereof, has been modified by at least one recombinant construct, and wherein said
3 recombinant construct has introduced a modification selected from the group consisting of

4 (a) insertion of nucleotide sequences encoding at least a functional domain of
5 a heterospecific normal CalDAG-GEF gene;

6 (b) insertion of nucleotide sequences encoding at least a functional domain of
7 a heterospecific mutant CalDAG-GEF gene;

8 (c) insertion of nucleotide sequences encoding at least a functional domain of
9 a conspecific homologue of a heterospecific mutant CalDAG-GEF gene;

10 (d) inactivation of an endogenous CalDAG-GEF gene;

11 (e) insertion of nucleotide sequences encoding at least a functional domain of
12 a heterospecific normal cAMP-GEF gene;

13 (f) insertion of nucleotide sequences encoding at least a functional domain of a
14 heterospecific mutant cAMP-GEF gene;

- (g) insertion of nucleotide sequences encoding at least a functional domain of a conspecific homologue of a heterospecific mutant cAMP-GEF gene; and
- (h) inactivation of an endogenous cAMP-GEF gene.

1 56. A non-human animal model as in claim 55 wherein said cancer is related to the Ras-
2 pathway.

1 57. A non human animal model as in claim 56 wherein said cancer is selected from the
2 group consisting of lung cancer, pancreatic cancer, breast cancer, colorectal cancer, and myeloid
3 leukemia.

1 58. An animal model as in claim 55 wherein said modification is an insertion of a
2 nucleotide sequence encoding at least a functional domain of a protein selected from the group
3 consisting of a normal human CalDAG-GEF, and a normal cAMP-GEF gene.

1 59. An animal model as in claim 55 wherein said modification is an insertion of a
2 nucleotide sequence encoding at least a functional domain of a protein selected from the group
3 consisting of a mutant human CalDAG-GEF, and a mutant human cAMP-GEF gene.

1 60. An animal as in claim 55 wherein said animal is selected from the group consisting of
2 rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates.

1 61. An animal as in claim 55 wherein said animal is an invertebrate.

1 62. A method for producing at least a functional domain of a protein selected from the
2 group consisting of a CalDAG-GEF protein, and a cAMP-GEF protein, said method comprising
3 culturing a host cell of any of claims 50-54 under suitable conditions to produce said protein by
4 expressing said nucleic acid.

1 63. A substantially pure preparation of a protein selected from the group consisting of a
2 normal CalDAG-GEF protein, a mutant CalDAG-GEF protein, a normal cAMP-GEF protein,
3 and a mutant cAMP-GEF protein.

4

1 64. A substantially pure preparation as in claim 63 wherein said protein comprises a
2 normal protein selected from the group consisting of
3 (a) a protein comprising the amino acid sequence of SEQ ID NO: 2;
4 (b) a protein comprising the amino acid sequence of SEQ ID NO: 4;
5 (c) a protein comprising the amino acid sequence of SEQ ID NO: 6;
6 (d) a protein comprising the amino acid sequence of SEQ ID NO: 8;
7 (e) a protein comprising the amino acid sequence of SEQ ID NO: 10;
8 (f) a protein comprising the amino acid sequence of SEQ ID NO: 12;
9 (g) a protein comprising the amino acid sequence of SEQ ID NO: 14;
10 (h) a protein comprising the amino acid sequence of SEQ ID NO: 16; and
11 (i) a protein comprising the amino acid sequence of SEQ ID NO: 18.

12

1 65. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 4 consecutive amino acid residues selected from the group consisting of SEQ ID NO:
3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

5

1 66. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 10 consecutive amino acid residues selected from the group consisting of SEQ ID NO:
3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

5

1 67. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 15 consecutive amino acid residues selected from the group consisting of SEQ ID NO:

3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

5

1 68. A substantially pure preparation of a polypeptide comprising at least one functional
2 domain of a protein selected from the group consisting of a normal CalDAG-GEF protein, a
3 mutant CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF protein.

4

1 69. A substantially pure preparation of a polypeptide comprising an antigenic determinant
2 of a protein selected from the group consisting of a normal CalDAG-GEF protein, a mutant
3 CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF protein.

4

1 70. A method of producing antibodies which selectively bind to a CalDAG-GEF protein
2 comprising the steps of

3 administering an immunogenically effective amount of a CalDAG-GEF immunogen
4 to an animal;

5 allowing said animal to produce antibodies to said immunogen; and
6 obtaining said antibodies from said animal or from a cell culture derived therefrom.

7

1 71. A method of producing antibodies which selectively bind to a cAMP-GEF protein
2 comprising the steps of

3 administering an immunogenically effective amount of a cAMP-GEF immunogen to
4 an animal;

5 allowing said animal to produce antibodies to said immunogen; and
6 obtaining said antibodies from said animal or from a cell culture derived therefrom.

7

1 72. A substantially pure preparation of an antibody which selectively binds to an
2 antigenic determinant of a protein selected from the group consisting of a normal CalDAG-GEF
3 protein, a mutant CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF
4 protein.

5

1 73. A substantially pure preparation of an antibody as in claim 72 wherein said antibody
2 selectively binds to an antigenic determinant of a mutant CalDAG-GEF and fails to bind to a
3 normal CalDAG-GEF protein.

4

1 74. A substantially pure preparation of an antibody as in claim 72 wherein said antibody
2 selectively binds to an antigenic determinant of a mutant cAMP-GEF and fails to bind to a
3 normal cAMP-GEF protein.

4

1 75. A cell line producing an antibody of any one of claims 72-74.

2

1 76. A method for identifying compounds which can modulate the expression of a
2 CalDAG-GEF gene comprising:
3 contacting a cell with a test candidate wherein said cell includes a regulatory region of
4 a CalDAG-GEF gene operably joined to a coding region; and
5 detecting a change in expression of said coding region.

6

1 77. A method for identifying compounds which can modulate the expression of a cAMP-
2 GEF gene comprising:
3 contacting a cell with a test candidate wherein said cell includes a regulatory region of
4 a cAMP-GEF gene operably joined to a coding region; and
5 detecting a change in expression of said coding region.

6

1 78. A method as in claim 76 or 77 wherein said change comprises a change in a level of
2 an mRNA transcript encoded by said coding region.

3

1 79. A method as in claim 78 wherein said change comprises a change in a level of a
2 protein encoded by said coding region.

3

1 80. A method as in claim 78 wherein said change is a result of an activity of a protein
2 encoded by said coding region.

3

1 81. A method as in claim 78 wherein said coding region encodes a marker protein
2 selected from the group consisting of β -galactosidase, alkaline phosphatase, green fluorescent
3 protein, and luciferase.

4

1 82. A method for identifying compounds which can selectively bind to a CalDAG-GEF

2 protein comprising the steps of

3 providing a preparation including at least one CalDAG-GEF component;

4 contacting said preparation with a sample including at least one candidate compound;

5 and

6 detecting binding of said CalDAG-GEF component to said candidate compound.

7

1 83. A method for identifying compounds which can selectively bind to a cAMP-GEF
2 protein comprising the steps of

3 providing a preparation including at least one cAMP-GEF component;

4 contacting said preparation with a sample including at least one candidate compound;

5 and

6 detecting binding of said cAMP-GEF component to said candidate compound.

7

1 84. The method in claim 82 wherein said binding to said CalDAG-GEF component is
2 detected by an assay selected from the group consisting of: affinity chromatography, co-
3 immunoprecipitation, a Biomolecular Interaction Assay, and a yeast two-hybrid system.

4

1 85. The method in claim 83 wherein said binding to said cAMP-GEF component is
2 detected by an assay selected from the group consisting of: affinity chromatography, co-
3 immunoprecipitation, a Biomolecular Interaction Assay, and a yeast two-hybrid system.

4

1 86. A method of identifying compounds which can modulate activity of a CalDAG-GEF
2 comprising the steps of
3 providing a cell expressing a normal or mutant CalDAG-GEF gene;
4 contacting said cell with at least one candidate compound; and
5 detecting a change in a marker of said activity.

6

1 87. A method of identifying compounds which can modulate activity of a cAMP-GEF
2 comprising the steps of
3 providing a cell expressing a normal or mutant cAMP-GEF gene;
4 contacting said cell with at least one candidate compound; and
5 detecting a change in a marker of said activity.

6

1 88. A method as in claim 86 wherein measurement of said marker indicates a difference
2 between cells bearing an expressed mutant CalDAG-GEF gene and otherwise identical cells free
3 of an expressed mutant CalDAG-GEF gene.

4

1 89. A method as in claim 86 wherein said change comprises a change in a non-specific
2 marker of cell physiology selected from the group consisting of pH, intracellular calcium, cyclic
3 AMP levels, GTP/GDP ratios, phosphatidylinositol activity, and protein phosphorylation.

4

1 90. A method as in claim 86 wherein said change comprises a change in expression of
2 said CalDAG-GEF.

3

1 91. A method as in claim 86 wherein said change comprises a change in occurrence or
2 rate of apoptosis or cell death.

3

1 92. A method as in claim 86 wherein said cell is a cell cultured *in vitro*.

2

1 93. A method as in claim 92 wherein said cell is a transformed host cell of any one of
2 claims 50-54.

3

1 94. A method as in claim 92 wherein said cell is explanted from a host bearing at least
2 one mutant CalDAG-GEF gene.

3

1 95. A method as in claim 92 wherein said cell is explanted from a transgenic animal of
2 any one of claims 55-61.

3

1 96. A method as in claim 86 wherein said cell is a cell in a live animal.

2

1 97. A method as in claim 96 wherein said cell is a cell of a transgenic animal of any one
2 of claims 55-61.

3

1 98. A method as in claim 86 wherein said cell is in a human subject in a clinical trial.

2

1 99. A method as in claim 87 wherein measurement of said marker indicates a difference
2 between cells bearing an expressed mutant cAMP-GEF gene and otherwise identical cells free of
3 an expressed mutant cAMP-GEF gene.

4

1 100. A method as in claim 87 wherein said change comprises a change in a non-specific
2 marker of cell physiology selected from the group consisting of pH, intracellular calcium, cyclic
3 AMP levels, GTP/GDP ratios, phosphatidylinositol activity, and protein phosphorylation.

4

1 101. A method as in claim 87 wherein said change comprises a change in expression of
2 said cAMP-GEF.

3

1 102. A method as in claim 87 wherein said change comprises a change in occurrence or
2 rate of apoptosis or cell death.

3

1 103. A method as in claim 87 wherein said cell is a cell cultured *in vitro*.

2

1 104. A method as in claim 103 wherein said cell is a transformed host cell of any one of
2 claims 50-54.

3

1 105. A method as in claim 103 wherein said cell is explanted from a host bearing at least
2 one mutant cAMP-GEF gene.

3

1 106. A method as in claim 103 wherein said cell is explanted from a transgenic animal of
2 any one of claims 55-61.

3

1 107. A method as in claim 87 wherein said cell is a cell in a live animal.

2

1 108. A method as in claim 107 wherein said cell is a cell of a transgenic animal of any one
2 of claims 55-61.

3

1 109. A method as in claim 87 wherein said cell is in a human subject in a clinical trial.

2

1 110. A diagnostic method for determining if a subject bears a mutant CalDAG-GEF gene
2 comprising the steps of

3 providing a biological sample of said subject; and

4 detecting in said sample a mutant CalDAG-GEF nucleic acid, a mutant CalDAG-GEF

5 protein, or a mutant CalDAG-GEF activity.

6

1 111. A method as in claim 111, wherein a mutant CalDAG-GEF nucleic acid is detected
2 by an assay selected from the group consisting of direct nucleotide sequencing, probe specific
3 hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR

4 detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch
5 cleavage.

6

1 112. A method as in claim 110, wherein a mutant CalDAG-GEF protein is detected by an
2 assay selected from the group consisting of an immunoassay, a protease assay, and an
3 electrophoretic mobility assay.

4

1 113. A diagnostic method for determining if a subject bears a mutant cAMP-GEF gene
2 comprising the steps of

3 providing a biological sample of said subject; and
4 detecting in said sample a mutant cAMP-GEF nucleic acid, a mutant cAMP-GEF
5 protein, or a mutant cAMP-GEF activity.

6

1 114. A method as in claim 113, wherein a mutant cAMP-GEF nucleic acid is detected by
2 an assay selected from the group consisting of direct nucleotide sequencing, probe specific
3 hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR
4 detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch
5 cleavage.

6

1 115. A method as in claim 113, wherein a mutant cAMP-GEF protein is detected by an
2 assay selected from the group consisting of an immunoassay, a protease assay, and an
3 electrophoretic mobility assay.

4

1 116. A pharmaceutical preparation comprising a substantially pure CalDAG-GEF protein
2 and a pharmaceutically acceptable carrier.

3

1 117. A pharmaceutical preparation comprising a substantially pure cAMP-GEF protein and
2 a pharmaceutically acceptable carrier.

3

1 118. A pharmaceutical preparation comprising an expression vector operably encoding a
2 protein selected from the group consisting of a CalDAG-GEF protein, and a cAMP-GEF protein,
3 wherein said expression vector may express said CalDAG-GEF protein or said cAMP-GEF
4 protein in a human subject, and a pharmaceutically acceptable carrier.

5

1 119. A pharmaceutical preparation comprising an expression vector operably encoding a
2 CalDAG-GEF antisense sequence, wherein said expression vector may express said CalDAG-
3 GEF antisense sequence in a human subject, and a pharmaceutically acceptable carrier.

4

1 120. A pharmaceutical preparation comprising an expression vector operably encoding a
2 cAMP-GEF antisense sequence, wherein said expression vector may express said cAMP-GEF
3 antisense sequence in a human subject, and a pharmaceutically acceptable carrier.

4

1 121. A pharmaceutical preparation comprising a substantially pure antibody, and a
2 pharmaceutically acceptable carrier,

3 wherein said antibody selectively binds to a mutant protein selected from the group
4 consisting of a mutant CalDAG-GEF protein, and a mutant cAMP-GEF protein.

5

1 122. A pharmaceutical preparation as in claim 121 wherein said preparation is essentially
2 free of an antibody which selectively binds a normal CalDAG-GEF protein.

3

1 123. A pharmaceutical preparation as in claim 121 wherein said preparation is essentially
2 free of an antibody which selectively binds a normal cAMP-GEF protein.

3

1 124. A pharmaceutical preparation comprising a substantially pure preparation of an
2 antigenic determinant of a mutant CalDAG-GEF protein or a mutant cAMP-GEF protein.

3

1 125. A pharmaceutical preparation as in claim 124 wherein said preparation is essentially
2 free of an antigenic determinant of a normal CalDAG-GEF protein.

3

1 126. A pharmaceutical preparation as in claim 124 wherein said preparation is essentially
2 free of an antigenic determinant of a normal cAMP-GEF protein.

3

1 127. A method for identifying compounds according to claim 83, wherein the cAMP-GEF
2 component is a cAMP-GEF domain selected from the group consisting of SCR1, SCR2, SCR3,
3 and cAMP-binding domain.

4

1 128. A method for identifying compounds according to claim 82, wherein the CalDAG-
2 GEF component is a CalDAG-GEF domain selected from the group consisting of SCR1, SCR2,
3 SCR3, DAG-binding and an EF hand domain.

4

1 129. A substantially pure preparation of a polypeptide comprising a domain selected from
2 the group consisting of a CalDAG-GEF SCR1 domain, a CalDAG-GEF SCR2 domain,
3 CalDAG-GEF SCR3 domain, CalDAG-GEF DAG-binding domain, CalDAG-GEF EF hand
4 domain.

5

1 130. A substantially pure preparation of a polypeptide comprising a domain selected from
2 the group consisting of a cAMP-GEF SCR1 domain, a cAMP-GEF SCR2 domain, cAMP-GEF
3 SCR3 domain, cAMP-GEF cAMP-binding domain.

4

GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS

Abstract of the Disclosure

The present invention describes the identification, isolation, sequencing and characterization of two human CalDAG-GEF, and two human cAMP-GEF genes, which are associated with the Ras pathway. Also identified are CalDAG-GEF gene homologues in mice and cAMP-GEF gene homologues in rats. Nucleic acids and proteins comprising or derived from the CalDAG-GEFs and/or cAMP-GEFs are useful in screening and diagnosing certain Ras-associated cancers, in identifying and developing therapeutics for treatment of certain Ras-associated cancers, and in producing cell lines and transgenic animals useful as models of Ras-associated cancers.

479JAC5473/111.878507-1

RECORDED BY AUTOMATIC DOCUMENT FEEDER SYSTEM
BOSTON RESEARCH & DEVELOPMENT INC.




Figure 1





Figure 2

Figure 3



PATENT
Attorney Docket No. MIT-103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Kawasaki et al.

SERIAL NO.: Not yet assigned GROUP NO.: Not yet assigned

FILING DATE: October 22, 1999 EXAMINER: Not yet assigned

TITLE: Genes Integrating Signal Transduction Pathways

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY
OF SEQUENCE LISTING FOR INVENTION
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. This replies to the Patent Office Letter dated _____

Note: If these papers are filed before the office letter issues adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

A copy of the Patent Office Letter is enclosed.

2. Submitted herewith is/are

(check each item as applicable)

A. a paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier.

B. a copy, in computer readable form, of the Sequence Listing for this application.

STATEMENT

3. I hereby state that:

(complete applicable items A, B and/or C)

- A. the content of the paper and computer readable copies submitted herewith are the same.
- B. the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on pages 60 to 108 of the original specification as filed on even date herewith.
- C. this submission includes no new matter.

Respectfully submitted,



Jennifer A. Camacho

Attorney for Applicant(s)
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: 10/22/99

Reg. No. 43,526

Tel. No.: (617) 248-7476

Fax No.: (617) 248-7100

479JAC5473/111.A877137-1

SEQUENCE LISTING

<110> Kawasaki, Hiroaki
Graybiel, Ann
Housman, David

<120> Genes Integrating Signal Transduction Pathways

<130> MIT-103

<140>
<141>

<150> US 60/105,507
<151> 1998-10-23

<150> US 60/108,685
<151> 1998-11-16

<160> 18

<170> PatentIn Ver. 2.0

<210> 1
<211> 2250
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (166)..(1989)
<223> CalDAG-GEFI

<400> 1
cgaaggatca gaggctgagc tggttcaagt gaacagaagg tctggaggt gaactgcatt 60
cgggttgca ttctgaagta aaggacttgg gacaggggta cgaatcgagc actgtggag 120
gctctgagag tgtaacttgg gtctagccc ctggcaccgg cagcc atg gcg agc act 177
Met Ala Ser Thr
1
ctg gac ctg gac aag ggt tgc acc gtg gag gag ctg ctc cgt ggc tgt 225
Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu Leu Arg Gly Cys
5 10 15 20
atc gaa gcc ttt gat gac tct gga aag gtg cga gat cca cag cta gtg 273
Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp Pro Gln Leu Val
25 30 35
cgc atg ttt ctc atg atg cac ccc tgg tac ata cct tcc tct cag ctg 321
Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro Ser Ser Gln Leu
40 45 50
gct tcg aaa ctg ctc cac ttc tat cag caa tcc cgg aag gac aac tcc 369
Ala Ser Lys Leu Leu His Phe Tyr Gln Gln Ser Arg Lys Asp Asn Ser
55 60 65
aat tcc cta cag gtg aaa acc tgt cac ctg gtc agg tac tgg gtc tca 417
Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg Tyr Trp Val Ser
70 75 80
gcc ttc cca gca gag ttc gac ttg aac cca gag ctg gct gaa ccg atc 465
Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu Ala Glu Pro Ile
85 90 95 100
aag gag ctg aag gct ctg tta gac caa gaa gga aac cgc agg cac agc 513
Lys Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn Arg Arg His Ser
105 110 115

agc ctc atc gac atc gag agt gtc ccc acc tac aag tgg aag cgg cag	561
Ser Leu Ile Asp Ile Glu Ser Val Pro Thr Tyr Lys Trp Lys Arg Gln	
120 125 130	
gtg acc cag cgg aac cct gtg gaa cag aaa aag cgc aag atg tcc ctg	609
Val Thr Gln Arg Asn Pro Val Glu Gln Lys Lys Arg Lys Met Ser Leu	
135 140 145	
ttg ttt gat cac ttg gag cct atg gaa ctg gca gaa cat ctc acc tac	657
Leu Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu His Leu Thr Tyr	
150 155 160	
ttg gag tat cgg tcc ttc tgc aag atc ctg ttc cag gac tat cac agc	705
Leu Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln Asp Tyr His Ser	
165 170 175 180	
ttt gtg act cat ggc tgc act gta gac aat ccg gtc ctg gag cga ttc	753
Phe Val Thr His Gly Cys Thr Val Asp Asn Pro Val Leu Glu Arg Phe	
185 190 195	
atc tcc ctc ttc aac agt gtc tct cag tgg gtc caa ctc atg atc ctc	801
Ile Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln Leu Met Ile Leu	
200 205 210	
agc aag ccc aca gcc acg cag cgg gcg ctg gtc atc aca cat ttc gtg	849
Ser Lys Pro Thr Ala Thr Gln Arg Ala Leu Val Ile Thr His Phe Val	
215 220 225	
cat gtg gca gag aag ctg ctg cag ctg cag aac ttc aac acg ttg atg	897
His Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe Asn Thr Leu Met	
230 235 240	
gcc gtc gtg gga ggc ctg agc cac agc tcc atc tca cgc ctc aag gag	945
Ala Val Val Gly Gly Leu Ser His Ser Ile Ser Arg Leu Lys Glu	
245 250 255 260	
acc cac agc cat gtc agc cct gac acc atc aag ctc tgg gaa ggt ctg	993
Thr His Ser His Val Ser Pro Asp Thr Ile Lys Leu Trp Glu Gly Leu	
265 270 275	
aca gaa cta gtg aca gct act ggc aac tac agc aac tac cgg cga agg	1041
Thr Glu Leu Val Thr Ala Thr Gly Asn Tyr Ser Asn Tyr Arg Arg Arg	
280 285 290	
ctg gcg gcc tgc gtg ggc ttc cgc ttt cct atc ctg ggt gtg cac ctc	1089
Leu Ala Ala Cys Val Gly Phe Arg Phe Pro Ile Leu Gly Val His Leu	
295 300 305	
aag gat cta gtg gct ctg cag ctg gct ctg cct gac tgg ctg gac cca	1137
Lys Asp Leu Val Ala Leu Gln Leu Ala Leu Pro Asp Trp Leu Asp Pro	
310 315 320	
ggt cgg acc cgg ctc aat gga gcc aag atg agg cag ctt ttc agc att	1185
Gly Arg Thr Arg Leu Asn Gly Ala Lys Met Arg Gln Leu Phe Ser Ile	
325 330 335 340	
ctg gag gag ttg gct atg gtg acc agt ctt cga cca cca gtg caa gcc	1233
Leu Glu Leu Ala Met Val Thr Ser Leu Arg Pro Pro Val Gln Ala	
345 350 355	
aac ccc gac ctg ctg agt ctg ctc acg gtg tcc ctg gac cag tat cag	1281
Asn Pro Asp Leu Leu Ser Leu Leu Thr Val Ser Leu Asp Gln Tyr Gln	
360 365 370	
acg gag gat gag ctg tat cag ctc tct ctg cag cga gag cca cgt tcc	1329
Thr Glu Asp Glu Leu Tyr Gln Leu Ser Leu Gln Arg Glu Pro Arg Ser	
375 380 385	

aag tca tcg ccc acc agc ccc acc agc tgc acc ccg cct ccc ccg ccg	1377
Lys Ser Ser Pro Thr Ser Pro Thr Ser Cys Thr Pro Pro Pro Arg Pro	
390 395 400	
cct gtg ctg gaa gag tgg acc tca gtt gcc aag cct aag ctg gac caa	1425
Pro Val Leu Glu Glu Trp Thr Ser Val Ala Lys Pro Lys Leu Asp Gln	
405 410 415 420	
gcc ttg gtg gcc gag cac att gag aag atg gtg gag tct gtg ttc ccg	1473
Ala Leu Val Ala Glu His Ile Glu Lys Met Val Glu Ser Val Phe Arg	
425 430 435	
aac ttt gac gtt gat ggg gac ggt cac atc tcc cag gag gag ttc cag	1521
Asn Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln Glu Glu Phe Gln	
440 445 450	
atc atc cgg ggc aac ttc cct tat ctc agc gcc ttt ggg gac ttg gac	1569
Ile Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe Gly Asp Leu Asp	
455 460 465	
cag aac cag gat ggc tgc atc agc cgg gag gag atg att tcc tac ttc	1617
Gln Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met Ile Ser Tyr Phe	
470 475 480	
ctg cgc tcc agc tcc gtg ctg gga ggc cgc atg ggc ttc gta cac aac	1665
Leu Arg Ser Ser Val Leu Gly Gly Arg Met Gly Phe Val His Asn	
485 490 495 500	
ttc cag gag agt aac tcg cta agg ccg gtc gcc tgc cga cac tgc aaa	1713
Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys Arg His Cys Lys	
505 510 515	
gct ctg atc ctg ggc atc tac aag cag ggc ctc aaa tgt aga gct tgt	1761
Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys Cys Arg Ala Cys	
520 525 530	
ggt gtg aac tgc cac aag cag tgc aaa gac cga ctg tca gtg gaa tgt	1809
Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu Ser Val Glu Cys	
535 540 545	
cgc cgc cgc gcc cag agt gtg agc ctg gag ggc tct gca ccc tct ccc	1857
Arg Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser Ala Pro Ser Pro	
550 555 560	
tca ccc aca cat acc cac cat cgg gcc ttc agc ttc tcc ctg cct cgc	1905
Ser Pro Thr His Thr His Arg Ala Phe Ser Phe Ser Leu Pro Arg	
565 570 575 580	
cca ggc agg cgc agc tct cgg cct cca gag atc cgt gaa gag gag gtg	1953
Pro Gly Arg Arg Ser Ser Arg Pro Pro Glu Ile Arg Glu Glu Val	
585 590 595	
cag act gtg gaa gat ggt gtg ttc gac atc cac tta taagacgctg	1999
Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu	
600 605	
tgactatcaa ggactcattc ctgccttggaa gaaaagactt ggagcagagc agggagccag	2059
ggattctggg gcaggagggtt ggggctgaag gtggggaaat ttgaagggtgg catgcactga	2119
aaaaaaaggcc agggctggtg tccctaaggt tgtacagact tctgtgaata tttgtatTTT	2179
ccagatggaa taaaaaggcc cgaataatta acctcgaaaa aaaaaaaaaaaa aaaaaaaaaaa	2239
aaaaaaaaaaa a	2250

<210> 2
<211> 608

<212> PRT

<213> Mus musculus

<400> 2
Met Ala Ser Thr Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu
1 5 10 15
Leu Arg Gly Cys Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp
20 25 30
Pro Gln Leu Val Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro
35 40 45
Ser Ser Gln Leu Ala Ser Lys Leu Leu His Phe Tyr Gln Gln Ser Arg
50 55 60
Lys Asp Asn Ser Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg
65 70 75 80
Tyr Trp Val Ser Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu
85 90 95
Ala Glu Pro Ile Lys Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn
100 105 110
Arg Arg His Ser Ser Leu Ile Asp Ile Glu Ser Val Pro Thr Tyr Lys
115 120 125
Trp Lys Arg Gln Val Thr Gln Arg Asn Pro Val Glu Gln Lys Lys Arg
130 135 140
Lys Met Ser Leu Leu Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu
145 150 155 160
His Leu Thr Tyr Leu Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln
165 170 175
Asp Tyr His Ser Phe Val Thr His Gly Cys Thr Val Asp Asn Pro Val
180 185 190
Leu Glu Arg Phe Ile Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln
195 200 205
Leu Met Ile Leu Ser Lys Pro Thr Ala Thr Gln Arg Ala Leu Val Ile
210 215 220
Thr His Phe Val His Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe
225 230 235 240
Asn Thr Leu Met Ala Val Val Gly Gly Leu Ser His Ser Ser Ile Ser
245 250 255
Arg Leu Lys Glu Thr His Ser His Val Ser Pro Asp Thr Ile Lys Leu
260 265 270
Trp Glu Gly Leu Thr Glu Leu Val Thr Ala Thr Gly Asn Tyr Ser Asn
275 280 285
Tyr Arg Arg Arg Leu Ala Ala Cys Val Gly Phe Arg Phe Pro Ile Leu
290 295 300
Gly Val His Leu Lys Asp Leu Val Ala Leu Gln Leu Ala Leu Pro Asp
305 310 315 320
Trp Leu Asp Pro Gly Arg Thr Arg Leu Asn Gly Ala Lys Met Arg Gln
325 330 335
Leu Phe Ser Ile Leu Glu Glu Leu Ala Met Val Thr Ser Leu Arg Pro
340 345 350

Pro Val Gln Ala Asn Pro Asp Leu Leu Ser Leu Leu Thr Val Ser Leu
355 360 365
Asp Gln Tyr Gln Thr Glu Asp Glu Leu Tyr Gln Leu Ser Leu Gln Arg
370 375 380
Glu Pro Arg Ser Lys Ser Ser Pro Thr Ser Pro Thr Ser Cys Thr Pro
385 390 395 400
Pro Pro Arg Pro Pro Val Leu Glu Trp Thr Ser Val Ala Lys Pro
405 410 415
Lys Leu Asp Gln Ala Leu Val Ala Glu His Ile Glu Lys Met Val Glu
420 425 430
Ser Val Phe Arg Asn Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln
435 440 445
Glu Glu Phe Gln Ile Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe
450 455 460
Gly Asp Leu Asp Gln Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met
465 470 475 480
Ile Ser Tyr Phe Leu Arg Ser Ser Val Leu Gly Gly Arg Met Gly
485 490 495
Phe Val His Asn Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys
500 505 510
Arg His Cys Lys Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys
515 520 525
Cys Arg Ala Cys Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu
530 535 540
Ser Val Glu Cys Arg Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser
545 550 555 560
Ala Pro Ser Pro Ser Pro Thr His Thr His Arg Ala Phe Ser Phe
565 570 575
Ser Leu Pro Arg Pro Gly Arg Arg Ser Ser Arg Pro Pro Glu Ile Arg
580 585 590
Glu Glu Glu Val Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu
595 600 605

<210> 3
<211> 2236
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (161)..(1987)
<223> CalDAG-GEFI

<400> 3
ggggactcaa ggctggcctg gctcaagtga acagcacgtc caggaggcga cctcgtccgc 60
gggtttgcat tctggggtgg acgagctggg ggttcggtcc gagcccggtg ggaggctccc 120
ggagcgcagc ctgggcccag cccaccccgcc gccggcggcc atg gca ggc acc ctg 175
Met Ala Gly Thr Leu
1 5

gac ctg gac aag ggc tgc acg gtg gag gag ctg ctc cgc ggg tgc atc	223
Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu Leu Arg Gly Cys Ile	
10 15 20	
gaa gcc ttc gat gac tcc ggg aag gtg cgg gac ccg cag ctg gtg cgc	271
Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp Pro Gln Leu Val Arg	
25 30 35	
atg ttc ctc atg cac ccc tgg tac atc ccc tcc tct cag ctg gcg	319
Met Phe Leu Met Met His Pro Trp Tyr Ile Pro Ser Ser Gln Leu Ala	
40 45 50	
gcc aag ctg ctc cac atc tac caa caa tcc cgg aag gac aac tcc aat	367
Ala Lys Leu Leu His Ile Tyr Gln Gln Ser Arg Lys Asp Asn Ser Asn	
55 60 65	
tcc ctg cag gtg aaa acg tgc cac ctg gtc agg tac tgg atc tcc gcc	415
Ser Leu Gln Val Lys Thr Cys His Leu Val Arg Tyr Trp Ile Ser Ala	
70 75 80 85	
ttc cca gcg gag ttt gac ttg aac ccg gag ttg gct gag cag atc aag	463
Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu Ala Glu Gln Ile Lys	
90 95 100	
gag ctg aag gct ctg cta gac caa gaa ggg aac cga cgg cac agc agc	511
Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn Arg Arg His Ser Ser	
105 110 115	
cta atc gac ata gac agc gtc cct acc tac aag tgg aag cgg cag gtg	559
Leu Ile Asp Ile Asp Ser Val Pro Thr Tyr Lys Trp Lys Arg Gln Val	
120 125 130	
act cag cgg aac cct gtg gga cag aaa aag cgc aag atg tcc ctg ttg	607
Thr Gln Arg Asn Pro Val Gly Gln Lys Arg Lys Met Ser Leu Leu	
135 140 145	
ttt gac cac ctg gag ccc atg gag ctg gcg gag cat ctc acc tac ttg	655
Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu His Leu Thr Tyr Leu	
150 155 160 165	
gag tat cgc tcc ttc tgc aag atc ctg ttt cag gac tat cac agt ttc	703
Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln Asp Tyr His Ser Phe	
170 175 180	
gtg act cat ggc tgc act gtg gac aac ccc gtc ctg gag cgg ttc atc	751
Val Thr His Gly Cys Thr Val Asp Asn Pro Val Leu Glu Arg Phe Ile	
185 190 195	
tcc ctc ttc aac agc gtc tca cag tgg gtg cag ctc atg atc ctc agc	799
Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln Leu Met Ile Leu Ser	
200 205 210	
aaa ccc aca gcc ccg cag cgg gcc ctg gtc atc aca cac ttt gtc cac	847
Lys Pro Thr Ala Pro Gln Arg Ala Leu Val Ile Thr His Phe Val His	
215 220 225	
gtg gcg gag aag ctg cta cag ctg cag aac ttc aac acg ctg atg gca	895
Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe Asn Thr Leu Met Ala	
230 235 240 245	
gtg gtc ggg ggc ctg agc cac agc tcc atc tcc cgc ctc aag gag acc	943
Val Val Gly Gly Leu Ser His Ser Ser Ile Ser Arg Leu Lys Glu Thr	
250 255 260	
cac agc cac gtt agc cct gag acc atc aag ctc tgg gag ggt ctc acg	991
His Ser His Val Ser Pro Glu Thr Ile Lys Leu Trp Glu Gly Leu Thr	
265 270 275	
gaa cta gtg acg gcg aca ggc aac tat ggc aac tac cgg cgt cgg ctg	1039

Glu	Leu	Val	Thr	Ala	Thr	Gly	Asn	Tyr	Gly	Asn	Tyr	Arg	Arg	Arg	Leu	
280						285						290				
gca	gcc	tgt	gtg	ggc	ttc	cgc	ttc	ccg	atc	ctg	ggt	gtg	cac	ctc	aag	1087
Ala	Ala	Cys	Val	Gly	Phe	Arg	Phe	Pro	Ile	Leu	Gly	Val	His	Leu	Lys	
295												305				
gac	ctg	gtg	gcc	ctg	cag	ctg	gca	ctg	cct	gac	tgg	ctg	gac	cca	gcc	1135
Asp	Leu	Val	Ala	Leu	Gln	Leu	Ala	Leu	Pro	Asp	Trp	Leu	Asp	Pro	Ala	
310												320			325	
cgg	acc	ccg	ctc	aac	ggg	gcc	aag	atg	aag	cag	ctc	ttt	agc	atc	ctg	1183
Arg	Thr	Arg	Leu	Asn	Gly	Ala	Lys	Met	Lys	Gln	Leu	Phe	Ser	Ile	Leu	
330												335			340	
gag	gag	ctg	gcc	atg	gtg	acc	agc	ctg	cgg	cca	cca	gta	cag	gcc	aac	1231
Glu	Glu	Leu	Ala	Met	Val	Thr	Ser	Leu	Arg	Pro	Pro	Val	Gln	Ala	Asn	
345												350			355	
ccc	gac	ctg	ctg	agc	ctg	ctc	acg	gtg	tct	ctg	gat	cag	tat	cag	acg	1279
Pro	Asp	Leu	Leu	Ser	Leu	Leu	Thr	Val	Ser	Leu	Asp	Gln	Tyr	Gln	Thr	
360												365			370	
gag	gat	gag	ctg	tac	cag	ctg	tcc	ctg	cag	cgg	gag	ccg	cgc	tcc	aag	1327
Glu	Asp	Glu	Leu	Tyr	Gln	Leu	Ser	Leu	Gln	Arg	Glu	Pro	Arg	Ser	Lys	
375												380			385	
tct	tcg	cca	acc	agc	ccc	acg	agt	tgc	acc	cca	cca	ccc	cgg	ccc	ccg	1375
Ser	Ser	Pro	Thr	Ser	Pro	Thr	Ser	Cys	Thr	Pro	Pro	Pro	Arg	Pro	Pro	
390												395			405	
400												400				
gta	ttg	gag	gag	tgg	acc	tcg	gct	gcc	aaa	ccc	aag	ctg	gat	cag	gcc	1423
Val	Leu	Glu	Glu	Trp	Thr	Ser	Ala	Ala	Lys	Pro	Lys	Leu	Asp	Gln	Ala	
410												415			420	
ctc	gtg	gtg	gag	cac	atc	gag	aag	atg	gtg	gag	tct	gtg	ttc	cgg	aac	1471
Leu	Val	Val	Glu	His	Ile	Glu	Lys	Met	Val	Glu	Ser	Val	Phe	Arg	Asn	
425												430			435	
ttt	gac	gtc	gat	ggg	gat	ggc	cac	atc	tca	cag	gaa	gaa	ttc	cag	atc	1519
Phe	Asp	Val	Asp	Gly	Asp	Gly	His	Ile	Ser	Gln	Glu	Glu	Phe	Gln	Ile	
440												445			450	
atc	cgt	ggg	aac	ttc	cct	tac	ctc	agc	gcc	ttt	ggg	gac	ctc	gac	cag	1567
Ile	Arg	Gly	Asn	Phe	Pro	Tyr	Leu	Ser	Ala	Phe	Gly	Asp	Leu	Asp	Gln	
455												460			465	
aac	cag	gat	ggc	tgc	atc	agc	agg	gag	gag	atg	gtt	tcc	tat	ttc	ctg	1615
Asn	Gln	Asp	Gly	Cys	Ile	Ser	Arg	Glu	Glu	Met	Val	Ser	Tyr	Phe	Leu	
470												475			485	
cgc	tcc	agc	tct	gtg	ttg	ggg	ggg	cgc	atg	ggc	ttc	gta	cac	aac	ttc	1663
Arg	Ser	Ser	Ser	Val	Leu	Gly	Gly	Arg	Met	Gly	Phe	Val	His	Asn	Phe	
490												495			500	
cag	gag	agc	aac	tcc	ttg	cgc	ccc	gtc	gcc	tgc	cac	tgc	aaa	gcc		1711
Gln	Glu	Ser	Asn	Ser	Leu	Arg	Pro	Val	Ala	Cys	Arg	His	Cys	Lys	Ala	
505												510			515	
ctg	atc	ctg	ggc	atc	tac	aag	cag	ggc	ctc	aaa	tgc	cga	gcc	tgt	gga	1759
Leu	Ile	Leu	Gly	Ile	Tyr	Lys	Gln	Gly	Leu	Lys	Cys	Arg	Ala	Cys	Gly	
520												525			530	
gtg	aac	tgc	cac	aag	cag	tgc	aag	gat	cgc	ctg	tca	gtt	gag	tgt	cgg	1807
Val	Asn	Cys	His	Lys	Gln	Cys	Lys	Asp	Arg	Leu	Ser	Val	Glu	Cys	Arg	
535												540			545	
cgc	agg	gcc	cag	agt	gtg	agc	ctg	gag	ggg	tct	gca	ccc	tca	ccc	tca	1855
Arg	Arg	Ala	Gln	Ser	Val	Ser	Leu	Glu	Gly	Ser	Ala	Pro	Ser	Pro	Ser	

550	555	560	565	
ccc atg cac agc cac cat cac cgcc gcc ttc agc ttc tct ctg ccc cgc				1903
Pro Met His Ser His His Arg Ala Phe Ser Phe Ser Leu Pro Arg				
570	575	580		
cct ggc agg cga ggc tcc agg cct cca gag atc cgt gag gag gag gta				1951
Pro Gly Arg Arg Gly Ser Arg Pro Pro Glu Ile Arg Glu Glu Val				
585	590	595		
cag acg gtg gag gat ggg gtg ttt gac atc cac ttg taatagatgc				1997
Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu				
600	605			

tgtggttgga tcaaggactc attcctgcct tggagaaaat acttcaacca gagcaggag 2057
cctgggggtg tcggggcagg aggctgggga tgggggtggg atatgaggtt ggcatgcagc 2117
tgagggcagg gccagggctg gtgtccctaa gtttgcacag actcttgcata atattgtat 2177
tttccagatg gaataaaaaag gcccgtgtaa ttaaccttca aaaaaaaaaa aaaaaaaaaa 2236

<210> 4
<211> 609
<212> PRT
<213> Homo sapiens

<400> 4
Met Ala Gly Thr Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu
1 5 10 15
Leu Arg Gly Cys Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp
20 25 30
Pro Gln Leu Val Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro
35 40 45
Ser Ser Gln Leu Ala Ala Lys Leu Leu His Ile Tyr Gln Gln Ser Arg
50 55 60
Lys Asp Asn Ser Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg
65 70 75 80
Tyr Trp Ile Ser Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu
85 90 95
Ala Glu Gln Ile Lys Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn
100 105 110
Arg Arg His Ser Ser Leu Ile Asp Ile Asp Ser Val Pro Thr Tyr Lys
115 120 125
Trp Lys Arg Gln Val Thr Gln Arg Asn Pro Val Gly Gln Lys Lys Arg
130 135 140
Lys Met Ser Leu Leu Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu
145 150 155 160
His Leu Thr Tyr Leu Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln
165 170 175
Asp Tyr His Ser Phe Val Thr His Gly Cys Thr Val Asp Asn Pro Val
180 185 190
Leu Glu Arg Phe Ile Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln
195 200 205
Leu Met Ile Leu Ser Lys Pro Thr Ala Pro Gln Arg Ala Leu Val Ile

210 215 220

Thr His Phe Val His Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe
225 230 235 240

Asn Thr Leu Met Ala Val Val Gly Gly Leu Ser His Ser Ser Ile Ser
245 250 255

Arg Leu Lys Glu Thr His Ser His Val Ser Pro Glu Thr Ile Lys Leu
260 265 270

Trp Glu Gly Leu Thr Glu Leu Val Thr Ala Thr Gly Asn Tyr Gly Asn
275 280 285

Tyr Arg Arg Arg Leu Ala Ala Cys Val Gly Phe Arg Phe Pro Ile Leu
290 295 300

Gly Val His Leu Lys Asp Leu Val Ala Leu Gln Leu Ala Leu Pro Asp
305 310 315 320

Trp Leu Asp Pro Ala Arg Thr Arg Leu Asn Gly Ala Lys Met Lys Gln
325 330 335

Leu Phe Ser Ile Leu Glu Glu Leu Ala Met Val Thr Ser Leu Arg Pro
340 345 350

Pro Val Gln Ala Asn Pro Asp Leu Leu Ser Leu Leu Thr Val Ser Leu
355 360 365

Asp Gln Tyr Gln Thr Glu Asp Glu Leu Tyr Gln Leu Ser Leu Gln Arg
370 375 380

Glu Pro Arg Ser Lys Ser Ser Pro Thr Ser Pro Thr Ser Cys Thr Pro
385 390 395 400

Pro Pro Arg Pro Pro Val Leu Glu Glu Trp Thr Ser Ala Ala Lys Pro
405 410 415

Lys Leu Asp Gln Ala Leu Val Val Glu His Ile Glu Lys Met Val Glu
420 425 430

Ser Val Phe Arg Asn Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln
435 440 445

Glu Glu Phe Gln Ile Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe
450 455 460

Gly Asp Leu Asp Gln Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met
465 470 475 480

Val Ser Tyr Phe Leu Arg Ser Ser Ser Val Leu Gly Gly Arg Met Gly
485 490 495

Phe Val His Asn Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys
500 505 510

Arg His Cys Lys Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys
515 520 525

Cys Arg Ala Cys Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu
530 535 540

Ser Val Glu Cys Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser
545 550 555 560

Ala Pro Ser Pro Ser Pro Met His Ser His His His Arg Ala Phe Ser
565 570 575

Phe Ser Leu Pro Arg Pro Gly Arg Arg Gly Ser Arg Pro Pro Glu Ile

580 585 590
Arg Glu Glu Glu Val Gln Thr Val Glu Asp Gly Val Phe Asp Ile His
595 600 605

Leu

<210> 5
<211> 3624
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (145)..(2529)
<223> CalDAG-GEFII

<400> 5
gcgcctgggt cggctcgccg ggctccgaga gtggccggct ccgggctgcg agggccggcg 60
gcggccgagg gatgcgcccgc tcccgccga gccgatccca ccgctccagg tgagacggct 120
ccaggggcgc agagagccgc ggcc atg gga acc ctg ggc aag gcg aga gag 171
Met Gly Thr Leu Gly Lys Ala Arg Glu
1 5
gct ccg cgg aaa cct tgc cat ggc tcc aga gct ggc ccc aaa gga aga 219
Ala Pro Arg Lys Pro Cys His Gly Ser Arg Ala Gly Pro Lys Gly Arg
10 15 20 25
cta gag gcc aaa tca acc aac agt cct ctc cct gcc cag ccc agc ttg 267
Leu Glu Ala Lys Ser Thr Asn Ser Pro Leu Pro Ala Gln Pro Ser Leu
30 35 40
gcc cag atc acc cag ttc cga atg atg gtg tcc ctg gga cat ctg gcc 315
Ala Gln Ile Thr Gln Phe Arg Met Met Val Ser Leu Gly His Leu Ala
45 50 55
aaa gga gcc agc ctg gat gat ctt att gac agc tgc att caa tct ttc 363
Lys Gly Ala Ser Leu Asp Asp Leu Ile Asp Ser Cys Ile Gln Ser Phe
60 65 70
gat gca gat gga aac ctg tgt cga agt aac cag ctg tta caa gtc atg 411
Asp Ala Asp Gly Asn Leu Cys Arg Ser Asn Gln Leu Leu Gln Val Met
75 80 85
cta acc atg cac cga atc atc atc tcc tcg gcc gag ctg ctg caa aaa 459
Leu Thr Met His Arg Ile Ile Ser Ser Ala Glu Leu Leu Gln Lys
90 95 100 105
ctc atg aat cta tat aag gac gcc ctg gaa aag aat tct cca gga att 507
Leu Met Asn Leu Tyr Lys Asp Ala Leu Glu Lys Asn Ser Pro Gly Ile
110 115 120
tgc ttg aag atc tgc tat ttt gtc agg tat tgg ata aca gaa ttc tgg 555
Cys Leu Lys Ile Cys Tyr Phe Val Arg Tyr Trp Ile Thr Glu Phe Trp
125 130 135
atc atg ttc aaa atg gat gcc agc ttg acc agc acc atg gaa gag ttt 603
Ile Met Phe Lys Met Asp Ala Ser Leu Thr Ser Thr Met Glu Glu Phe
140 145 150
cag gac ctg gtg aaa gcc aat ggt gag gag tcc cac tgc cac ctc atc 651
Gln Asp Leu Val Lys Ala Asn Gly Glu Glu Ser His Cys His Leu Ile
155 160 165
gac acg aca caa att aat tct cga gac tgg tcc agg aaa ctg act cag 699

Asp	Thr	Thr	Gln	Ile	Asn	Ser	Arg	Asp	Trp	Ser	Arg	Lys	Leu	Thr	Gln	
170				175				180				185				
agg	ata	aaa	tca	aat	acc	agc	aag	aag	cg	aaa	gt	tcc	ctg	ctg	ttt	747
Arg	Ile	Lys	Ser	Asn	Thr	Ser	Lys	Lys	Arg	Lys	Val	Ser	Leu	Leu	Phe	
				190				195				200				
gac	cat	ctt	gaa	cct	gaa	gaa	ctg	tct	gaa	cac	ctc	acc	tac	ctt	gag	795
Asp	His	Leu	Glu	Pro	Glu	Glu	Leu	Ser	Glu	His	Leu	Thr	Tyr	Leu	Glu	
				205				210				215				
ttc	aag	tcc	tcc	cga	cg	ata	tct	tcc	tct	gat	tat	cag	aat	tac	ctt	843
Phe	Lys	Ser	Phe	Arg	Arg	Ile	Ser	Phe	Ser	Asp	Tyr	Gln	Asn	Tyr	Leu	
				220				225				230				
gta	aac	agc	tgc	gta	aag	gag	aac	ccc	acc	atg	gag	cg	tcc	att	gcc	891
Val	Asn	Ser	Cys	Val	Lys	Glu	Asn	Pro	Thr	Met	Glu	Arg	Ser	Ile	Ala	
				235				240				245				
ctg	tgc	aat	ggc	atc	tcc	cag	tgg	gta	caa	ctg	atg	gtt	ctc	agc	cgt	939
Leu	Cys	Asn	Gly	Ile	Ser	Gln	Trp	Val	Gln	Leu	Met	Val	Leu	Ser	Arg	
				250				255				260			265	
ccc	acc	cca	cag	ctc	cg	gca	gag	gtc	tcc	atc	aag	ttc	atc	cat	gtg	987
Pro	Thr	Pro	Gln	Leu	Arg	Ala	Glu	Val	Phe	Ile	Lys	Phe	Ile	His	Val	
				270				275				280				
gct	cag	aag	ctc	cac	cag	cta	cag	aac	tcc	aac	acg	cta	atg	gct	gtg	1035
Ala	Gln	Lys	Leu	His	Gln	Leu	Gln	Asn	Phe	Asn	Thr	Leu	Met	Ala	Val	
				285				290				295				
atc	ggg	gga	ctg	tgt	cac	agc	tcc	atc	tcc	agg	ctc	aag	gag	aca	agt	1083
Ile	Gly	Gly	Leu	Cys	His	Ser	Ser	Ile	Ser	Arg	Leu	Lys	Glu	Thr	Ser	
				300				305				310				
tca	cat	gtc	cca	cat	gag	atc	aat	aag	gtt	ctg	ggt	gag	atg	act	gaa	1131
Ser	His	Val	Pro	His	Glu	Ile	Asn	Lys	Val	Leu	Gly	Glu	Met	Thr	Glu	
				315				320				325				
ctg	ctg	tcc	tcc	tgc	aga	aac	tat	gac	aac	tac	agg	cg	gcc	tat	ggt	1179
Leu	Leu	Ser	Ser	Cys	Arg	Asn	Tyr	Asp	Asn	Tyr	Arg	Arg	Ala	Tyr	Gly	
				330				335				340			345	
gag	tgc	acc	cac	ttc	aaa	atc	ccc	ata	ctg	ggt	gt	cac	ctc	aag	gac	1227
Glu	Cys	Thr	His	Phe	Lys	Ile	Pro	Ile	Leu	Gly	Val	His	Leu	Lys	Asp	
				350				355				360				
ctc	ata	tcc	cta	tat	gaa	gcc	atg	cct	gac	tac	ctg	gaa	gac	ggg	aag	1275
Leu	Ile	Ser	Leu	Tyr	Glu	Ala	Met	Pro	Asp	Tyr	Leu	Glu	Asp	Gly	Lys	
				365				370				375				
gtg	aat	gtc	caa	aag	ctc	ctg	gcc	ctt	tac	aat	cac	atc	aat	gag	ttg	1323
Val	Asn	Val	Gln	Lys	Leu	Leu	Ala	Leu	Tyr	Asn	His	Ile	Asn	Glu	Leu	
				380				385				390				
gtc	cag	ctg	cag	gac	gt	gcc	cca	cca	ttg	gat	gcc	aac	aag	gac	ctg	1371
Val	Gln	Leu	Gln	Asp	Val	Ala	Pro	Pro	Leu	Asp	Ala	Asn	Lys	Asp	Leu	
				395				400				405				
gtg	cac	ctg	ctg	acg	tta	tcc	ctg	gat	cta	tac	tac	acc	gaa	gat	gaa	1419
Val	His	Leu	Leu	Thr	Leu	Ser	Leu	Asp	Leu	Tyr	Tyr	Thr	Glu	Asp	Glu	
				410				415				420			425	
atc	tat	gag	ctt	tcc	tac	gcc	cgt	gaa	cca	agg	aac	cac	agg	gcc	ccg	1467
Ile	Tyr	Glu	Leu	Ser	Tyr	Ala	Arg	Glu	Pro	Arg	Asn	His	Arg	Ala	Pro	
				430				435				440				
cca	ctg	aca	cct	tcg	aag	cca	cca	gtt	gta	gt	gac	tgg	gcc	tct	gga	1515
Pro	Leu	Thr	Pro	Ser	Lys	Pro	Pro	Val	Val	Val	Asp	Trp	Ala	Ser	Gly	

445	450	455	
gtg tct ccc aaa cct gac ccg aag acc atc agc aaa cac gtc caa agg			1563
Val Ser Pro Lys Pro Asp Pro Lys Thr Ile Ser Lys His Val Gln Arg			
460	465	470	
atg gtg gat tct gtc ttt aag aac tat gat ctc gac cag gat gga tat			1611
Met Val Asp Ser Val Phe Lys Asn Tyr Asp Leu Asp Gln Asp Gly Tyr			
475	480	485	
atc tct cag gag gag ttt gaa aag att gct gcg agc ttt cca ttt tcc			1659
Ile Ser Gln Glu Glu Phe Glu Lys Ile Ala Ala Ser Phe Pro Phe Ser			
490	495	500	505
ttc tgt gtg atg gac aaa gat agg gag ggc ctc atc agc aga gac gag			1707
Phe Cys Val Met Asp Lys Asp Arg Glu Gly Leu Ile Ser Arg Asp Glu			
510	515	520	
atc aca gcc tac ttc atg agg gcc agc tcc atc tat tcc aag ctg ggc			1755
Ile Thr Ala Tyr Phe Met Arg Ala Ser Ser Ile Tyr Ser Lys Leu Gly			
525	530	535	
cta ggc ttt cca cac aac ttt caa gag acc act tac ctg aag ccc acc			1803
Leu Gly Phe Pro His Asn Phe Gln Glu Thr Thr Tyr Leu Lys Pro Thr			
540	545	550	
ttc tgt gac aac tgt gct ggc ttt ctc tgg ggt gtg atc aag caa ggc			1851
Phe Cys Asp Asn Cys Ala Gly Phe Leu Trp Gly Val Ile Lys Gln Gly			
555	560	565	
tat cgc tgt aaa gac tgt ggg atg aac tgc cac aaa cag tgc aaa gac			1899
Tyr Arg Cys Lys Asp Cys Gly Met Asn Cys His Lys Gln Cys Lys Asp			
570	575	580	585
ctg gta gtg ttt gag tgc aag aaa cga tcc aag agc ccg gcg gta tcc			1947
Leu Val Val Phe Glu Cys Lys Arg Ser Lys Ser Pro Ala Val Ser			
590	595	600	
aca gaa aac atc agc tct gtg gtg cca atg tcc act ctt tgt cca ctg			1995
Thr Glu Asn Ile Ser Ser Val Val Pro Met Ser Thr Leu Cys Pro Leu			
605	610	615	
gga acc aaa gat ctg ctc cat gca ccc gaa gaa gga tct ttc att ttc			2043
Gly Thr Lys Asp Leu Leu His Ala Pro Glu Glu Gly Ser Phe Ile Phe			
620	625	630	
cag aat gga gag gtt gtg gac cac agt gag gag agc aag gat agg acc			2091
Gln Asn Gly Glu Val Val Asp His Ser Glu Glu Ser Lys Asp Arg Thr			
635	640	645	
atc atg ctc ttg ggc gta tcc tca cag aaa att tca gtt cgg ctg aag			2139
Ile Met Leu Leu Gly Val Ser Ser Gln Lys Ile Ser Val Arg Leu Lys			
650	655	660	665
agg act gtt gcc cac aag acc acc cag aca gaa tca ttt cct tgg gtt			2187
Arg Thr Val Ala His Lys Thr Thr Gln Thr Glu Ser Phe Pro Trp Val			
670	675	680	
ggc ggc gag atg ccc cct ggt cac ttt gtg ctg act tct cca aga aag			2235
Gly Gly Glu Met Pro Pro Gly His Phe Val Leu Thr Ser Pro Arg Lys			
685	690	695	
tca gca caa ggg gct ctt tat gtg cac agt cca gca tct ccg tgc ccc			2283
Ser Ala Gln Gly Ala Leu Tyr Val His Ser Pro Ala Ser Pro Cys Pro			
700	705	710	
agc cca gca ctg gtc cgg aag cgg gca ttc gtc aag tgg gag aac aaa			2331
Ser Pro Ala Leu Val Arg Lys Arg Ala Phe Val Lys Trp Glu Asn Lys			
715	720	725	

gag tcc ctt atc aaa cca aaa cca gag ctt cac ctc agg ctc cg ^g acc	2379
Glu Ser Leu Ile Lys Pro Lys Pro Glu Leu His Leu Arg Leu Arg Thr	
730 735 740 745	
tac caa gaa ctg gaa cag gag gta aat acc ctg agg gca gat aac gat	2427
Tyr Gln Glu Leu Glu Gln Glu Val Asn Thr Leu Arg Ala Asp Asn Asp	
750 755 760	
gct ctg aag atc cag ctg aag tat gca cag aaa caa ata gaa tcc ctg	2475
Ala Leu Lys Ile Gln Leu Lys Tyr Ala Gln Lys Gln Ile Glu Ser Leu	
765 770 775	
cag ctt ggc aaa agc aat cac gtc tta gca cag atg gac cac ggt gat	2523
Gln Leu Gly Lys Ser Asn His Val Leu Ala Gln Met Asp His Gly Asp	
780 785 790	
ggt act taatccagaa attcaaggaa cagaatctgc agacgggtt actggatct	2579
Gly Thr	
795	
cacttcaaaa ctgattgcag aggttcagca actttagact gattgacttt taaagggcag	2639
agatagccac tgttattgggt gtccttgggt tttccctaa ctgtctttaa tgtgagtcgt	2699
gggttttcag tcagttgagt aaaaggaaag aaaagttcca gcatgtaaaa cactgagcag	2759
tcatattcta acctttctt tctttactg aaaccaatac caaacatgtg ctaaaataag	2819
agtatagttt cctgacagtg ttcaggcag cctgcttac tgattcgac tttagataaag	2879
agccccctggt gaatcaattt gctgccttcc ccagggttc tgcaaactgg gagttacttt	2939
gttctacccg aaaacctgct cataatggaa acaataccct aaaagtgtg actttgacat	2999
gcctgcattt tttgtgaagc tgatccctac cttattcact acctcagatc tcaagagcct	3059
ctttccctgt ctttacttg ccccttattt ctccttgc ttgttaggcac atcagcatat	3119
ctacctagaa gtgacctcct agagatgtag cctgtgtta aatccagagc ttcttaattt	3179
aacttgacat tgtctgattt caggccaaact tatagtctta ggtcttagtc attatgaaat	3239
acaaaataaa actacccata atcatcaatt accatgtcat acacagaact cattatctaa	3299
gtcaaacgcac gtaaacacgc ctgtccagat agtcttctt tagtgatag aattaacaat	3359
ctgtgacctt ttaaaagaca tggtctgtta acagtgtta gttcttcacg ttcttagtctc	3419
tctctctctc tctctctctc tctctctctc tctctctctc tctctcaagt aaactatcgt	3479
aaggtcctct tttgaactga atctgtgttt aaaattgtct tcacttttat tatctacaaa	3539
taagctatgg gaggcgatgg cttaaacagc tgacagcatt tacctatgtg tagaatatgt	3599
gtatatagtt tcaggcatgc atgga	3624

<210> 6
<211> 795
<212> PRT
<213> Rattus norvegicus

<400> 6
Met Gly Thr Leu Gly Lys Ala Arg Glu Ala Pro Arg Lys Pro Cys His
1 5 10 15
Gly Ser Arg Ala Gly Pro Lys Gly Arg Leu Glu Ala Lys Ser Thr Asn
20 25 30

Ser Pro Leu Pro Ala Gln Pro Ser Leu Ala Gln Ile Thr Gln Phe Arg
35 40 45

Met Met Val Ser Leu Gly His Leu Ala Lys Gly Ala Ser Leu Asp Asp
50 55 60

Leu Ile Asp Ser Cys Ile Gln Ser Phe Asp Ala Asp Gly Asn Leu Cys
65 70 75 80

Arg Ser Asn Gln Leu Leu Gln Val Met Leu Thr Met His Arg Ile Ile
85 90 95

Ile Ser Ser Ala Glu Leu Leu Gln Lys Leu Met Asn Leu Tyr Lys Asp
100 105 110

Ala Leu Glu Lys Asn Ser Pro Gly Ile Cys Leu Lys Ile Cys Tyr Phe
115 120 125

Val Arg Tyr Trp Ile Thr Glu Phe Trp Ile Met Phe Lys Met Asp Ala
130 135 140

Ser Leu Thr Ser Thr Met Glu Glu Phe Gln Asp Leu Val Lys Ala Asn
145 150 155 160

Gly Glu Glu Ser His Cys His Leu Ile Asp Thr Thr Gln Ile Asn Ser
165 170 175

Arg Asp Trp Ser Arg Lys Leu Thr Gln Arg Ile Lys Ser Asn Thr Ser
180 185 190

Lys Lys Arg Lys Val Ser Leu Leu Phe Asp His Leu Glu Pro Glu Glu
195 200 205

Leu Ser Glu His Leu Thr Tyr Leu Glu Phe Lys Ser Phe Arg Arg Ile
210 215 220

Ser Phe Ser Asp Tyr Gln Asn Tyr Leu Val Asn Ser Cys Val Lys Glu
225 230 235 240

Asn Pro Thr Met Glu Arg Ser Ile Ala Leu Cys Asn Gly Ile Ser Gln
245 250 255

Trp Val Gln Leu Met Val Leu Ser Arg Pro Thr Pro Gln Leu Arg Ala
260 265 270

Glu Val Phe Ile Lys Phe Ile His Val Ala Gln Lys Leu His Gln Leu
275 280 285

Gln Asn Phe Asn Thr Leu Met Ala Val Ile Gly Gly Leu Cys His Ser
290 295 300

Ser Ile Ser Arg Leu Lys Glu Thr Ser Ser His Val Pro His Glu Ile
305 310 315 320

Asn Lys Val Leu Gly Glu Met Thr Glu Leu Leu Ser Ser Cys Arg Asn
325 330 335

Tyr Asp Asn Tyr Arg Arg Ala Tyr Gly Glu Cys Thr His Phe Lys Ile
340 345 350

Pro Ile Leu Gly Val His Leu Lys Asp Leu Ile Ser Leu Tyr Glu Ala
355 360 365

Met Pro Asp Tyr Leu Glu Asp Gly Lys Val Asn Val Gln Lys Leu Leu
370 375 380

Ala Leu Tyr Asn His Ile Asn Glu Leu Val Gln Leu Gln Asp Val Ala
385 390 395 400

Pro Pro Leu Asp Ala Asn Lys Asp Leu Val His Leu Leu Thr Leu Ser
405 410 415

Leu Asp Leu Tyr Tyr Thr Glu Asp Glu Ile Tyr Glu Leu Ser Tyr Ala
420 425 430

Arg Glu Pro Arg Asn His Arg Ala Pro Pro Leu Thr Pro Ser Lys Pro
435 440 445

Pro Val Val Val Asp Trp Ala Ser Gly Val Ser Pro Lys Pro Asp Pro
450 455 460

Lys Thr Ile Ser Lys His Val Gln Arg Met Val Asp Ser Val Phe Lys
465 470 475 480

Asn Tyr Asp Leu Asp Gln Asp Gly Tyr Ile Ser Gln Glu Glu Phe Glu
485 490 495

Lys Ile Ala Ala Ser Phe Pro Phe Ser Phe Cys Val Met Asp Lys Asp
500 505 510

Arg Glu Gly Leu Ile Ser Arg Asp Glu Ile Thr Ala Tyr Phe Met Arg
515 520 525

Ala Ser Ser Ile Tyr Ser Lys Leu Gly Leu Gly Phe Pro His Asn Phe
530 535 540

Gln Glu Thr Thr Tyr Leu Lys Pro Thr Phe Cys Asp Asn Cys Ala Gly
545 550 555 560

Phe Leu Trp Gly Val Ile Lys Gln Gly Tyr Arg Cys Lys Asp Cys Gly
565 570 575

Met Asn Cys His Lys Gln Cys Lys Asp Leu Val Val Phe Glu Cys Lys
580 585 590

Lys Arg Ser Lys Ser Pro Ala Val Ser Thr Glu Asn Ile Ser Ser Val
595 600 605

Val Pro Met Ser Thr Leu Cys Pro Leu Gly Thr Lys Asp Leu Leu His
610 615 620

Ala Pro Glu Glu Gly Ser Phe Ile Phe Gln Asn Gly Glu Val Val Asp
625 630 635 640

His Ser Glu Glu Ser Lys Asp Arg Thr Ile Met Leu Leu Gly Val Ser
645 650 655

Ser Gln Lys Ile Ser Val Arg Leu Lys Arg Thr Val Ala His Lys Thr
660 665 670

Thr Gln Thr Glu Ser Phe Pro Trp Val Gly Gly Glu Met Pro Pro Gly
675 680 685

His Phe Val Leu Thr Ser Pro Arg Lys Ser Ala Gln Gly Ala Leu Tyr
690 695 700

Val His Ser Pro Ala Ser Pro Cys Pro Ser Pro Ala Leu Val Arg Lys
705 710 715 720

Arg Ala Phe Val Lys Trp Glu Asn Lys Glu Ser Leu Ile Lys Pro Lys
725 730 735

Pro Glu Leu His Leu Arg Leu Arg Thr Tyr Gln Glu Leu Glu Gln Glu
740 745 750

Val Asn Thr Leu Arg Ala Asp Asn Asp Ala Leu Lys Ile Gln Leu Lys
755 760 765

Tyr Ala Gln Lys Gln Ile Glu Ser Leu Gln Leu Gly Lys Ser Asn His
770 775 780

Val Leu Ala Gln Met Asp His Gly Asp Gly Thr
785 790 795

<210> 7
<211> 5075
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (104)..(2494)
<223> CalDAG-GEFII

<400> 7
cccggggggg agagagccgg caggcggcgg cggtggtggc gggggcgatg cgccgcgc 60

ggccgcgcta ggtgagccgg caccgggagc gcgggcccgcg gcc atg ggc acc ctg 115
Met Gly Thr Leu
1

gac aag gcg aga gag gct ccg cgg aaa cct tcc cat ggc tgc aga gct 163
Gly Lys Ala Arg Glu Ala Pro Arg Lys Pro Ser His Gly Cys Arg Ala
5 10 15 20

gcc tct aaa gca aga cta gag gca aag cca gcc aac agc ccc ttc ccc 211
Ala Ser Lys Ala Arg Leu Glu Ala Lys Pro Ala Asn Ser Pro Phe Pro
25 30 35

tcc cat ccc agc ttg gcc cac atc acc cag ttc cga atg atg gtg tct 259
Ser His Pro Ser Leu Ala His Ile Thr Gln Phe Arg Met Met Val Ser
40 45 50

ctg gga cat tta gcc aaa gga gcc agc ctg gac gat ctc att gac agc 307
Leu Gly His Leu Ala Lys Gly Ala Ser Leu Asp Asp Leu Ile Asp Ser
55 60 65

tgc att caa tct ttt gat gca gat gga aac ctg tgt cga agt aac caa 355
Cys Ile Gln Ser Phe Asp Ala Asp Gly Asn Leu Cys Arg Ser Asn Gln
70 75 80

ctg ttg caa gtc atg ctg acc atg cac cga att gtc atc tcc tct gca 403
Leu Leu Gln Val Met Leu Thr Met His Arg Ile Val Ile Ser Ser Ala
85 90 95 100

gaa ctg ctc caa aaa gtt atc acc ctc tat aag gat gct ttg gca aag 451
Glu Leu Leu Gln Lys Val Ile Thr Leu Tyr Lys Asp Ala Leu Ala Lys
105 110 115

aat tca cca gga ctt tgc ctg aag atc tgt tat ttt gta agg tat tgg 499
Asn Ser Pro Gly Leu Cys Leu Lys Ile Cys Tyr Phe Val Arg Tyr Trp
120 125 130

ata aca gaa ttc tgg gtc atg ttt aaa atg gac gcc agc ttg aca gac 547
Ile Thr Glu Phe Trp Val Met Phe Lys Met Asp Ala Ser Leu Thr Asp
135 140 145

act atg gag gag ttt cag gaa ctg gtg aaa gct aag ggt gag gag tta 595
Thr Met Glu Glu Phe Gln Glu Leu Val Lys Ala Lys Gly Glu Glu Leu
150 155 160

cat tgc cgc ctg att gac aca act caa atc aat gcc cgt gac tgg tcc 643
His Cys Arg Leu Ile Asp Thr Thr Gln Ile Asn Ala Arg Asp Trp Ser
165 170 175 180

agg aaa ctt actcaa agg ata aaa tca aat acc agc aag aaa	cgg aaa	691	
Arg Lys Leu Thr Gln Arg Ile Lys Ser Asn Thr Ser Lys Lys Arg Lys			
185	190	195	
gtc tcc ctg ctc ttt gac cat ctg gaa cca gaa gag cta tcc gag cac		739	
Val Ser Leu Leu Phe Asp His Leu Glu Pro Glu Glu Leu Ser Glu His			
200	205	210	
ctc acc tac ctt gag ttc aag tct ttc cg agg ata tcg ttc tct gat		787	
Leu Thr Tyr Leu Glu Phe Lys Ser Phe Arg Arg Ile Ser Phe Ser Asp			
215	220	225	
tat cag aat tac ctt gta aat agc tgg tgg aag gaa aac ccc acc atg		835	
Tyr Gln Asn Tyr Leu Val Asn Ser Cys Val Lys Glu Asn Pro Thr Met			
230	235	240	
gag cga tct att gct ctg tgc aac ggc atc tcc cag tgg gta caa ctg		883	
Glu Arg Ser Ile Ala Leu Cys Asn Gly Ile Ser Gln Trp Val Gln Leu			
245	250	255	260
atg gtt ctc agc cgc ccc acg ccg cag ctc cga gca gaa gtc ttc atc		931	
Met Val Leu Ser Arg Pro Thr Pro Gln Leu Arg Ala Glu Val Phe Ile			
265	270	275	
aag ttc atc cag gtg gct cag aag ctc cac caa cta cag aac ttc aat		979	
Lys Phe Ile Gln Val Ala Gln Lys Leu His Gln Leu Gln Asn Phe Asn			
280	285	290	
aca ctg atg gct gtg ata ggt ggg ctg tgg cac agc tca atc tcg agg		1027	
Thr Leu Met Ala Val Ile Gly Gly Leu Cys His Ser Ser Ile Ser Arg			
295	300	305	
ctc aag gag aca agt tcg cat gtc cca cat gaa atc aat aag gtt ctc		1075	
Leu Lys Glu Thr Ser Ser His Val Pro His Glu Ile Asn Lys Val Leu			
310	315	320	
ggt gag atg act gag ctg ctg tcc tcc tcc aga aac tac gac aat tac		1123	
Gly Glu Met Thr Glu Leu Leu Ser Ser Arg Asn Tyr Asp Asn Tyr			
325	330	335	340
cgg cga gcc tat gga gag tgc acc gac ttc aag atc ccc att ctg ggt		1171	
Arg Arg Ala Tyr Gly Glu Cys Thr Asp Phe Lys Ile Pro Ile Leu Gly			
345	350	355	
gtg cat ctc aag gac ctc atc tcc ctg tat gaa gcc atg cct gac tat		1219	
Val His Leu Lys Asp Leu Ile Ser Leu Tyr Glu Ala Met Pro Asp Tyr			
360	365	370	
ctg ggg gac ggg aaa gtg aac gtc cat aag cta ctg gcc cta tac aat		1267	
Leu Gly Asp Gly Lys Val Asn Val His Lys Leu Leu Ala Leu Tyr Asn			
375	380	385	
cat atc agt gaa ttg gtc cag ctg caa gag gtg gcc cca ccc ttg gag		1315	
His Ile Ser Glu Leu Val Gln Leu Gln Glu Val Ala Pro Pro Leu Glu			
390	395	400	
gct aac aag gac ttg gta cac ttg ctg acg tta tcc ctg gat ctt tac		1363	
Ala Asn Lys Asp Leu Val His Leu Leu Thr Leu Ser Leu Asp Leu Tyr			
405	410	415	420
tac act gag gat gaa atc tat gag ctt tcc tat gcc cg gaa cca agg		1411	
Tyr Thr Glu Asp Glu Ile Tyr Glu Leu Ser Tyr Ala Arg Glu Pro Arg			
425	430	435	
aac cac aga gct cca cca cta aca cct tca aag cca cca gta gta gtg		1459	
Asn His Arg Ala Pro Pro Leu Thr Pro Ser Lys Pro Pro Val Val Val			
440	445	450	
gac tgg gct tct gga gtg tct ccc aaa cct gat cca aaa acc att agc		1507	

Asp	Trp	Ala	Ser	Gly	Val	Ser	Pro	Lys	Pro	Asp	Pro	Lys	Thr	Ile	Ser	
455					460							465				
aaa	cac	gtc	cag	agg	atg	gtg	gat	tct	gtc	ttc	aag	aac	tat	gat	cac	1555
Lys	His	Val	Gln	Arg	Met	Val	Asp	Ser	Val	Phe	Lys	Asn	Tyr	Asp	His	
470					475						480					
gac	cag	gat	gga	tac	att	tct	cag	gaa	gaa	ttt	gaa	aag	att	gct	gcg	1603
Asp	Gln	Asp	Gly	Tyr	Ile	Ser	Gln	Glu	Glu	Phe	Glu	Lys	Ile	Ala	Ala	
485					490					495					500	
agt	ttt	cca	ttt	tcc	ttc	tgt	gtg	atg	gac	aaa	gac	agg	gaa	ggc	ctc	1651
Ser	Phe	Pro	Phe	Ser	Phe	Cys	Val	Met	Asp	Lys	Asp	Arg	Glu	Gly	Leu	
									505		510			515		
atc	agc	agg	gat	gag	atc	aca	gcc	tac	ttc	atg	aga	gcc	agc	tca	atc	1699
Ile	Ser	Arg	Asp	Glu	Ile	Thr	Ala	Tyr	Phe	Met	Arg	Ala	Ser	Ser	Ile	
									520		525			530		
tat	tcc	aag	ctg	ggc	ctg	ggc	ttt	cct	cac	aac	ttc	caa	gag	acc	acc	1747
Tyr	Ser	Lys	Leu	Gly	Leu	Gly	Phe	Pro	His	Asn	Phe	Gln	Glu	Thr	Thr	
							535		540			545				
tac	ctg	aag	ccc	act	ttt	tgt	gac	aac	tgt	gct	gga	ttt	ctc	tgg	gga	1795
Tyr	Leu	Lys	Pro	Thr	Phe	Cys	Asp	Asn	Cys	Ala	Gly	Phe	Leu	Trp	Gly	
						550		555			560					
gtg	atc	aaa	caa	gga	tat	cga	tgt	aaa	gac	tgc	ggg	atg	aac	tgt	cac	1843
Val	Ile	Lys	Gln	Gly	Tyr	Arg	Cys	Lys	Asp	Cys	Gly	Met	Asn	Cys	His	
						565		570			575			580		
aaa	caa	tgc	aaa	gat	ctg	gtt	ttt	gag	tgt	aag	aag	cga	gcc	aag		1891
Lys	Gln	Cys	Lys	Asp	Leu	Val	Val	Phe	Glu	Cys	Lys	Lys	Arg	Ala	Lys	
						585		590					595			
aac	cca	gta	gct	ccc	aca	gag	aac	aac	act	tct	gtg	ggg	cca	gtg	tcc	1939
Asn	Pro	Val	Ala	Pro	Thr	Glu	Asn	Asn	Thr	Ser	Val	Gly	Pro	Val	Ser	
						600		605			610					
aac	ctt	tgc	tca	ttg	gga	gcc	aaa	gat	ctg	ctc	cat	gca	cct	gag	gaa	1987
Asn	Leu	Cys	Ser	Leu	Gly	Ala	Lys	Asp	Leu	Leu	His	Ala	Pro	Glu	Glu	
						615		620			625					
gga	cct	ttt	aca	ttc	cct	aat	ggg	gag	gct	gtg	gaa	cat	ggt	gag	gag	2035
Gly	Pro	Phe	Thr	Phe	Pro	Asn	Gly	Glu	Ala	Val	Glu	His	Gly	Glu	Glu	
						630		635			640					
agt	aag	gat	cgg	acc	atc	atg	ctg	atg	gga	gtg	tcc	tca	cag	aag	att	2083
Ser	Lys	Asp	Arg	Thr	Ile	Met	Leu	Met	Gly	Val	Ser	Ser	Gln	Lys	Ile	
						645		650			655			660		
tct	ctt	cgg	ctg	aag	agg	gct	gtt	gcc	cac	aag	gcc	acc	cag	act	gaa	2131
Ser	Leu	Arg	Leu	Lys	Arg	Ala	Val	Ala	His	Lys	Ala	Thr	Gln	Thr	Glu	
						665		670			675					
tca	cag	cct	tgg	att	ggc	agt	gag	ggc	cct	tca	ggt	ccc	ttt	gtg	ctg	2179
Ser	Gln	Pro	Trp	Ile	Gly	Ser	Glu	Gly	Pro	Ser	Gly	Pro	Phe	Val	Leu	
						680		685			690					
tct	tcc	cca	agg	aag	aca	gcc	cag	gat	act	cta	tat	gtg	ctt	ccc	agt	2227
Ser	Ser	Pro	Arg	Lys	Thr	Ala	Gln	Asp	Thr	Leu	Tyr	Val	Leu	Pro	Ser	
						695		700			705					
ccc	acc	tct	cca	tgt	cct	agc	cca	gtc	ttg	gtc	aga	aag	cgg	gct	ttt	2275
Pro	Thr	Ser	Pro	Cys	Pro	Ser	Pro	Val	Leu	Val	Arg	Lys	Arg	Ala	Phe	
						710		715			720					
gtc	aag	tgg	gag	aat	aaa	gac	tcc	ctc	ata	aaa	tca	aag	gag	gag	ctc	2323
Val	Lys	Trp	Glu	Asn	Lys	Asp	Ser	Leu	Ile	Lys	Ser	Lys	Glu	Glu	Leu	

725	730	735	740	
cgt cac ctc aga ctg cct acc tac caa gaa ctg gaa cag gaa ata aat				2371
Arg His Leu Arg Leu Pro Thr Tyr Gln Glu Leu Glu Gln Glu Ile Asn				
745	750	755		
act ctg aaa gca gat aat gat gcc cta aag atc caa ctg aaa tat gca				2419
Thr Leu Lys Ala Asp Asn Asp Ala Leu Lys Ile Gln Leu Lys Tyr Ala				
760	765	770		
cag aag aaa ata gaa tcc ctc cag ctt gaa aaa agc aat cat gtc tta				2467
Gln Lys Lys Ile Glu Ser Leu Gln Leu Glu Lys Ser Asn His Val Leu				
775	780	785		
gct caa atg gag cag ggt gac tgt tct tagcccagaa actaaggtagc				2514
Ala Gln Met Glu Gln Gly Asp Cys Ser				
790	795			
acaatctgta gatgagtata gtgatctcat ttccctaaact gtaatgcaca gacctgagga				2574
actttacact gaccagctt aaaacagtac tttaaaagga aaagcctgtt actgtttatt				2634
tacctaaaag attcctaattg tgccgactg tttctcttt cagttagttg actcaaagg				2694
ggaaaaactaa agaatgcaaa acttttgcta ttccataccac tgatgttcat caaaaagtatg				2754
cgtatctaaaa catgactatc atttcctgac aatggggcat ctccggggcc tgcctggctg				2814
attcttcctt aaaactaaaa tctctggaaa atggatttgc ttcttaccct gtgtttctg				2874
caaactgact tactttgttc cagccaaagc ttgctaataa tagaaaaacta cccatattcc				2934
aaaagtagat ttccctgtt tcccagcata ctttgtgaac ctggctcctt cttcaactacc				2994
tcagatctaa tcaatttagtc catgtaccct ccttcctcac tacagtacata acacatgagc				3054
atatctacct agaagccaaat ttctactgtat gtagccacaa ctttttagag gcctattaaa				3114
catgacgta tccaattgca ggtcaactta tagttgtgc cttacaactt acaggcatca				3174
gaaaataagt aatcaaattt ggtacctgga aacatagcta ttaccatctc atattactgt				3234
ctaattaaaa taaacataac gcaaacatgt ttgtccttat atattctaca gtggatagaa				3294
tttaggaattt atggcttaaa aaaaaaaagtc tatgaagagt ctgttaact cttcatgtt				3354
catcttc ttcgttgaagta aactatttt aaagttctt tttgaaatg aatttgtgt				3414
taactgtctt cactattaaat actatttaga aataagctaa ttggatcagt ggcttaataa				3474
atagctgact gtgtgtacat atgtatataa tatgtatata caatatcagg catgcatgt				3534
gcttggaaatt ttgtttcctc cataaaatgt ggaagtgaat taaacaagtt ttagtcatt				3594
atacaaagtc acaaataataa agttcagttt gtcacaagat taaattgctc acaaggtaaa				3654
attgtattgt ttggcaaaaat cacaagtaac aatcctgtga gttttcttatt atgaaggta				3714
ataataaaatg ggctcattta gttgcctggg cacctattca caaattcatt tgcagccctc				3774
tttttagttc tcttaaaaaaa aaaaaaaatca tatgtatcatt ttcccttttggggacttca				3834
gcttccatgc ctataaaagtc tggtaccaga ctgacttgaa attcataaac aagttgtcca				3894
attgccaaga atatgttaac aattaaaagt tccaaactaa agccaaatagc accaagtctt				3954
cataagaata caaagtatac atacagtatt gcttacctgg aggattcaga tcatttaga				4014
attctctttt atgaaaagatc agttcccatt tgagttcctc cttgcactga gtttttagtga				4074

tatagaacta gctttagtt agtgttcat tacattataa agaatagtt tacacacgta 4134
tttaccgtt tccaaattta aactcagaaa tacccaaagc aggcctgctt aagcccacta 4194
cctggcatat aaacctatag taacactttg ttactttctt ttaatagga caagcatgag 4254
ttaggacaaa ctctaaaaat tcatattctt cactattctt gtttcctt gattgatata 4314
gaccaagat ggtgtactct aatttttaa aacagtaatg gaacacaatt ttttcattc 4374
ttcctcctct ccattcgaag taaagatccc cagttagttt ttatataaat aatctatagg 4434
gattcaaaag gtgtcacagt ccacttaatt agtcaaatta gcaatggcta aacagtatca 4494
agtactgcag aatttatcac tgaatggat aagaggaaat agtttagtca caggtttta 4554
cagtcagca agggccaaag aggtatagta tacaagttaa tagtatttgt gttgagcaac 4614
atggggctag tgggatcaca gaaatctgga aaaaaaaaaaaa aaaaggctt ggcttatcaa 4674
gcctagtgt aatttctgca tctcacacga cttagttt gccaggtatt tatctgcaa 4734
aacaaggaca aatcttggtg tattaacagc agggtaactt ctcattttct ttgctgactt 4794
accttttac tgaccgttgtt gaatttctgtt ctcaaatgtt ataataataga aatgcaagaa 4854
aaaaacaaat gtacagattt taaagtttt tgataacctaa tgtaagttt ctttgtgtaa 4914
tatttatatg ataaaaagaca ttaggatccc tacaaaaaaaaaaaaaaaaaaaaaaaa 4974
aaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa 5034
acgactcccc gggggggccc ggtccaattc ccccaaaagg g 5075

<210> 8

<211> 797

<212> PRT

<213> Homo sapiens

<400> 8

Met Gly Thr Leu Gly Lys Ala Arg Glu Ala Pro Arg Lys Pro Ser His

1

5

10

15

Gly Cys Arg Ala Ala Ser Lys Ala Arg Leu Glu Ala Lys Pro Ala Asn

20

25

30

Ser Pro Phe Pro Ser His Pro Ser Leu Ala His Ile Thr Gln Phe Arg

35

40

45

Met Met Val Ser Leu Gly His Leu Ala Lys Gly Ala Ser Leu Asp Asp

50

55

60

Leu Ile Asp Ser Cys Ile Gln Ser Phe Asp Ala Asp Gly Asn Leu Cys

65

70

75

80

Arg Ser Asn Gln Leu Leu Gln Val Met Leu Thr Met His Arg Ile Val

85

90

95

Ile Ser Ser Ala Glu Leu Leu Gln Lys Val Ile Thr Leu Tyr Lys Asp

100

105

110

Ala Leu Ala Lys Asn Ser Pro Gly Leu Cys Leu Lys Ile Cys Tyr Phe

115

120

125

Val Arg Tyr Trp Ile Thr Glu Phe Trp Val Met Phe Lys Met Asp Ala

130

135

140

Ser Leu Thr Asp Thr Met Glu Glu Phe Gln Glu Leu Val Lys Ala Lys
145 150 155 160

Gly Glu Glu Leu His Cys Arg Leu Ile Asp Thr Thr Gln Ile Asn Ala
165 170 175

Arg Asp Trp Ser Arg Lys Leu Thr Gln Arg Ile Lys Ser Asn Thr Ser
180 185 190

Lys Lys Arg Lys Val Ser Leu Leu Phe Asp His Leu Glu Pro Glu Glu
195 200 205

Leu Ser Glu His Leu Thr Tyr Leu Glu Phe Lys Ser Phe Arg Arg Ile
210 215 220

Ser Phe Ser Asp Tyr Gln Asn Tyr Leu Val Asn Ser Cys Val Lys Glu
225 230 235 240

Asn Pro Thr Met Glu Arg Ser Ile Ala Leu Cys Asn Gly Ile Ser Gln
245 250 255

Trp Val Gln Leu Met Val Leu Ser Arg Pro Thr Pro Gln Leu Arg Ala
260 265 270

Glu Val Phe Ile Lys Phe Ile Gln Val Ala Gln Lys Leu His Gln Leu
275 280 285

Gln Asn Phe Asn Thr Leu Met Ala Val Ile Gly Gly Leu Cys His Ser
290 295 300

Ser Ile Ser Arg Leu Lys Glu Thr Ser Ser His Val Pro His Glu Ile
305 310 315 320

Asn Lys Val Leu Gly Glu Met Thr Glu Leu Leu Ser Ser Arg Asn
325 330 335

Tyr Asp Asn Tyr Arg Arg Ala Tyr Gly Glu Cys Thr Asp Phe Lys Ile
340 345 350

Pro Ile Leu Gly Val His Leu Lys Asp Leu Ile Ser Leu Tyr Glu Ala
355 360 365

Met Pro Asp Tyr Leu Gly Asp Gly Lys Val Asn Val His Lys Leu Leu
370 375 380

Ala Leu Tyr Asn His Ile Ser Glu Leu Val Gln Leu Gln Glu Val Ala
385 390 395 400

Pro Pro Leu Glu Ala Asn Lys Asp Leu Val His Leu Leu Thr Leu Ser
405 410 415

Leu Asp Leu Tyr Tyr Thr Glu Asp Glu Ile Tyr Glu Leu Ser Tyr Ala
420 425 430

Arg Glu Pro Arg Asn His Arg Ala Pro Pro Leu Thr Pro Ser Lys Pro
435 440 445

Pro Val Val Val Asp Trp Ala Ser Gly Val Ser Pro Lys Pro Asp Pro
450 455 460

Lys Thr Ile Ser Lys His Val Gln Arg Met Val Asp Ser Val Phe Lys
465 470 475 480

Asn Tyr Asp His Asp Gln Asp Gly Tyr Ile Ser Gln Glu Glu Phe Glu
485 490 495

Lys Ile Ala Ala Ser Phe Pro Phe Ser Phe Cys Val Met Asp Lys Asp
500 505 510

Arg Glu Gly Leu Ile Ser Arg Asp Glu Ile Thr Ala Tyr Phe Met Arg
515 520 525

Ala Ser Ser Ile Tyr Ser Lys Leu Gly Leu Gly Phe Pro His Asn Phe
530 535 540

Gln Glu Thr Thr Tyr Leu Lys Pro Thr Phe Cys Asp Asn Cys Ala Gly
545 550 555 560

Phe Leu Trp Gly Val Ile Lys Gln Gly Tyr Arg Cys Lys Asp Cys Gly
565 570 575

Met Asn Cys His Lys Gln Cys Lys Asp Leu Val Val Phe Glu Cys Lys
580 585 590

Lys Arg Ala Lys Asn Pro Val Ala Pro Thr Glu Asn Asn Thr Ser Val
595 600 605

Gly Pro Val Ser Asn Leu Cys Ser Leu Gly Ala Lys Asp Leu Leu His
610 615 620

Ala Pro Glu Glu Gly Pro Phe Thr Phe Pro Asn Gly Glu Ala Val Glu
625 630 635 640

His Gly Glu Glu Ser Lys Asp Arg Thr Ile Met Leu Met Gly Val Ser
645 650 655

Ser Gln Lys Ile Ser Leu Arg Leu Lys Arg Ala Val Ala His Lys Ala
660 665 670

Thr Gln Thr Glu Ser Gln Pro Trp Ile Gly Ser Glu Gly Pro Ser Gly
675 680 685

Pro Phe Val Leu Ser Ser Pro Arg Lys Thr Ala Gln Asp Thr Leu Tyr
690 695 700

Val Leu Pro Ser Pro Thr Ser Pro Cys Pro Ser Pro Val Leu Val Arg
705 710 715 720

Lys Arg Ala Phe Val Lys Trp Glu Asn Lys Asp Ser Leu Ile Lys Ser
725 730 735

Lys Glu Glu Leu Arg His Leu Arg Leu Pro Thr Tyr Gln Glu Leu Glu
740 745 750

Gln Glu Ile Asn Thr Leu Lys Ala Asp Asn Asp Ala Leu Lys Ile Gln
755 760 765

Leu Lys Tyr Ala Gln Lys Lys Ile Glu Ser Leu Gln Leu Glu Lys Ser
770 775 780

Asn His Val Leu Ala Gln Met Glu Gln Gly Asp Cys Ser
785 790 795

<210> 9
<211> 3373
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (197)..(2848)
<223> cAMP-GEFI

<400> 9
cgctaaggcct ggggtggtgg taggaaggtc cagtcctcc ggccgatggc tgtccacttt 60
cctcccccca tcacaggtca gctggccagg tgagaaccac tggcaggtgg gcccagctgt 120

ggtggagagt ccagctgtgg gggcaccgca ggtgcgaggt ctccggacg tggtccgga 180
gggcacgctg ctcaat atg gtg ctg aag aga atg cac cgt ccc cgg tgc tgc 232
Met Val Leu Lys Arg Met His Arg Pro Arg Cys Cys
1 5 10

tct tac cag cta gtg ttc gag cac cgg cgc cca agc tgc atc cag gga 280
Ser Tyr Gln Leu Val Phe Glu His Arg Arg Pro Ser Cys Ile Gln Gly
15 20 25

ctt cgc tgg acg cca ctt acc aac agt gag ggc tcc ctg gac ttc aga 328
Leu Arg Trp Thr Pro Leu Thr Asn Ser Glu Gly Ser Leu Asp Phe Arg
30 35 40

gtg agc ctg gag cag gcc acc aca gag cat gtg cac aag gcc ggg aag 376
Val Ser Leu Glu Gln Ala Thr Thr Glu His Val His Lys Ala Gly Lys
45 50 55 60

ctc ctg tac cgt cat ctc ttg gca acg tac cct acc ctc atc cga gac 424
Leu Leu Tyr Arg His Leu Leu Ala Thr Tyr Pro Thr Leu Ile Arg Asp
65 70 75

aga aaa tac cat ctg cga cta cat cgg cag tgc tgc tct ggc cgg gag 472
Arg Lys Tyr His Leu Arg Leu His Arg Gln Cys Cys Ser Gly Arg Glu
80 85 90

cta gtg gat ggg atc ttg gct ctg ggt ctt ggg gtc cac tca cgg agc 520
Leu Val Asp Gly Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser
95 100 105

caa gct gtg ggc atc tgc cag gtg ttg ctg gat gag ggt gcc ctt tgc 568
Gln Ala Val Gly Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys
110 115 120

cat gta aaa cat gac tgg acc ttc cag gac cga gac gcc caa ttc tac 616
His Val Lys His Asp Trp Thr Phe Gln Asp Arg Asp Ala Gln Phe Tyr
125 130 135 140

aga ttc cct gga ccg gag ccc cag cct gca gga act cat gac gtg gaa 664
Arg Phe Pro Gly Pro Glu Pro Gln Pro Ala Gly Thr His Asp Val Glu
145 150 155

gag gag ctt gtt gag gca atg gcc cta ctc tcc cag cga ggg cct gat 712
Glu Glu Leu Val Glu Ala Met Ala Leu Leu Ser Gln Arg Gly Pro Asp
160 165 170

gcc cta ctc act gtt gca ctc cgg aag tcc ccg ggt cag cgt aca gat 760
Ala Leu Leu Thr Val Ala Leu Arg Lys Ser Pro Gly Gln Arg Thr Asp
175 180 185

gaa gag ctg gac ctc atc ttc gag gag ctc gta cat atc aag gcc gtg 808
Glu Glu Leu Asp Leu Ile Phe Glu Glu Leu Val His Ile Lys Ala Val
190 195 200

gct cac ctt tct aac tcg gtg aaa cgg gaa cta gct gct gtt ctg ctc 856
Ala His Leu Ser Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu
205 210 215 220

ttt gaa cca cac agc aag gca gga act gtg ttg ttc agc cag ggg gac 904
Phe Glu Pro His Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp
225 230 235

aag ggt acc tca tgg tac att atc tgg aag gga tct gtc aat gtg gtg 952
Lys Gly Thr Ser Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val
240 245 250

acc cgt ggc aag ggg ctg gtg acc acg ttg cac gag gga gat gac ttt 1000
Thr Arg Gly Lys Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe

255	260	265	
gga cag ctg gct ctg gtg aac gac gca cct cga gca gcc acc atc atc Gly Gln Leu Ala Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile 270 275 280			1048
ctt cga gaa aat aac tgt cac ttt ctg cgt gtg gac aag cag gac ttc Leu Arg Glu Asn Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe 285 290 295 300			1096
aac cgc atc atc aag gat gtg gaa gca aaa acc atg aga ctg gaa gaa Asn Arg Ile Ile Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu 305 310 315			1144
cac ggc aaa gtg gtg tta gtt ttg gag aga acc tct cag ggt gct ggc His Gly Lys Val Val Leu Val Leu Glu Arg Thr Ser Gln Gly Ala Gly 320 325 330			1192
cct tcc cgc cct ccg acc cca ggc agg aac cga tat acg gta atg tct Pro Ser Arg Pro Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser 335 340 345			1240
ggc acc cca gag aaa atc cta gaa ctc ctg ttg gag gct atg aga ccg Gly Thr Pro Glu Lys Ile Leu Glu Leu Leu Leu Glu Ala Met Arg Pro 350 355 360			1288
gat tcc agt gct cat gac cca aca gag aca ttc ctc agt gac ttc ctg Asp Ser Ser Ala His Asp Pro Thr Glu Thr Phe Leu Ser Asp Phe Leu 365 370 375 380			1336
ctg acg cac agt gtc ttc atg ccc tgc aca cag ctc ttt gcc gcc ctc Leu Thr His Ser Val Phe Met Pro Cys Thr Gln Leu Phe Ala Ala Leu 385 390 395			1384
ctg cac cac ttc cac gtg gag cca tca gag cct gcc ggg ggc agc gag Leu His His Phe His Val Glu Pro Ser Glu Pro Ala Gly Gly Ser Glu 400 405 410			1432
cag gaa cgc agc acc tac atc tgc aac aag agg cag cag att ctg cgt Gln Glu Arg Ser Thr Tyr Ile Cys Asn Lys Arg Gln Gln Ile Leu Arg 415 420 425			1480
ctg gtc agc cgg tgg gtg gcc ctc tac agc ccc atg ctc cgc tca gat Leu Val Ser Arg Trp Val Ala Leu Tyr Ser Pro Met Leu Arg Ser Asp 430 435 440			1528
ccc gtg gcc acc agc ttc ctc cag aaa ctc tca gac ctg gtg agc aga Pro Val Ala Thr Ser Phe Leu Gln Lys Ile Ser Asp Leu Val Ser Arg 445 450 455 460			1576
gat acc cga ctt agc aac ttg ctg agg gaa cag tat ccg gag aga cgg Asp Thr Arg Leu Ser Asn Leu Leu Arg Glu Gln Tyr Pro Glu Arg Arg 465 470 475			1624
cga cac cac agg ttg gag aat ggc tgg aat gta tct cct cag acc Arg His His Arg Leu Glu Asn Gly Cys Gly Asn Val Ser Pro Gln Thr 480 485 490			1672
aag gcc cgg aat gca cct gtt tgg ttt cct aac cat gag gaa ccc ctc Lys Ala Arg Asn Ala Pro Val Trp Phe Pro Asn His Glu Glu Pro Leu 495 500 505			1720
cca agc agc gct ggg gcc atc cga gtc ggg gac aaa gtc ccc tat gat Pro Ser Ser Ala Gly Ala Ile Arg Val Gly Asp Lys Val Pro Tyr Asp 510 515 520			1768
atc tgc aga ccc gac cac tcg gtg ctg acc ctg cac ctg ccg gtg aca Ile Cys Arg Pro Asp His Ser Val Leu Thr Leu His Leu Pro Val Thr 525 530 535 540			1816

gcc tcc gtg agg gaa gtg atg gca gct ttg gcc cat gag gac cac tgg	1864
Ala Ser Val Arg Glu Val Met Ala Ala Leu Ala His Glu Asp His Trp	
545 550 555	
acc aag ggg cag gtg ctg gta aag gtc aat tct gcc ggt gat gtc gtt	1912
Thr Lys Gly Gln Val Leu Val Lys Val Asn Ser Ala Gly Asp Val Val	
560 565 570	
ggc ttg cag cca gat gcc cgc ggt gtg gcc aca tcc ctg ggg ctc aat	1960
Gly Leu Gln Pro Asp Ala Arg Gly Val Ala Thr Ser Leu Gly Leu Asn	
575 580 585	
gag cgg atc ttt gtt gtc gac cca cag gaa gtg cac gag ctg acc cca	2008
Glu Arg Ile Phe Val Val Asp Pro Gln Glu Val His Glu Leu Thr Pro	
590 595 600	
cac cct gag cag ctg ggg ccc act ctg ggt tct tct gag atg ctg gac	2056
His Pro Glu Gln Leu Gly Pro Thr Leu Gly Ser Ser Glu Met Leu Asp	
605 610 615 620	
cta gtg agt gcc aag gac ctg gca ggc cag ctc aca gag cat gac tgg	2104
Leu Val Ser Ala Lys Asp Leu Ala Gly Gln Leu Thr Glu His Asp Trp	
625 630 635	
aac ctc ttc aac agg atc cac cag gtg gag ctg atc cac tat gta ctg	2152
Asn Leu Phe Asn Arg Ile His Gln Val Glu Leu Ile His Tyr Val Leu	
640 645 650	
ggc ccc cag cac ctg cgg gac gtc acc act gca aac ctg gag cgc ttc	2200
Gly Pro Gln His Leu Arg Asp Val Thr Thr Ala Asn Leu Glu Arg Phe	
655 660 665	
atg cga cgc ttc aac gag ctg cag tac tgg gtg gcc acc gaa ctc tgt	2248
Met Arg Arg Phe Asn Glu Leu Gln Tyr Trp Val Ala Thr Glu Leu Cys	
670 675 680 685	
ctc tgc ccg gtt cct ggc ccc cgg gct cag cta ctc cgg aag ttc atc	2296
Leu Cys Pro Val Pro Gly Pro Arg Ala Gln Leu Leu Arg Lys Phe Ile	
685 690 695 700	
aag ctg gca gcc cac ctc aag gag cag aag aat ctc aac tct ttc ttt	2344
Lys Leu Ala Ala His Leu Lys Glu Gln Lys Asn Leu Asn Ser Phe Phe	
705 710 715	
gcg gtc atg ttt ggc ctc agc aac tcg gcc atc agc cgc ctg gcc cac	2392
Ala Val Met Phe Gly Leu Ser Asn Ser Ala Ile Ser Arg Leu Ala His	
720 725 730	
acc tgg gag cgt ctg ccc cat aaa gta cgg aag ctg tac tcg gcc ctg	2440
Thr Trp Glu Arg Leu Pro His Lys Val Arg Lys Leu Tyr Ser Ala Leu	
735 740 745	
gaa agg ttg ctg gac cct tcc tgg aac cac cga gtg tac cga ttg gct	2488
Glu Arg Leu Leu Asp Pro Ser Trp Asn His Arg Val Tyr Arg Leu Ala	
750 755 760	
ctc acc aag ctc tct cct cct gtc atc cct ttc atg ccc ctg cta ctc	2536
Leu Thr Lys Leu Ser Pro Pro Val Ile Pro Phe Met Pro Leu Leu Leu	
765 770 775 780	
aaa gac atg acc ttc att cat gaa ggg aac cac aca ctg gta gaa aac	2584
Lys Asp Met Thr Phe Ile His Glu Gly Asn His Thr Leu Val Glu Asn	
785 790 795	
ctc atc aac ttt gag aag atg cga atg atg gcc aga gcc gtg cgg atg	2632
Leu Ile Asn Phe Glu Lys Met Arg Met Met Ala Arg Ala Val Arg Met	
800 805 810	

ctc cac cac tgc cga agc cac agc acc gcg cct cta tca cca ctc aga	2680
Leu His His Cys Arg Ser His Ser Thr Ala Pro Leu Ser Pro Leu Arg	
815 820 825	
agc cgg gtt tcc cac atc cac gag gac agc cag gca tca aga atc tcc	2728
Ser Arg Val Ser His Ile His Glu Asp Ser Gln Ala Ser Arg Ile Ser	
830 835 840	
aca tgt tcc gag cag tcc ctg agc acc cgg agt cca gcc agc acc tgg	2776
Thr Cys Ser Glu Gln Ser Leu Ser Thr Arg Ser Pro Ala Ser Thr Trp	
845 850 855 860	
gct tat gtc cag cag ctg aag gtc att gac aac cag cgg gaa ctg tcc	2824
Ala Tyr Val Gln Gln Leu Lys Val Ile Asp Asn Gln Arg Glu Leu Ser	
865 870 875	
cgc ctc tcc cgg gaa ctg gaa cca tgaggaagga ctggctggag caggcacttc	2878
Arg Leu Ser Arg Glu Leu Glu Pro	
880	
tctcagagaa agccagagcc tggcaacca agaggtccag aggcgcagcca cagctggca	2938
gggctctcca cagagcggac tcaaggccct ggagtggca gtgtcgaggc agctgtcctc	2998
tgtgatgact gtcagctgtg aagatcttg atgttacgg ccaaggaaaa ggggcattg	3058
aggccccaga gggtaggag agctgggagg tgcaggactc tggttcagta gagagccctc	3118
ccaccgggct ttctgcatgt ctgtatgtct gtacatgcag ctgtgtgtcc tggatgccag	3178
gccctgtgct tgtattcaca ggagccagcg agctcacatc tgcattgtgt gtgtgtgtgt	3238
gtgtgtgtgt gtgtgtgtgt gtgtgtgtga gcactgggtg gtgcattgtcc tggagaggg	3298
tggggagttc tgctattctc accacacatc tgagataaac agctgggtgt gggcaaaaaa	3358
aaaaaaaaaaaa aaaaaa	3373

<210> 10
<211> 884
<212> PRT
<213> Rattus norvegicus

<400> 10
Met Val Leu Lys Arg Met His Arg Pro Arg Cys Cys Ser Tyr Gln Leu
1 5 10 15

Val Phe Glu His Arg Arg Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
20 25 30

Pro Leu Thr Asn Ser Glu Gly Ser Leu Asp Phe Arg Val Ser Leu Glu
35 40 45

Gln Ala Thr Thr Glu His Val His Lys Ala Gly Lys Leu Leu Tyr Arg
50 55 60

His Leu Leu Ala Thr Tyr Pro Thr Leu Ile Arg Asp Arg Lys Tyr His
65 70 75 80

Leu Arg Leu His Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
85 90 95

Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Ala Val Gly
100 105 110

Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
115 120 125

Asp Trp Thr Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
130 135 140

Pro Glu Pro Gln Pro Ala Gly Thr His Asp Val Glu Glu Leu Val
145 150 155 160

Glu Ala Met Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
165 170 175

Val Ala Leu Arg Lys Ser Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
180 185 190

Leu Ile Phe Glu Glu Leu Val His Ile Lys Ala Val Ala His Leu Ser
195 200 205

Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
210 215 220

Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
225 230 235 240

Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr Arg Gly Lys
245 250 255

Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe Gly Gln Leu Ala
260 265 270

Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile Leu Arg Glu Asn
275 280 285

Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe Asn Arg Ile Ile
290 295 300

Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu His Gly Lys Val
305 310 315 320

Val Leu Val Leu Glu Arg Thr Ser Gln Gly Ala Gly Pro Ser Arg Pro
325 330 335

Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser Gly Thr Pro Glu
340 345 350

Lys Ile Leu Glu Leu Leu Leu Glu Ala Met Arg Pro Asp Ser Ser Ala
355 360 365

His Asp Pro Thr Glu Thr Phe Leu Ser Asp Phe Leu Leu Thr His Ser
370 375 380

Val Phe Met Pro Cys Thr Gln Leu Phe Ala Ala Leu Leu His His Phe
385 390 395 400

His Val Glu Pro Ser Glu Pro Ala Gly Gly Ser Glu Gln Glu Arg Ser
405 410 415

Thr Tyr Ile Cys Asn Lys Arg Gln Gln Ile Leu Arg Leu Val Ser Arg
420 425 430

Trp Val Ala Leu Tyr Ser Pro Met Leu Arg Ser Asp Pro Val Ala Thr
435 440 445

Ser Phe Leu Gln Lys Leu Ser Asp Leu Val Ser Arg Asp Thr Arg Leu
450 455 460

Ser Asn Leu Leu Arg Glu Gln Tyr Pro Glu Arg Arg Arg His His Arg
465 470 475 480

Leu Glu Asn Gly Cys Gly Asn Val Ser Pro Gln Thr Lys Ala Arg Asn
485 490 495

Ala Pro Val Trp Phe Pro Asn His Glu Glu Pro Leu Pro Ser Ser Ala
500 505 510

Gly Ala Ile Arg Val Gly Asp Lys Val Pro Tyr Asp Ile Cys Arg Pro
515 520 525

Asp His Ser Val Leu Thr Leu His Leu Pro Val Thr Ala Ser Val Arg
530 535 540

Glu Val Met Ala Ala Leu Ala His Glu Asp His Trp Thr Lys Gly Gln
545 550 555 560

Val Leu Val Lys Val Asn Ser Ala Gly Asp Val Val Gly Leu Gln Pro
565 570 575

Asp Ala Arg Gly Val Ala Thr Ser Leu Gly Leu Asn Glu Arg Ile Phe
580 585 590

Val Val Asp Pro Gln Glu Val His Glu Leu Thr Pro His Pro Glu Gln
595 600 605

Leu Gly Pro Thr Leu Gly Ser Ser Glu Met Leu Asp Leu Val Ser Ala
610 615 620

Lys Asp Leu Ala Gly Gln Leu Thr Glu His Asp Trp Asn Leu Phe Asn
625 630 635 640

Arg Ile His Gln Val Glu Leu Ile His Tyr Val Leu Gly Pro Gln His
645 650 655

Leu Arg Asp Val Thr Thr Ala Asn Leu Glu Arg Phe Met Arg Arg Phe
660 665 670

Asn Glu Leu Gln Tyr Trp Val Ala Thr Glu Leu Cys Leu Cys Pro Val
675 680 685

Pro Gly Pro Arg Ala Gln Leu Leu Arg Lys Phe Ile Lys Leu Ala Ala
690 695 700

His Leu Lys Glu Gln Lys Asn Leu Asn Ser Phe Phe Ala Val Met Phe
705 710 715 720

Gly Leu Ser Asn Ser Ala Ile Ser Arg Leu Ala His Thr Trp Glu Arg
725 730 735

Leu Pro His Lys Val Arg Lys Leu Tyr Ser Ala Leu Glu Arg Leu Leu
740 745 750

Asp Pro Ser Trp Asn His Arg Val Tyr Arg Leu Ala Leu Thr Lys Leu
755 760 765

Ser Pro Pro Val Ile Pro Phe Met Pro Leu Leu Leu Lys Asp Met Thr
770 775 780

Phe Ile His Glu Gly Asn His Thr Leu Val Glu Asn Leu Ile Asn Phe
785 790 795 800

Glu Lys Met Arg Met Met Ala Arg Ala Val Arg Met Leu His His Cys
805 810 815

Arg Ser His Ser Thr Ala Pro Leu Ser Pro Leu Arg Ser Arg Val Ser
820 825 830

His Ile His Glu Asp Ser Gln Ala Ser Arg Ile Ser Thr Cys Ser Glu
835 840 845

Gln Ser Leu Ser Thr Arg Ser Pro Ala Ser Thr Trp Ala Tyr Val Gln
850 855 860

Gln Leu Lys Val Ile Asp Asn Gln Arg Glu Leu Ser Arg Leu Ser Arg
865 870 875 880

Glu Leu Glu Pro

<210> 11
<211> 3394
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (216)..(2858)
<223> cAMP-GEFI

<400> 11
ggatcccctt atcaaagctg atgggggtcg ctggggaccc cccagccttt tgctagagcc 60
tgcacggctg tggagcttg aaaagaaaca tgaaggtggg ctggccaggt gagagctgct 120
ggcaggtggg cctggctgtg gaggatagcc cagctctggg agcacccgcgg gtgggagccc 180
tccctgacgt ggtgccggag gggacactac tcaac atg gtg ttg aga agg atg 233
Met Val Leu Arg Arg Met
1 5
cac cgg ccc cga agc tgc tcc tac cag ctg ctg gag cac cag cat 281
His Arg Pro Arg Ser Cys Ser Tyr Gln Leu Leu Leu Glu His Gln His
10 15 20
ccg agc tgc atc cag ggg ctg cgc tgg aca cca ctc acc aac agc gag 329
Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr Pro Leu Thr Asn Ser Glu
25 30 35
gag tcc ctg gat ttc agc gag agc ctg gag cag gcc tcc aca gag cgg 377
Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu Gln Ala Ser Thr Glu Arg
40 45 50
gtg ctc agg gct ggg agg cag ctg cat cag cat cta ctg gcc acc tgc 425
Val Leu Arg Ala Gly Arg Gln Leu His Gln His Leu Leu Ala Thr Cys
55 60 65 70
cca aac ctc atc cga gac cgg aag tac cac ctt agg ctc tat cgg cag 473
Pro Asn Leu Ile Arg Asp Arg Lys Tyr His Leu Arg Leu Tyr Arg Gln
75 80 85
tgc tgc tct ggc cgg gag ctg gtg gat ggg atc ttg gcc ctg gga ctt 521
Cys Cys Ser Gly Arg Glu Leu Val Asp Gly Ile Leu Ala Leu Gly Leu
90 95 100
ggg gtc cat tcc cgg agc caa gtt gtg gga atc tgc cag gtg ctg ctg 569
Gly Val His Ser Arg Ser Gln Val Val Gly Ile Cys Gln Val Leu Leu
105 110 115
gat gaa ggt gcc ctc tgc cat gtg aaa cac gac tgg gcc ttc cag gac 617
Asp Glu Gly Ala Leu Cys His Val Lys His Asp Trp Ala Phe Gln Asp
120 125 130
cga gat gcc caa ttc tac cgg ttc ccc ggg ccc gag ccc gag ccc gtg 665
Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly Pro Glu Pro Glu Pro Val
135 140 145 150
gga act cat gag atg gag gag gag ttg gcc gaa gct gtg gcc ctg ctc 713
Gly Thr His Glu Met Glu Glu Glu Leu Ala Glu Ala Val Ala Leu Leu
155 160 165
tcc cag cgg ggg cct gac gcc ctg ctc act gtg gca ctt cga aag ccc 761

Ser	Gln	Arg	Gly	Pro	Asp	Ala	Leu	Leu	Thr	Val	Ala	Leu	Arg	Lys	Pro	
170								175								
cca	ggc	cag	cgc	acg	gat	gaa	gag	ctg	gac	ctc	atc	ttt	gag	gag	ctg	809
Pro	Gly	Gln	Arg	Thr	Asp	Glu	Glu	Leu	Asp	Leu	Ile	Phe	Glu	Glu	Leu	
185							190						195			
ctg	cac	atc	aag	gct	gtg	gcc	cac	ctc	tcc	aac	tcg	gtg	aag	cga	gaa	857
Leu	His	Ile	Lys	Ala	Val	Ala	His	Leu	Ser	Asn	Ser	Val	Lys	Arg	Glu	
200						205						210				
tta	gcg	gct	gtt	ctg	ctc	ttt	gaa	cca	cac	agc	aag	gca	ggg	acc	gtg	905
Leu	Ala	Ala	Val	Leu	Leu	Phe	Glu	Pro	His	Ser	Lys	Ala	Gly	Thr	Val	
215					220					225				230		
ttg	ttc	agc	cag	ggg	gac	aag	ggc	act	tcg	tgg	tac	att	atc	tgg	aag	953
Leu	Phe	Ser	Gln	Gly	Asp	Lys	Gly	Thr	Ser	Trp	Tyr	Ile	Ile	Trp	Lys	
235						240						245				
gga	tct	gtc	aac	gtg	gtg	acc	cat	ggc	aag	ggg	ctg	gtg	acc	acc	ctg	1001
Gly	Ser	Val	Asn	Val	Val	Thr	His	Gly	Lys	Gly	Leu	Val	Thr	Thr	Leu	
250						255						260				
cat	gag	gga	gat	gat	ttt	gga	cag	ctg	gct	ctg	gtg	aat	gat	gca	ccc	1049
His	Glu	Gly	Asp	Asp	Phe	Gly	Gln	Leu	Ala	Leu	Val	Asn	Asp	Ala	Pro	
265						270						275				
cg	gca	gcc	acc	atc	atc	ctg	cga	gaa	tac	aac	tgt	cat	ttc	ctg	cgt	1097
Arg	Ala	Ala	Thr	Ile	Ile	Leu	Arg	Glu	Tyr	Asn	Cys	His	Phe	Leu	Arg	
280					285						290					
gtg	gac	aag	cag	gac	ttc	aac	cgt	atc	atc	aag	gat	gtg	gag	gca	aag	1145
Val	Asp	Lys	Gln	Asp	Phe	Asn	Arg	Ile	Ile	Lys	Asp	Val	Glu	Ala	Lys	
295					300					305				310		
acc	atg	cg	ctg	gaa	gaa	cat	ggc	aaa	gtg	gtg	ctg	gtg	ctg	gag	aga	1193
Thr	Met	Arg	Leu	Glu	Glu	His	Gly	Lys	Val	Val	Leu	Val	Leu	Glu	Arg	
					315				320					325		
gcc	tct	cag	ggc	gcc	ggc	cct	tcc	cga	ccc	cca	acc	cca	ggc	agg	aac	1241
Ala	Ser	Gln	Gly	Ala	Gly	Pro	Ser	Arg	Pro	Pro	Thr	Pro	Gly	Arg	Asn	
					330			335				340				
cg	tat	aca	gtg	atg	tct	ggc	act	cca	gat	aag	atc	cta	gag	ctt	ctg	1289
Arg	Tyr	Thr	Val	Met	Ser	Gly	Thr	Pro	Asp	Lys	Ile	Leu	Glu	Leu	Leu	
345						350						355				
ttg	gag	gcc	atg	gga	cta	gat	tcc	agt	gct	cat	gac	cca	aaa	gaa	aca	1337
Leu	Glu	Ala	Met	Gly	Leu	Asp	Ser	Ser	Ala	His	Asp	Pro	Lys	Glu	Thr	
360						365						370				
ttc	ctc	agc	gac	ttc	ctc	ctg	acc	cac	agg	gtc	ttc	atg	ccc	agc	gcc	1385
Phe	Leu	Ser	Asp	Phe	Leu	Leu	Thr	His	Arg	Val	Phe	Met	Pro	Ser	Ala	
375						380			385					390		
caa	ctc	tgc	gct	gcc	ctt	ctg	cac	cac	ttc	cat	gtg	gag	cct	gcg	ggt	1433
Gln	Leu	Cys	Ala	Ala	Leu	Leu	His	His	Phe	His	Val	Glu	Pro	Ala	Gly	
						395			400					405		
ggc	agc	gag	cag	gag	cgc	agc	acc	tac	gtc	tgc	aac	aag	agg	cag	cag	1481
Gly	Ser	Glu	Gln	Glu	Arg	Ser	Thr	Tyr	Val	Cys	Asn	Lys	Arg	Gln	Gln	
410							415						420			
atc	ttg	cg	ctg	gtc	agc	cag	tgg	gtg	gcc	ctg	tat	ggc	tcc	atg	ctc	1529
Ile	Leu	Arg	Leu	Val	Ser	Gln	Trp	Val	Ala	Leu	Tyr	Gly	Ser	Met	Leu	
425							430					435				
cac	act	gac	cct	gtg	gcc	acc	agc	ttc	ctc	cac	aaa	ctc	tca	gac	ctg	1577
His	Thr	Asp	Pro	Val	Ala	Thr	Ser	Phe	Leu	His	Lys	Leu	Ser	Asp	Leu	

440	445	450	
gtg ggc agg gac acc cga ctc agc aac ctg ctg agg gag cag tgg cca Val Gly Arg Asp Thr Arg Leu Ser Asn Leu Leu Arg Glu Gln Trp Pro 455 460 465 470			1625
gag agg cgg cga tgc cac agg ttg gag aat ggc tgc ggg aat gca tct Glu Arg Arg Arg Cys His Arg Leu Glu Asn Gly Cys Gly Asn Ala Ser 475 480 485			1673
cct cag atg aag gcc cgg aac ttg cct gtt tgg ctc ccc aac cag gac Pro Gln Met Lys Ala Arg Asn Leu Pro Val Trp Leu Pro Asn Gln Asp 490 495 500			1721
gag ccc ctt cct ggc agc agc tgc gtc atc caa gtt ggg gat aaa gtc Glu Pro Leu Pro Gly Ser Ser Cys Ala Ile Gln Val Gly Asp Lys Val 505 510 515			1769
ccc tat gac atc tgc cgg cca gac cac tca gtc ttg acc ctg cag ctg Pro Tyr Asp Ile Cys Arg Pro Asp His Ser Val Leu Thr Leu Gln Leu 520 525 530			1817
cct gtg aca gcc tcc gtg aga gag gtc atg gca gcg ttg gcc cag gag Pro Val Thr Ala Ser Val Arg Glu Val Met Ala Ala Leu Ala Gln Glu 535 540 545 550			1865
gat ggc tgg acc aag ggg cag gtc ctg gtg aag gtc aat tct gca ggt Asp Gly Trp Thr Lys Gly Gln Val Leu Val Lys Val Asn Ser Ala Gly 555 560 565			1913
gat gcc att ggc ctg cag cca gat gcc cgt ggt gtc gcc aca tct ctg Asp Ala Ile Gly Leu Gln Pro Asp Ala Arg Gly Val Ala Thr Ser Leu 570 575 580			1961
ggg ctc aat gag cgt ctc ttt gtt gtc aac cca cag gaa gtc cat gag Gly Leu Asn Glu Arg Leu Phe Val Val Asn Pro Gln Glu Val His Glu 585 590 595			2009
ctg atc cca cac cct gac cag ctg ggg ccc act gtc ggc tct gct gag Leu Ile Pro His Pro Asp Gln Leu Gly Pro Thr Val Gly Ser Ala Glu 600 605 610			2057
ggg ctg gac ctg gtc agt gcc aag gac ctg gca ggc cag ctg acg gac Gly Leu Asp Leu Val Ser Ala Lys Asp Leu Ala Gly Gln Leu Thr Asp 615 620 625 630			2105
cac gac tgg agc ctc ttc aac agt atc cac cag gtc gag ctg atc cac His Asp Trp Ser Leu Phe Asn Ser Ile His Gln Val Glu Leu Ile His 635 640 645			2153
tat gtg ctg ggc ccc cag cat ctg cgg gat gtc acc acc gcc aac ctg Tyr Val Leu Gly Pro Gln His Leu Arg Asp Val Thr Thr Ala Asn Leu 650 655 660			2201
gag cgc ttc atg cgc cgc ttc aat gag ctg cag tac tgg gtc gcc acc Glu Arg Phe Met Arg Arg Phe Asn Glu Leu Gln Tyr Trp Val Ala Thr 665 670 675			2249
gag ctg tgt ctc tgc ccc gtg ccc ggc ccc cgg gcc cag ctg ctc aaa Glu Leu Cys Leu Cys Pro Val Pro Gly Pro Arg Ala Gln Leu Leu Lys 680 685 690			2297
aag ttc att aag ctg gcg gcc cac ctc aag gag cag aag aat gtc aat Lys Phe Ile Lys Leu Ala Ala His Leu Lys Glu Gln Lys Asn Val Asn 695 700 705 710			2345
tcc ttc ttt gcc gtc atg ttt ggc ctc agc aac tcg ccc atc agc cgc Ser Phe Phe Ala Val Met Phe Gly Leu Ser Asn Ser Pro Ile Ser Arg 715 720 725			2393

cta gcc cac acc tgg gag cg ^g ctg cct cac aaa gtc cg ^g aag ctg tac	2441
Leu Ala His Thr Trp Glu Arg Leu Pro His Lys Val Arg Lys Leu Tyr	
730 735 740	
tcc gcc ctc gag agg ctg ctg gat ccc tca tgg aac cac cg ^g gta tac	2489
Ser Ala Leu Glu Arg Leu Leu Asp Pro Ser Trp Asn His Arg Val Tyr	
745 750 755	
cga ctg gcc ctc gcc aag ctc tcc cct gtc atc ccc ttc atg ccc	2537
Arg Leu Ala Leu Ala Lys Leu Ser Pro Pro Val Ile Pro Phe Met Pro	
760 765 770	
ctt ctt ctc aaa gac atg acc ttc att cat gag gga aac cac aca cta	2585
Leu Leu Leu Lys Asp Met Thr Phe Ile His Glu Gly Asn His Thr Leu	
775 780 785 790	
gtg gag aat ctc atc aac ttt gag aag atg aga atg atg gcc aga gcc	2633
Val Glu Asn Leu Ile Asn Phe Glu Lys Met Arg Met Met Ala Arg Ala	
795 800 805	
g ^c g ^c g ^c g ^c g ^c g ^c atg ^c ctg ^c cac ^c cac ^c tgc ^c cga ^c agc ^c cac ^c aac ^c cct ^c gtg ^c cct ^c ctc ^c tca ^c	2681
Ala Arg Met Leu His His Cys Arg Ser His Asn Pro Val Pro Leu Ser	
810 815 820	
cca ctc aga agc cga gtt tcc cac ctc cac gag gac agc cag gtg g ^c g ^c	2729
Pro Leu Arg Ser Arg Val Ser His Leu His Glu Asp Ser Gln Val Ala	
825 830 835	
agg att tcc aca tgc tcg gag cag tcc ctg agc acc cg ^g agt cca g ^c c ^c	2777
Arg Ile Ser Thr Cys Ser Glu Gln Ser Leu Ser Thr Arg Ser Pro Ala	
840 845 850	
agc acc tgg gct tat gtc cag cag ctg aag gtc att gac aac cag cg ^g	2825
Ser Thr Trp Ala Tyr Val Gln Gln Leu Lys Val Ile Asp Asn Gln Arg	
855 860 865 870	
gaa ctc tcc cgc ctg tcc cga gag ctg gag cca tgaggaggg ctggactgg	2878
Glu Leu Ser Arg Leu Ser Arg Glu Leu Glu Pro	
875 880	
agctggagca ggcacttgca gccggaaag ccaggggtgt ccgggccaag atactcacag	2938
gctggccaca gctggcaag gctctccgtg gagtgactc gagtcctgg agcaggcagt	2998
gtggaggcag ccatccccctg tgatgactgg cagctaagga ggacctcgga gtggaccaaa	3058
gccaggaata acgaatgacc aaggccaag gaaggagga cagagaggcc ccaggagtgg	3118
gtggagagtg gagtgcgctg ggacgttgtg tgcaatagag aggtctccac accagatgtc	3178
ttccagattc tgtgcctctg gctttgttgc ccagccaggc ctgcagttt tttcacagt	3238
ggacagagag agagagagag gctgcatgtg tgtaccgtgt gtggcaaggg cagggccttg	3298
gcctggggca gggccccctg ctttcttcc acagtttct tccaacagca ggcagtgggg	3358
ctgcgggcct gaaaaaaaaaaaaaaa aaaaaaaaaaaa aaaaaaa	3394

<210> 12
<211> 881
<212> PRT
<213> Homo sapiens

<400> 12
Met Val Leu Arg Arg Met His Arg Pro Arg Ser Cys Ser Tyr Gln Leu
1 5 10 15

Leu Leu Glu His Gln His Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
20 25 30

Pro Leu Thr Asn Ser Glu Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu
35 40 45

Gln Ala Ser Thr Glu Arg Val Leu Arg Ala Gly Arg Gln Leu His Gln
50 55 60

His Leu Leu Ala Thr Cys Pro Asn Leu Ile Arg Asp Arg Lys Tyr His
65 70 75 80

Leu Arg Leu Tyr Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
85 90 95

Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Val Val Gly
100 105 110

Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
115 120 125

Asp Trp Ala Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
130 135 140

Pro Glu Pro Glu Pro Val Gly Thr His Glu Met Glu Glu Leu Ala
145 150 155 160

Glu Ala Val Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
165 170 175

Val Ala Leu Arg Lys Pro Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
180 185 190

Leu Ile Phe Glu Glu Leu Leu His Ile Lys Ala Val Ala His Leu Ser
195 200 205

Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
210 215 220

Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
225 230 235 240

Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr His Gly Lys
245 250 255

Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe Gly Gln Leu Ala
260 265 270

Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile Leu Arg Glu Tyr
275 280 285

Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe Asn Arg Ile Ile
290 295 300

Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu His Gly Lys Val
305 310 315 320

Val Leu Val Leu Glu Arg Ala Ser Gln Gly Ala Gly Pro Ser Arg Pro
325 330 335

Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser Gly Thr Pro Asp
340 345 350

Lys Ile Leu Glu Leu Leu Glu Ala Met Gly Leu Asp Ser Ser Ala
355 360 365

His Asp Pro Lys Glu Thr Phe Leu Ser Asp Phe Leu Leu Thr His Arg
370 375 380

Val Phe Met Pro Ser Ala Gln Leu Cys Ala Ala Leu Leu His His Phe
385 390 395 400

His Val Glu Pro Ala Gly Gly Ser Glu Gln Glu Arg Ser Thr Tyr Val
405 410 415

Cys Asn Lys Arg Gln Gln Ile Leu Arg Leu Val Ser Gln Trp Val Ala
420 425 430

Leu Tyr Gly Ser Met Leu His Thr Asp Pro Val Ala Thr Ser Phe Leu
435 440 445

His Lys Leu Ser Asp Leu Val Gly Arg Asp Thr Arg Leu Ser Asn Leu
450 455 460

Leu Arg Glu Gln Trp Pro Glu Arg Arg Arg Cys His Arg Leu Glu Asn
465 470 475 480

Gly Cys Gly Asn Ala Ser Pro Gln Met Lys Ala Arg Asn Leu Pro Val
485 490 495

Trp Leu Pro Asn Gln Asp Glu Pro Leu Pro Gly Ser Ser Cys Ala Ile
500 505 510

Gln Val Gly Asp Lys Val Pro Tyr Asp Ile Cys Arg Pro Asp His Ser
515 520 525

Val Leu Thr Leu Gln Leu Pro Val Thr Ala Ser Val Arg Glu Val Met
530 535 540

Ala Ala Leu Ala Gln Glu Asp Gly Trp Thr Lys Gly Gln Val Leu Val
545 550 555 560

Lys Val Asn Ser Ala Gly Asp Ala Ile Gly Leu Gln Pro Asp Ala Arg
565 570 575

Gly Val Ala Thr Ser Leu Gly Leu Asn Glu Arg Leu Phe Val Val Asn
580 585 590

Pro Gln Glu Val His Glu Leu Ile Pro His Pro Asp Gln Leu Gly Pro
595 600 605

Thr Val Gly Ser Ala Glu Gly Leu Asp Leu Val Ser Ala Lys Asp Leu
610 615 620

Ala Gly Gln Leu Thr Asp His Asp Trp Ser Leu Phe Asn Ser Ile His
625 630 635 640

Gln Val Glu Leu Ile His Tyr Val Leu Gly Pro Gln His Leu Arg Asp
645 650 655

Val Thr Thr Ala Asn Leu Glu Arg Phe Met Arg Arg Phe Asn Glu Leu
660 665 670

Gln Tyr Trp Val Ala Thr Glu Leu Cys Leu Cys Pro Val Pro Gly Pro
675 680 685

Arg Ala Gln Leu Leu Lys Lys Phe Ile Lys Leu Ala Ala His Leu Lys
690 695 700

Glu Gln Lys Asn Val Asn Ser Phe Phe Ala Val Met Phe Gly Leu Ser
705 710 715 720

Asn Ser Pro Ile Ser Arg Leu Ala His Thr Trp Glu Arg Leu Pro His
725 730 735

Lys Val Arg Lys Leu Tyr Ser Ala Leu Glu Arg Leu Leu Asp Pro Ser
740 745 750

Trp Asn His Arg Val Tyr Arg Leu Ala Leu Ala Lys Leu Ser Pro Pro
755 760 765

Val Ile Pro Phe Met Pro Leu Leu Leu Lys Asp Met Thr Phe Ile His
770 775 780

Glu Gly Asn His Thr Leu Val Glu Asn Leu Ile Asn Phe Glu Lys Met
785 790 795 800

Arg Met Met Ala Arg Ala Ala Arg Met Leu His His Cys Arg Ser His
805 810 815

Asn Pro Val Pro Leu Ser Pro Leu Arg Ser Arg Val Ser His Leu His
820 825 830

Glu Asp Ser Gln Val Ala Arg Ile Ser Thr Cys Ser Glu Gln Ser Leu
835 840 845

Ser Thr Arg Ser Pro Ala Ser Thr Trp Ala Tyr Val Gln Gln Leu Lys
850 855 860

Val Ile Asp Asn Gln Arg Glu Leu Ser Arg Leu Ser Arg Glu Leu Glu
865 870 875 880

Pro

<210> 13

<211> 4109

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (216)..(1883)

<223> Alternate splicing of cAMP--GEFI

<400> 13

ggatccccctt atcaaagctg atgggggtcg ctggggaccc cccagccttt tgctagagcc 60
tgcacggctg tggagcttg aaaagaaaca tgaaggtggg ctggccaggt gagagctgct 120
ggcaggtggg cctggctgtg gaggatagcc cagctctggg agcaccgcgg gtgggagccc 180
tccctgacgt ggtgccggag gggacactac tcaac atg gtg ttg aga agg atg 233
Met Val Leu Arg Arg Met 5
1

cac cgg ccc cga agc tgc tcc tac cag ctg ctg ctg gag cac cag cat 281
His Arg Pro Arg Ser Cys Ser Tyr Gln Leu Leu Leu Glu His Gln His
10 15 20

ccg agc tgc atc cag ggg ctg cgc tgg aca cca ctc acc aac agc gag 329
Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr Pro Leu Thr Asn Ser Glu
25 30 35

gag tcc ctg gat ttc agc gag agc ctg gag cag gcc tcc aca gag cgg 377
Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu Gln Ala Ser Thr Glu Arg
40 45 50

gtg ctc agg gct ggg agg cag ctg cat cag cat cta ctg gcc acc tgc 425
Val Leu Arg Ala Gly Arg Gln Leu His Gln His Leu Leu Ala Thr Cys
55 60 65 70

cca aac ctc atc cga gac cgg aag tac cac ctt agg ctc tat cgg cag 473
Pro Asn Leu Ile Arg Asp Arg Lys Tyr His Leu Arg Leu Tyr Arg Gln
75 80 85

tgc tgc tct ggc cg ^g gag ctg gtg gat ggg atc ttg gcc ctg gga ctt	521
Cys Cys Ser Gly Arg Glu Leu Val Asp Gly Ile Leu Ala Leu Gly Leu	
90 95 100	
ggg gtc cat tcc cg ^g agc caa gtt gtg gga atc tgc cag gtg ctg ctg	569
Gly Val His Ser Arg Ser Gln Val Val Gly Ile Cys Gln Val Leu Leu	
105 110 115	
gat gaa ggt gcc ctc tgc cat gtg aaa cac gac tgg gcc ttc cag gac	617
Asp Glu Gly Ala Leu Cys His Val Lys His Asp Trp Ala Phe Gln Asp	
120 125 130	
cga gat gcc caa ttc tac cg ^g ttc ccc ggg ccc gag ccc gag ccc gtg	665
Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly Pro Glu Pro Glu Pro Val	
135 140 145 150	
gga act cat gag atg gag gag ttg gcc gaa gct gtg gcc ctg ctc	713
Gly Thr His Glu Met Glu Glu Leu Ala Glu Ala Val Ala Leu Leu	
155 160 165	
tcc cag cg ^g ggg cct gac gcc ctg ctc act gtg gca ctt cga aag ccc	761
Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr Val Ala Leu Arg Lys Pro	
170 175 180	
cca ggt cag cgc acg gat gaa gag ctg gac ctc atc ttt gag gag ctg	809
Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp Leu Ile Phe Glu Glu Leu	
185 190 195	
ctg cac atc aag gct gtg gcc cac ctc tcc aac tcg gtg aag cga gaa	857
Leu His Ile Lys Ala Val Ala His Leu Ser Asn Ser Val Lys Arg Glu	
200 205 210	
tta gcg gct gtt ctg ctc ttt gaa cca cac agc aag gca ggg acc gtg	905
Leu Ala Ala Val Leu Leu Phe Glu Pro His Ser Lys Ala Gly Thr Val	
215 220 225 230	
ttg ttc agc cag ggg gac aag ggc act tcg tgg tac att atc tgg aag	953
Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser Trp Tyr Ile Ile Trp Lys	
235 240 245	
gga tct gtc aac gtg gtg acc cat ggc aag ggg ctg gtg acc acc ctg	1001
Gly Ser Val Asn Val Val Thr His Gly Lys Gly Leu Val Thr Thr Leu	
250 255 260	
cat gag gga gat gat ttt gga cag ctg gct ctg gtg aat gat gca ccc	1049
His Glu Gly Asp Asp Phe Gly Gln Leu Ala Leu Val Asn Asp Ala Pro	
265 270 275	
cg ^g gca gcc acc atc atc ctg cga gaa tac aac tgt cat ttc ctg cgt	1097
Arg Ala Ala Thr Ile Ile Leu Arg Glu Tyr Asn Cys His Phe Leu Arg	
280 285 290	
gtg gac aag cag gac ttc aac cgt atc atc aag gat gtg gag gca aag	1145
Val Asp Lys Gln Asp Phe Asn Arg Ile Ile Lys Asp Val Glu Ala Lys	
295 300 305 310	
acc atg cgg ctg gaa gaa cat ggc aaa gtg gtg ctg gtg ctg gag aga	1193
Thr Met Arg Leu Glu Glu His Gly Lys Val Val Leu Val Leu Glu Arg	
315 320 325	
gcc tct cag ggc gcc ggc cct tcc cga ccc cca acc cca ggc agg aac	1241
Ala Ser Gln Gly Ala Gly Pro Ser Arg Pro Pro Thr Pro Gly Arg Asn	
330 335 340	
cg ^g tat aca gtg atg tct ggc act cca gat aag atc cta gag ctt ctg	1289
Arg Tyr Thr Val Met Ser Gly Thr Pro Asp Lys Ile Leu Glu Leu Leu	
345 350 355	
ttg gag gcc atg gga cta gat tcc agt gct cat gac cca aaa gaa aca	1337

Leu Glu Ala Met Gly Leu Asp Ser Ser Ala His Asp Pro Lys Glu Thr
360 365 370

ttc ctc agc gac ttc ctc ctg acc cac agg gtc ttc atg ccc agc gcc 1385
Phe Leu Ser Asp Phe Leu Leu Thr His Arg Val Phe Met Pro Ser Ala
375 380 385 390

caa ctc tgc gct gcc ctt ctg cac cac ttc cat gtg gag cct gcg ggt 1433
Gln Leu Cys Ala Ala Leu Leu His His Phe His Val Glu Pro Ala Gly
395 400 405

gac agc gag cag gag cgc agc acc tac gtc tgc aac aag agg cag cag 1481
Gly Ser Glu Gln Glu Arg Ser Thr Tyr Val Cys Asn Lys Arg Gln Gln
410 415 420

atc ttg cgg ctg gtc agc cag tgg gtg gcc ctg tat ggc tcc atg ctc 1529
Ile Leu Arg Leu Val Ser Gln Trp Val Ala Leu Tyr Gly Ser Met Leu
425 430 435

cac act gac cct gtg gcc acc agc ttc ctc cag aaa ctc tca gac ctg 1577
His Thr Asp Pro Val Ala Thr Ser Phe Leu Gln Lys Leu Ser Asp Leu
440 445 450

gtg ggc agg gac acc cga ctc agc aac ctg ctg agg gag cag tgg cca 1625
Val Gly Arg Asp Thr Arg Leu Ser Asn Leu Leu Arg Glu Gln Trp Pro
455 460 465 470

gag agg cgg cga tgc cac agg ttg gag aat ggc tgt ggg aat gca tct 1673
Glu Arg Arg Arg Cys His Arg Leu Glu Asn Gly Cys Gly Asn Ala Ser
475 480 485

cct cag atg aag gtg tct gcc tgg ccc cag ttt ctt tcc tct gct cct 1721
Pro Gln Met Lys Val Ser Ala Trp Pro Gln Phe Leu Ser Ser Ala Pro
490 495 500

cct gga ctg cag gca cct cct tcg ccc cct gac cct gag ggg ctc tgt 1769
Pro Gly Leu Gln Ala Pro Pro Ser Pro Pro Asp Pro Glu Gly Leu Cys
505 510 515

ggg cgt ggg aag ctc tcc tcc cac aga cac acc ctt ggg tct ctg ata 1817
Gly Arg Gly Lys Leu Ser Ser His Arg His Thr Leu Gly Ser Leu Ile
520 525 530

ggt gtt cac ggg gcc ctt gct gca tgt ggt gcc ctg ggc cag gcc gtg 1865
Gly Val His Gly Ala Leu Ala Ala Cys Gly Ala Leu Gly Gln Ala Val
535 540 545 550

cca gga ggc gca gag gcc taagggtggcc tccctcctcg cccactccct 1913
Pro Gly Gly Ala Glu Ala
555

gactcaatgg gccttttatt ccttttggaa ggttaattcat gcccacaggt agaggcctggg 1973
agatgaggaa tggggctgg agttggccccc tgaggccac ggggctcctg gtggccagtg 2033
ctgtgggagc tcagaggaag gcgaggccccc tccctggaaa gtcagagggg gccccaggcc 2093
attctcagct gggcttaaa gggaaagcaa gagggatga gaagatgtga ctgcagccag 2153
gatttggttg aggaatggtg ggagaaagaa ctggaaaggt agatttagtt ggtgggtgggg 2213
agggctgcac tggaaataaa atccaggggc ctcaccatcc agcaggctcc ccatggtccc 2273
accctactgt gtgtcccagc ccctgcctgc tggagactct tactggcttc ttctcctccg 2333
caggcgaagc ccgttctccc ctcaggccct ttgcacttat cccttagccct ggaagggtct 2393
ttctctggct ctgcctggca ggatccttct cgttctcatc tcagccaaat gctgggttcc 2453

cagacaggcc ccctcccggt tcccttatccg gagcaccctc ccctttctcc caccacgctc 2513
tgccttgggt tcctctgtga ttttttcaa agcactctcg ccatgtggag ttgtttctt 2573
tgcctacttg ctttctgtcc tttggtatct ctccatccc actggagagt tgacttccct 2633
cctgcgggcc cccacctccg cttctccttg ctcacatgct gcctggctct tggctgacgc 2693
tcagaaaactg atgtgggctc accctcgcaag gctgggcaact gcgctagggtg ctgatgctgc 2753
acctcattca accctggcct gtggtggctg cagtcaggca aggggcagag cagttcaaca 2813
acccgtgatg tgcagtgaca cgggacactt tccctgaatg tgcactggag tcggctctc 2873
caactgttagg tcccgctgcct taaaccagga aggggaagag ccaactccag tgcagattca 2933
gggaaagtgt cccgtgtaag cgactactgg agttgagagc tgcagggggc aagggtggag 2993
gaagaagagg attccctggtg ggcaaaccoca ggaggaaagg gaacccagga ggaggatccc 3053
tggaggagcg agagtaagag taggaccoca gagcaggcag gaggtggca gggcccccctg 3113
ggcaaggaca ggggtctgat ctttgcctta agagcagtgc aaaccattaa aggggtttga 3173
gccaagggttgc gcaaagtctg atttgtgttt tgaataggtc agctaaagag cctggcctt 3233
ctccagcaga caatggacac cactgaagtc gagtgccggga gcttcacagg gctctggta 3293
ggcagattgg aggaggaggg ctggaggcac ctggaggaga ggaggaggag catagttggg 3353
ccattggagt agtaaggagt gaggcctcggt gggcaggtgg aactggagtt agcctggca 3413
ggggaggagg gggcacagaa gacccacttc aaagaagaat cttcaaagca agatgacaag 3473
ctacggaagt gtggaggagc ctggagctgg ggagaatggc tggggAACAG agtggctgg 3533
gagggcaggat gcaaggatcc gatgggtata tggagtgtga ggtaatgggtt cattcatgtg 3593
gaaggatgca ggggtttt gagaccaggg ttttggaaagag agttcagcac tgctggtagt 3653
tttgggaatc acccatgtgc aggcgacaca tgaggcagta aggaactctg caggggtccc 3713
tgagatttgg aaatgttaggg aagagcaatg gattgaggc cgaacctggta ggatctgcta 3773
tacgcagagc tggggaggagg gacagagtca gtaccagagt cggaaaaaaag caggggtggga 3833
aggggaacct gagtcaggag acttgcctgg caggcgctgc cctgccagca gaggcctgac 3893
agtggtttcc atgaactgca tccctgctgt gggctggac agggccactg acacagtatc 3953
ggagcacaga agggaaagg agcaggaggg attccaactc tgccagttag cagctgtgt 4013
gctttggca tggacttaa cctctctgag cctcatttat ttcatccata aaatggaaat 4073
aaaaataata ctgggtcaaa aaaaaaaaaa aaaaaa 4109

<210> 14
<211> 556
<212> PRT
<213> Homo sapiens

<400> 14
Met Val Leu Arg Arg Met His Arg Pro Arg Ser Cys Ser Tyr Gln Leu
1 5 10 15
Leu Leu Glu His Gln His Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
20 25 30

Pro Leu Thr Asn Ser Glu Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu
35 40 45

Gln Ala Ser Thr Glu Arg Val Leu Arg Ala Gly Arg Gln Leu His Gln
50 55 60

His Leu Leu Ala Thr Cys Pro Asn Leu Ile Arg Asp Arg Lys Tyr His
65 70 75 80

Leu Arg Leu Tyr Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
85 90 95

Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Val Val Gly
100 105 110

Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
115 120 125

Asp Trp Ala Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
130 135 140

Pro Glu Pro Glu Pro Val Gly Thr His Glu Met Glu Glu Glu Leu Ala
145 150 155 160

Glu Ala Val Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
165 170 175

Val Ala Leu Arg Lys Pro Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
180 185 190

Leu Ile Phe Glu Glu Leu Leu His Ile Lys Ala Val Ala His Leu Ser
195 200 205

Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
210 215 220

Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
225 230 235 240

Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr His Gly Lys
245 250 255

Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe Gly Gln Leu Ala
260 265 270

Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile Leu Arg Glu Tyr
275 280 285

Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe Asn Arg Ile Ile
290 295 300

Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu His Gly Lys Val
305 310 315 320

Val Leu Val Leu Glu Arg Ala Ser Gln Gly Ala Gly Pro Ser Arg Pro
325 330 335

Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser Gly Thr Pro Asp
340 345 350

Lys Ile Leu Glu Leu Leu Glu Ala Met Gly Leu Asp Ser Ser Ala
355 360 365

His Asp Pro Lys Glu Thr Phe Leu Ser Asp Phe Leu Leu Thr His Arg
370 375 380

Val Phe Met Pro Ser Ala Gln Leu Cys Ala Ala Leu Leu His His Phe
385 390 395 400

His Val Glu Pro Ala Gly Gly Ser Glu Gln Glu Arg Ser Thr Tyr Val
405 410 415

Cys Asn Lys Arg Gln Gln Ile Leu Arg Leu Val Ser Gln Trp Val Ala
420 425 430

Leu Tyr Gly Ser Met Leu His Thr Asp Pro Val Ala Thr Ser Phe Leu
435 440 445

Gln Lys Leu Ser Asp Leu Val Gly Arg Asp Thr Arg Leu Ser Asn Leu
450 455 460

Leu Arg Glu Gln Trp Pro Glu Arg Arg Arg Cys His Arg Leu Glu Asn
465 470 475 480

Gly Cys Gly Asn Ala Ser Pro Gln Met Lys Val Ser Ala Trp Pro Gln
485 490 495

Phe Leu Ser Ser Ala Pro Pro Gly Leu Gln Ala Pro Pro Ser Pro Pro
500 505 510

Asp Pro Glu Gly Leu Cys Gly Arg Gly Lys Leu Ser Ser His Arg His
515 520 525

Thr Leu Gly Ser Leu Ile Gly Val His Gly Ala Leu Ala Ala Cys Gly
530 535 540

Ala Leu Gly Gln Ala Val Pro Gly Gly Ala Glu Ala
545 550 555

<210> 15

<211> 1966

<212> DNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (3)..(875)

<223> cAMP-GEFII

<400> 15

aa ggt gtg ctc aaa cct aat gat gtt tca gta ttt acg acg ctc acc 47
Gly Val Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr
1 5 10 15

att aat gga cgc ctg ttt gcc tgc ccg cga gag caa ttc gac tca ctg 95
Ile Asn Gly Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu
20 25 30

act ccc ttg cca gaa cag gag ggc ccg acc act ggg aca gtg ggg acg 143
Thr Pro Leu Pro Glu Gln Glu Gly Pro Thr Thr Gly Thr Val Gly Thr
35 40 45

ttt gaa ctg atg agc tcg aaa gac ttg gcg tac cag atg aca acg tat 191
Phe Glu Leu Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Thr Tyr
50 55 60

gac tgg gaa ctc ttc aac tgt gtg ctc gag ctg gag cta atc tac cac 239
Asp Trp Glu Leu Phe Asn Cys Val Leu Glu Leu Glu Leu Ile Tyr His
65 70 75

aca ttt gga agg cat aat ttt aaa aag acc aca gca aac ttg gat ttg 287
Thr Phe Gly Arg His Asn Phe Lys Lys Thr Ala Asn Leu Asp Leu
80 85 90 95

ttc ctg agg aga ttt aat gaa att cag ttt tgg gtt gtc act gag atc 335
Phe Leu Arg Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile
100 105 110

tgc ctt tgt tcc cag ctc agc aag cgt gtt cag ctt ttg aaa aaa tgt 383
Cys Leu Cys Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Cys
115 120 125

atc aag ata gcg gct cac tgc aag gag tac aaa aac ttg aat tcc ttc 431
Ile Lys Ile Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe
130 135 140

ttc ggc atc gtc atg ggg ctc agt aac gtg gct gag agc cgc ctg gca 479
Phe Gly Ile Val Met Gly Leu Ser Asn Val Ala Glu Ser Arg Leu Ala
145 150 155

tta aca tgg gag aaa ctg ccg agc aag ttt aag aag ttc tat gcg gag 527
Leu Thr Trp Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu
160 165 170 175

ttt gag agc tta atg gat cct tcc aga aat cac aag gcg tac agg ctg 575
Phe Glu Ser Leu Met Asp Pro Ser Arg Asn His Lys Ala Tyr Arg Leu
180 185 190

aca gca gct aaa ctg gag ccc ccc ctc atc cct ttc atg ccc ttg ctt 623
Thr Ala Ala Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu
195 200 205

att aaa gat atg aca ttt act cat gag ggg aac aag aca ttc att gac 671
Ile Lys Asp Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp
210 215 220

aat cta gta aac ttt gaa aaa atg cgc atg att gca aat act gcc aga 719
Asn Leu Val Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg
225 230 235

acg gtg cgc tac tac agg agc cag cca ttc aat ccg gat gct gct caa 767
Thr Val Arg Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln
240 245 250 255

gct aat aag aac cat cag gat gtc cgg agt tat gta cgg caa tta aat 815
Ala Asn Lys Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn
260 265 270

gtg att gac aac cag aga act tta tca cag atg tca cac aga tta gag 863
Val Ile Asp Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu
275 280 285

cct cgc agg cca tagacatctg cagtgcggcag agtgtatgctc cgtctccagt 915
Pro Arg Arg Pro
290

ccacaatctt tcaaaagatg ctgtgtatgc tactactgac tgtgttgcta ctagagaatt 975
ccccagaatg agcaagagac acctcctgag agcccccgg ggccacatcc tgcttccga 1035
ccacacagga gaaggatctg tcttgtctaa cgcggacatg ccgttagctt ggaaccatca 1095
gctgttagtca tcttcttcac ggttggcaca ccaccgcagg ctcacgtcaa ggcataacct 1155
ggcgaggcta caccaggccc ctgacatccc ttcccaggct gttgcagcat gagactgtcc 1215
cgtggatagg tttgacttgg aatcgctgca atgatataat tgaatgattt gtttacttag 1275
caccttattt ggggtctggg ttctggggag ggtgttgacc ataaaagtcc aaatttatcca 1335
tcatgttcct ccatcgatcat aatcttacct ctgaaggaat ggaacctcat cacaacacta 1395
tgaaacattna tgactgttca gtctgttaatt tcgaaatgat ctatagaata atatgtttac 1455
attgttaactt ttaaaaactt acaaattcagg attacacaca tgagaattcc actaagaaac 1515

accaagggttc ttaatatcgc cagcgtaag atagaaagta acatttcaga agagcacaat 1575
atacacaaaaa catttttca aattgaaata ttttcctggg cattaaaaaa cctttccact 1635
acaaatttat tgttactgat gaaaaaaaaa gcatatttc tggacttaaa tgttattaca 1695
aaaatcttaa tttcagcaa ttgtttgca ct当地agata gattgtaaat aggttatgca 1755
gtcaatggta tagaattatt tatttgctac ataatagaca ttgtgccaaa taattcctt 1815
ttatatttt tattcagttat gaaattttgg agtacatttt ttctgtttc ttaatttagac 1875
tacatttaat gtataggaat tgtatgtaca tatctttct gtaaataaca gccagttatct 1935
tcattaaata tacttgacaa gaaaaaaaaa a 1966

<210> 16
<211> 291
<212> PRT
<213> Rattus norvegicus

<400> 16
Gly Val Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr Ile
1 5 10 15
Asn Gly Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr
20 25 30
Pro Leu Pro Glu Gln Glu Gly Pro Thr Thr Gly Thr Val Gly Thr Phe
35 40 45
Glu Leu Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Thr Tyr Asp
50 55 60
Trp Glu Leu Phe Asn Cys Val Leu Glu Leu Glu Leu Ile Tyr His Thr
65 70 75 80
Phe Gly Arg His Asn Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe
85 90 95
Leu Arg Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys
100 105 110
Leu Cys Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Cys Ile
115 120 125
Lys Ile Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe
130 135 140
Gly Ile Val Met Gly Leu Ser Asn Val Ala Glu Ser Arg Leu Ala Leu
145 150 155 160
Thr Trp Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe
165 170 175
Glu Ser Leu Met Asp Pro Ser Arg Asn His Lys Ala Tyr Arg Leu Thr
180 185 190
Ala Ala Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu Ile
195 200 205
Lys Asp Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn
210 215 220
Leu Val Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr
225 230 235 240
Val Arg Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala

245 250 255
Asn Lys Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val
260 265 270

Ile Asp Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro
275 280 285

Arg Arg Pro
290

<210> 17
<211> 3013
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (407)..(2953)
<223> cAMP-GEFII

<400> 17
gatccagcga agatgtggat ataatcttca ctcgactgaa agaagttaaa gcttttgaga 60
aatttcaccc aaatctcctt catcagattt gcttatgtgg ttattatgag aatctggaaa 120
aggaaataac attatttcgc cagggtgata tggaacaaac tggtatgctg cctggcaggg 180
tctttggatg ttaaagtatc tgagaccagc agtcaccagg atgctgtac catctgtacc 240
ctggaaattt ggacggcctt tggagagtcc attctggaca acacaccccg ccatgcaacc 300
atcgttacca gggagagcag tgaactgctc cgcatcgagc agaaggactt caaggcacta 360
tgggagaaat atcgacagta tatggcagga cttctggctc ctcctt atg gta tta 415
Met Val Leu
1

tgg aaa cgg gct cta aca atg aca gga ttc ctg aca agg aga aca cac 463
Trp Lys Arg Ala Leu Thr Met Thr Gly Phe Leu Thr Arg Arg Thr His
5 10 15

ctc att gaa cct cac gtt cct ctt cgt cct gct aac acc att acc aag 511
Leu Ile Glu Pro His Val Pro Leu Arg Pro Ala Asn Thr Ile Thr Lys
20 25 30 35

gtc cct tca gag aag atc ctc aga gct gga aaa att tta cga aat gcc 559
Val Pro Ser Glu Lys Ile Leu Arg Ala Gly Lys Ile Leu Arg Asn Ala
40 45 50

att ctc tct cga gca cct cac atg ata aga gat aga aaa tac cac cta 607
Ile Leu Ser Arg Ala Pro His Met Ile Arg Asp Arg Lys Tyr His Leu
55 60 65

aag aca tac aga caa tgc tgt gtg gga act gaa ctg gtg gac tgg atg 655
Lys Thr Tyr Arg Gln Cys Cys Val Gly Thr Glu Leu Val Asp Trp Met
70 75 80

atc gac gag aca cca tgt gtt cac tcc cgg act caa gct gtt ggc atg 703
Ile Asp Glu Thr Pro Cys Val His Ser Arg Thr Gln Ala Val Gly Met
85 90 95

tgg caa gtc ctg tta gaa gat ggt gtt ctc aac cac gtg gac cag gag 751
Trp Gln Val Leu Leu Glu Asp Gly Val Leu Asn His Val Asp Gln Glu
100 105 110 115

cac cat ttc caa gac ttt tat tta ttc tat cga ttt ctg gat gat gag 799
His His Phe Gln Asp Phe Tyr Leu Phe Tyr Arg Phe Leu Asp Asp Glu

120	125	130	
cac gag gat gcc cct ttg cct act gag gag gag aag aag aag gat			847
His Glu Asp Ala Pro Leu Pro Thr Glu Glu Glu Lys Lys Glu Cys Asp			
135	140	145	
gag gag ctc cag gac acc atg ctg ctg ctg tca cag atg ggc ccc gac			895
Glu Glu Leu Gln Asp Thr Met Leu Leu Leu Ser Gln Met Gly Pro Asp			
150	155	160	
gcc cac atg agg atg atc ctt cgc aaa cca cct ggc cag agg act gtg			943
Ala His Met Arg Met Ile Leu Arg Lys Pro Pro Gly Gln Arg Thr Val			
165	170	175	
gat gac cta gag att atc tat gag gag ctt ctt cat att aaa gcc tta			991
Asp Asp Leu Glu Ile Ile Tyr Glu Glu Leu Leu His Ile Lys Ala Leu			
180	185	190	195
tcc cat ctt tct acc aca gtg aaa cga gag tta gca ggt gtt ctc att			1039
Ser His Leu Ser Thr Thr Val Lys Arg Glu Leu Ala Gly Val Leu Ile			
200	205	210	
ttt gag tct cac gcc aaa gga ggg act gtg ttg ttt aac cag ggg gaa			1087
Phe Glu Ser His Ala Lys Gly Gly Thr Val Leu Phe Asn Gln Gly Glu			
215	220	225	
gaa ggt acc tcc tgg tac att att cta aaa gga tca gtg aat gta gtc			1135
Glu Gly Thr Ser Trp Tyr Ile Ile Leu Lys Gly Ser Val Asn Val Val			
230	235	240	
att tac ggc aag ggt gtg gtc tgc acc ctg cat gaa gga gat gac ttc			1183
Ile Tyr Gly Lys Gly Val Val Cys Thr Leu His Glu Gly Asp Asp Phe			
245	250	255	
ggc aag tta gca cta gtg aat gat gcc cca cga gct gcc tct atc gtc			1231
Gly Lys Leu Ala Leu Val Asn Asp Ala Pro Arg Ala Ala Ser Ile Val			
260	265	270	275
tta cga gaa gat aac tgc cat ttc tta aga gta gac aag gag gat ttc			1279
Leu Arg Glu Asp Asn Cys His Phe Leu Arg Val Asp Lys Glu Asp Phe			
280	285	290	
aac cgg atc cta agg gac gtg gag gcg aat aca gtc aga ctt aaa gaa			1327
Asn Arg Ile Leu Arg Asp Val Glu Ala Asn Thr Val Arg Leu Lys Glu			
295	300	305	
cat gac caa gat gtc ttg gtg ctg gag aag gtc cca gca ggg aac aga			1375
His Asp Gln Asp Val Leu Val Leu Glu Lys Val Pro Ala Gly Asn Arg			
310	315	320	
gct tct aat caa gga aac tca cag cct cag caa aag tat act gtg atg			1423
Ala Ser Asn Gln Gly Asn Ser Gln Pro Gln Gln Lys Tyr Thr Val Met			
325	330	335	
tca gga aca cct gaa aaa att tta gag cat ttt cta gaa aca ata cgc			1471
Ser Gly Thr Pro Glu Lys Ile Leu Glu His Phe Leu Glu Thr Ile Arg			
340	345	350	355
ctt gag gca act tta aat gaa gca aca gat tct gtt tta aat gac ttt			1519
Leu Glu Ala Thr Leu Asn Glu Ala Thr Asp Ser Val Leu Asn Asp Phe			
360	365	370	
att atg atg cac tgt gtt ttt atg cca aat acc cag ctt tgc ccg gca			1567
Ile Met Met His Cys Val Phe Met Pro Asn Thr Gln Leu Cys Pro Ala			
375	380	385	
ctg gtg gcc cac tac cac gca cag cct tca caa ggt aca gaa cag gag			1615
Leu Val Ala His Tyr His Ala Gln Pro Ser Gln Gly Thr Glu Gln Glu			
390	395	400	

aaa atg gat tat gcc ctc aac aat aag agg cga gtc atc cgc ctg gtt	1663
Lys Met Asp Tyr Ala Leu Asn Asn Lys Arg Arg Val Ile Arg Leu Val	
405 410 415	
cta cag tgg gct gcc atg tat gga gac ctc ctg caa gag gat gac gta	1711
Leu Gln Trp Ala Ala Met Tyr Gly Asp Leu Leu Gln Glu Asp Asp Val	
420 425 430 435	
tct atg gcc ttc ctg gag gag ttt tat gta tct gta tca gat gat gcc	1759
Ser Met Ala Phe Leu Glu Glu Phe Tyr Val Ser Val Ser Asp Asp Ala	
440 445 450	
cgg atg att gct gcc ctc aag gag caa ctg cca gag ttg gag aag att	1807
Arg Met Ile Ala Ala Leu Lys Glu Gln Leu Pro Glu Leu Glu Lys Ile	
455 460 465	
gtc aag caa atc tca gaa gat gca aag gca cca caa aag aag cac aag	1855
Val Lys Gln Ile Ser Glu Asp Ala Lys Ala Pro Gln Lys Lys His Lys	
470 475 480	
gtt ctt ttg caa cag ttc aat acg ggc gat gag aga gcc cag aag cgc	1903
Val Leu Leu Gln Gln Phe Asn Thr Gly Asp Glu Arg Ala Gln Lys Arg	
485 490 495	
cag cct atc cgc ggc tct gat gaa gtt ctg ttt aag gtc tat tgc atg	1951
Gln Pro Ile Arg Gly Ser Asp Glu Val Leu Phe Lys Val Tyr Cys Met	
500 505 510 515	
gac cac acc tac aca acc att cgg gtg cca gtg gcc act tcg gtg aag	1999
Asp His Thr Tyr Thr Ile Arg Val Pro Val Ala Thr Ser Val Lys	
520 525 530	
gaa gtc atc agt gca gtt gcc gac aag ctg ggc tcc ggg gag ggc ctg	2047
Glu Val Ile Ser Ala Val Ala Asp Lys Leu Gly Ser Gly Glu Gly Leu	
535 540 545	
atc ata gtc aag atg agt tcc gga gga gaa aag gtg gtg ctc aaa cct	2095
Ile Ile Val Lys Met Ser Ser Gly Gly Glu Lys Val Val Leu Lys Pro	
550 555 560	
aat gat gtt tca gta ttt acg acg ctc acc att aat gga cgc ctg ttt	2143
Asn Asp Val Ser Val Phe Thr Thr Leu Thr Ile Asn Gly Arg Leu Phe	
565 570 575	
gct tgc ccg cga gag caa ttc gat tca ctg act ccc tta cca gaa cag	2191
Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr Pro Leu Pro Glu Gln	
580 585 590 595	
gaa ggc cca act gtt gga aca gtg gga act ttt gaa ctg atg agc tcc	2239
Glu Gly Pro Thr Val Gly Thr Val Gly Thr Phe Glu Leu Met Ser Ser	
600 605 610	
aaa gat tta gca tac cag atg aca att tat gat tgg gaa ctc ttc aac	2287
Lys Asp Leu Ala Tyr Gln Met Thr Ile Tyr Asp Trp Glu Leu Phe Asn	
615 620 625	
tgc gtg cat gag ctg gag cta atc tat cac aca ttt gga agg cat aat	2335
Cys Val His Glu Leu Glu Leu Ile Tyr His Thr Phe Gly Arg His Asn	
630 635 640	
ttt aaa aag acc aca gca aac ttg gat ttg ttc ctg agg aga ttt aat	2383
Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe Leu Arg Arg Phe Asn	
645 650 655	
gaa att cag ttt tgg gtc gtc act gag atc tgc ctt tgt tct cag ctc	2431
Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys Leu Cys Ser Gln Leu	
660 665 670 675	

agc aag cgt gtt cag cta tta aaa aaa ttt att aag ata gca gcc cac	2479
Ser Lys Arg Val Gln Leu Leu Lys Lys Phe Ile Lys Ile Ala Ala His	
680 685 690	
tgt aag gag tat aaa aat ctg aat tcc ttt ttt gcc atc gtc atg gga	2527
Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe Ala Ile Val Met Gly	
695 700 705	
cta agt aac att gct gtg agc cgc ttg gca cta acg tgg gag aaa ctg	2575
Leu Ser Asn Ile Ala Val Ser Arg Leu Ala Leu Thr Trp Glu Lys Leu	
710 715 720	
cca agc aag ttc aag aag ttc tat gcg gag ttt gaa agt tta atg gac	2623
Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe Glu Ser Leu Met Asp	
725 730 735	
cct tca agg aac cac agg gcc tac agg ctg aca gta gct aag ctg gaa	2671
Pro Ser Arg Asn His Arg Ala Tyr Arg Leu Thr Val Ala Lys Leu Glu	
740 745 750 755	
cct cct ctc atc ccc ttc atg cct ttg ctc att aaa gat atg aca ttt	2719
Pro Pro Leu Ile Pro Phe Met Pro Leu Leu Ile Lys Asp Met Thr Phe	
760 765 770	
act cat gag ggg aac aag acg ttc att gac aat cta gta aac ttt gaa	2767
Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn Leu Val Asn Phe Glu	
775 780 785	
aaa atg cgc atg att gca aat acg gcc aga aca gta gca tac tac agg	2815
Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr Val Arg Tyr Tyr Arg	
790 795 800	
agc caa ccc ttc aat cct gat gca gct caa gct aat aag aac cat cag	2863
Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala Asn Lys Asn His Gln	
805 810 815	
gat gtc cgg act tat gta cgg caa tta aat gtg att gac aac cag aga	2911
Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val Ile Asp Asn Gln Arg	
820 825 830 835	
act tta tca cag atg tca cac aga tta gag cct cgt cga cca	2953
Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro Arg Arg Pro	
840 845	
tagacatttc aaatgcccaa agcaacagtt tgtctccagt ccacaattt caaaaatgcc	3013

<210> 18
<211> 849
<212> PRT
<213> Homo sapiens

<400> 18
Met Val Leu Trp Lys Arg Ala Leu Thr Met Thr Gly Phe Leu Thr Arg
1 5 10 15
Arg Thr His Leu Ile Glu Pro His Val Pro Leu Arg Pro Ala Asn Thr
20 25 30
Ile Thr Lys Val Pro Ser Glu Lys Ile Leu Arg Ala Gly Lys Ile Leu
35 40 45
Arg Asn Ala Ile Leu Ser Arg Ala Pro His Met Ile Arg Asp Arg Lys
50 55 60
Tyr His Leu Lys Thr Tyr Arg Gln Cys Cys Val Gly Thr Glu Leu Val
65 70 75 80
Asp Trp Met Ile Asp Glu Thr Pro Cys Val His Ser Arg Thr Gln Ala

	85	90	95													
Val	Gly	Met	Trp	Gln	Val	Leu	Leu	Glu	Asp	Gly	Val	Leu	Asn	His	Val	
100								105						110		
Asp	Gln	Glu	His	His	Phe	Gln	Asp	Phe	Tyr	Leu	Phe	Tyr	Arg	Phe	Leu	
115								120						125		
Asp	Asp	Glu	His	Glu	Asp	Ala	Pro	Leu	Pro	Thr	Glu	Glu	Glu	Lys	Lys	
130								135						140		
Glu	Cys	Asp	Glu	Glu	Leu	Gln	Asp	Thr	Met	Leu	Leu	Leu	Ser	Gln	Met	
145								150						155		160
Gly	Pro	Asp	Ala	His	Met	Arg	Met	Ile	Leu	Arg	Lys	Pro	Pro	Gly	Gln	
165								170						175		
Arg	Thr	Val	Asp	Asp	Leu	Glu	Ile	Ile	Tyr	Glu	Glu	Leu	Leu	His	Ile	
180								185						190		
Lys	Ala	Leu	Ser	His	Leu	Ser	Thr	Thr	Val	Lys	Arg	Glu	Leu	Ala	Gly	
195								200						205		
Val	Leu	Ile	Phe	Glu	Ser	His	Ala	Lys	Gly	Gly	Thr	Val	Leu	Phe	Asn	
210								215						220		
Gln	Gly	Glu	Glu	Gly	Thr	Ser	Trp	Tyr	Ile	Ile	Leu	Lys	Gly	Ser	Val	
225								230						235		240
Asn	Val	Val	Ile	Tyr	Gly	Lys	Gly	Val	Val	Cys	Thr	Leu	His	Glu	Gly	
245								250						255		
Asp	Asp	Phe	Gly	Lys	Leu	Ala	Leu	Val	Asn	Asp	Ala	Pro	Arg	Ala	Ala	
260								265						270		
Ser	Ile	Val	Leu	Arg	Glu	Asp	Asn	Cys	His	Phe	Leu	Arg	Val	Asp	Lys	
275								280						285		
Glu	Asp	Phe	Asn	Arg	Ile	Leu	Arg	Asp	Val	Glu	Ala	Asn	Thr	Val	Arg	
290								295						300		
Leu	Lys	Glu	His	Asp	Gln	Asp	Val	Leu	Val	Leu	Glu	Lys	Val	Pro	Ala	
305								310						315		320
Gly	Asn	Arg	Ala	Ser	Asn	Gln	Gly	Asn	Ser	Gln	Pro	Gln	Gln	Lys	Tyr	
325								330						335		
Thr	Val	Met	Ser	Gly	Thr	Pro	Glu	Lys	Ile	Leu	Glu	His	Phe	Leu	Glu	
340								345						350		
Thr	Ile	Arg	Leu	Glu	Ala	Thr	Leu	Asn	Glu	Ala	Thr	Asp	Ser	Val	Leu	
355								360						365		
Asn	Asp	Phe	Ile	Met	Met	His	Cys	Val	Phe	Met	Pro	Asn	Thr	Gln	Leu	
370								375						380		
Cys	Pro	Ala	Leu	Val	Ala	His	Tyr	His	Ala	Gln	Pro	Ser	Gln	Gly	Thr	
385								390						395		400
Glu	Gln	Glu	Lys	Met	Asp	Tyr	Ala	Leu	Asn	Asn	Lys	Arg	Arg	Val	Ile	
405								410						415		
Arg	Leu	Val	Leu	Gln	Trp	Ala	Ala	Met	Tyr	Gly	Asp	Leu	Leu	Gln	Glu	
420								425						430		
Asp	Asp	Val	Ser	Met	Ala	Phe	Leu	Glu	Glu	Phe	Tyr	Val	Ser	Val	Ser	
435								440						445		
Asp	Asp	Ala	Arg	Met	Ile	Ala	Ala	Leu	Lys	Glu	Gln	Leu	Pro	Glu	Leu	

450 455 460
Glu Lys Ile Val Lys Gln Ile Ser Glu Asp Ala Lys Ala Pro Gln Lys
465 470 475 480
Lys His Lys Val Leu Leu Gln Gln Phe Asn Thr Gly Asp Glu Arg Ala
485 490 495
Gln Lys Arg Gln Pro Ile Arg Gly Ser Asp Glu Val Leu Phe Lys Val
500 505 510
Tyr Cys Met Asp His Thr Tyr Thr Ile Arg Val Pro Val Ala Thr
515 520 525
Ser Val Lys Glu Val Ile Ser Ala Val Ala Asp Lys Leu Gly Ser Gly
530 535 540
Glu Gly Leu Ile Ile Val Lys Met Ser Ser Gly Gly Glu Lys Val Val
545 550 555 560
Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr Ile Asn Gly
565 570 575
Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr Pro Leu
580 585 590
Pro Glu Gln Glu Gly Pro Thr Val Gly Thr Val Gly Thr Phe Glu Leu
595 600 605
Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Ile Tyr Asp Trp Glu
610 615 620
Leu Phe Asn Cys Val His Glu Leu Glu Leu Ile Tyr His Thr Phe Gly
625 630 635 640
Arg His Asn Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe Leu Arg
645 650 655
Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys Leu Cys
660 665 670
Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Phe Ile Lys Ile
675 680 685
Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe Ala Ile
690 695 700
Val Met Gly Leu Ser Asn Ile Ala Val Ser Arg Leu Ala Leu Thr Trp
705 710 715 720
Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe Glu Ser
725 730 735
Leu Met Asp Pro Ser Arg Asn His Arg Ala Tyr Arg Leu Thr Val Ala
740 745 750
Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu Ile Lys Asp
755 760 765
Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn Leu Val
770 775 780
Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr Val Arg
785 790 795 800
Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala Asn Lys
805 810 815
Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val Ile Asp

820

825

830

Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro Arg Arg
835 840 845

Pro